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Background: Stroke is a leading cause of mortality and disability in Canada. Persons with atrial 
fibrillation (AF) have a five-fold increased risk of developing a stroke. AF occurs when there are 
ineffective rapid contractions of the atrium, which leads to stagnant blood flow and promotes the 
formation of thrombi. AF is a significant contributor to stroke at all ages and the prevalence of AF 
is rising with age. In Canada, the treatment for persons with chronic non-valvular AF is to provide 
long-term oral anticoagulation therapy (OAT) with warfarin, which has been shown to reduce the 
risk of stroke by two-thirds. Routine care administered by physicians is often inconvenient because 
it requires regular doctor visits, a time lag between laboratory testing and follow ups, and frequent 
ad-hoc dose adjustments to prevent adverse outcomes. These challenges often contribute to poor 
OAT management to result in an increased risk of bleeding and clotting. These risks are further 
complicated for people with AF who are older, frail, have multiple co-morbidities and 
polypharmacy. The solution is to offset these complications through optimizing delivery of OAT 
using anticoagulation management services (AMS). Research has shown that pharmacist or nurse-
led AMS are comparable or better than physician-led care in terms of cost-effectiveness and patient 
outcomes. Despite this, AMS clinics need to establish a more integrated approach for the optimal 
delivery of OAT management. Published and available in the literature are clinical 
recommendations by Garcia et al. (2008) on how to optimize OAT delivery in outpatient AMS 
settings; however, the deliberate implementation of the guideline remains an issue. To address the 
problem, this thesis explores the pharmacists and nurses’ perception of implementing the guideline 
in community-based AMS clinics, especially for older and frail patients with AF.  
Objectives: In the context of a frail, aging population, this study explores the pharmacists and 





management in existing specialized AMS clinics within the Waterloo-Wellington Local Health 
Integration Network (WWLHIN) community. Specifically, this study uses Michie et al.’s (2005) 
psychological theory to explore (1) how existing intrinsic and extrinsic factors hindered or 
supported; and (2) how behavioural changes facilitate the implementation of Garcia et al.’s (2008) 
clinical guideline for optimal OAT management. In essence, this study investigated the clinicians’ 
perceptions on how different factors hindered, supported or facilitate the implementation of clinical 
recommendations to inform a coordinated, regional approach to OAT management.   
Methods: This study used a qualitative, explorative design with a purposive sample of clinicians 
(key informants) working in AMS clinics within the WWLHIN community: Waterloo-Kitchener, 
Cambridge and Guelph.  Key informants were recruited from family health teams (FHTs) and 
community pharmacies, and sampled until the point of saturation. Semi-structured interview 
questions covered 12 domains under a theoretical lens, Michie et al.’s (2005) psychological theory: 
(1) Knowledge, (2) Skills, (3) Social/professional role and identity, (4) Beliefs about capabilities, 
(5) Beliefs about consequences, (6) Motivation and goals, (7) Memory, attention and decision 
processes, (8) Environmental context and resources, (9) Social influences, (10) Emotion, (11) 
Behavioural regulation, and (12) Nature of the behaviours. These 12 domains represent the 
relevant factors that influence the implementation of clinical guidelines. Garcia et al. (2008) 
published a clinical guideline with 9 key recommendations for optimal delivery of OAT 
management in outpatient AMS settings: (1) Qualifications of Personnel, (2) Supervision, (3) Care 
Management and Coordination, (4) Documentation, (5) Patient Education, (6) Patient Selection 
and Assessment, (7) Laboratory Monitoring, (8) Initiation and Stabilization of Warfarin Therapy, 





a total of 108 pages of transcript. Data were coded and analyzed using NVIVO Pro 11 based on 
the theoretical framework, and summarized into key findings to address the research objectives.  
Results: There were six clinics that participated in the study: three family health teams and three 
community pharmacies with AMS clinics. Within these six clinics, there were a total of eight key 
informants:  six pharmacists and two registered nurses. The majority of key informants were from 
the Kitchener-Waterloo region with more than one-year experience in OAT in the community 
setting. There were five salient themes in the results: (1) Inadequate reimbursement for logistical 
operation of AMS clinics; (2) Clinicians’ awareness of how to apply knowledge to support 
practices; (3) Tailored organizational supports for the frail elderly; (4) Engagement of efforts to 
improve interprofessional communication and collaboration; and (5) Use of  compatible software 
platforms for documentation. Theme 1 hindered, theme 2 and 3 supported, and theme 4 and 5 
facilitate the implementation of Garcia et al.’s (2008) clinical guideline for the optimal delivery of 
OAT management in participating AMS clinics.  
Discussion: In determining that inadequate funding was a key barrier to implementation, the 
finding suggests that if key informants cannot cover their costs, they cannot offer optimal OAT 
management per the clinical guideline. There is currently no coverage of services and materials 
for OAT management by pharmacists and nurses in Canada, except for Quebec. Instead, Ontario’s 
pharmacists in community AMS clinics use other means to recover costs for OAT management 
services. In light of these findings, there needs to be appropriate funding for community AMS to 
continue their valuable services, otherwise OAT management may fall back to usual care and block 
optimal practices. Other factors affecting implementation are awareness of how to apply each 
recommendation of the clinical guideline to support practice and tailored organizational supports 





was the finding that suggests that key informants relied on an incomplete frailty assessment; this 
finding reflected other work showing that clinicians tend to diagnose frailty syndrome based on 
chronological age rather than biological age. Furthermore, other work corroborated the finding 
that tailored organizational supports for the frail elderly, such as physical tools, face-to-face 
interactions and home visits, enabled the implementation of the clinical guideline via improving 
medication adherence and monitoring of other health issues.  
In addition, other studies supported the finding that clinicians should engage in 
interprofessional communication and collaboration, especially during care transitions to facilitate 
optimal practices. One strategy was for nurse navigators to act as the focal point of contact for 
seamless care transitions, but existing pharmacists and nurses can also expand their scope of 
practice to methodically provide continuity of care and coordination of services in community-
based AMS settings. Other work also supported the finding that social networking with experts in 
the local and wider regions facilitated optimal practices through maintaining competencies and 
gaining new knowledge. Another facilitator of optimal OAT management was to use compatible 
software platforms for standardized OAT documentation to integrate a systematic approach to 
management. However, the selection of an anticoagulation software program is complicated with 
many considerations, depending on individual clinic’s needs.  There needs to be further 
investigation on the limited literature on the implications of using compatible software platforms 
for standardized documentation of OAT management.  
Conclusion: Linking key themes to the domains of Michie et al.’s (2005) psychological theory 
that influenced the implementation of the clinical guideline: (1) Inadequate reimbursement for 
logistical operation of AMS clinics was an environmental constraint (domain #8); (2) Clinicians’ 





(domains #1 and 2); (3) Tailored organizational supports for the frail elderly were environmental 
resources within their context (domain #8); (4) Engagement of efforts to improve interprofessional 
communication and collaboration was using social influences to prompt behavioural changes 
(domains #9 and 12); and (5) Use of compatible software platforms for documentation was a 
proposed system to change the nature of behaviours related to tracking and recording 
anticoagulation data (domain #12). Using the underlying theory, these key themes represent 
important factors for the deliberate implementation of the clinical guideline for optimizing delivery 
of OAT management.  
Significance:  Few studies use specific theories to understand the reasons underlying the uptake 
or not of clinical guidelines. This study contributes to the literature because it uses Michie et al.’s 
(2005) psychological theory to explore clinicians’ perceptions on the deliberate implementation of 
clinical recommendations for optimized OAT delivery in practice. These data can help the 
Waterloo-Wellington Local Health Integration Network (WWLHIN) focus on factors that are 
important to improving systems of OAT delivery in outpatient settings that serve a frail population. 
In turn, there can be improvements in the quality and consistency of patient care, government 
funding, and the lessons learned can be portable to other LHINs.  Ultimately, this study brought 
insight on how various factors affect the implementation the clinical guideline and can help key 
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1 CHAPTER 1: INTRODUCTION 
1.1 Overview  
Stroke is a leading cause of mortality and disability in Canada (Statistics Canada, 2014). It 
is characterized by an impairment in the function of the brain due to an insufficient amount of 
blood supply caused by a clot (ischemic stroke), or by a ruptured blood vessel (Heart and Stroke 
Foundation of Canada, 2014). Persons with atrial fibrillation (AF), a common cardiac arrhythmia, 
are characterized by an abnormal heart rhythm and may be classified as having non-valvular, or 
valvular AF, which links to rheumatic valvular disease or prosthetic heart valves (Hobbs, Taylor, 
Geersing, Rutten, & Brouwer, 2016). AF is a significant contributor to stroke at all ages (Wolf, 
Abbott, & Kannel, 1987). In the Framingham study, persons with AF have a five-fold increased 
risk of having a stroke (Ciervo, Granger, & Schaller, 2012; Fang, Panguluri, Machtinger, & 
Schillinger, 2009; Go et al., 2014; McKelvie et al., 2013; Wolf et al., 1987). The risk of stroke is 
increased with AF because a fibrillating atrium can produce stagnant blood that can potentially 
form thrombi to block cerebral circulation, thereby restricting blood flow through the arteries 
(Bereznicki, Peterson, Jackson, & Jeffrey, 2006; Ciervo et al., 2012; McKelvie et al., 2013). AF is 
a morbid cardiovascular condition with negative implications on the quality of life, work 
productivity and health resource utilization.   
More specifically, AF causes more than 529,000 hospitalizations each year in the United 
States, costing approximately $6.65 billion to manage and treat AF-related stroke (Ciervo et al., 
2012). In North America, 6% of all health and social services expenditures are used for stroke 
related causes (Quinn & Dawson, 2009). AF-related strokes are more severe with a 12% rate of 
recurrence that causes longer hospitalizations and greater morbidity, thus requiring a higher need 
for outpatient care (Ciervo et al., 2012). Stroke also has negative psychological effects such as 




following a stroke is between 10-25% (Chemerinski et al., 2001). A stroke event can affect the 
patient, as well as their family members, particularly spouses and adult children, who are prone to 
anxiety and depression following a relative’s stroke event (Chow, Wong, & Poon, 2007).  Persons 
with AF also have a major independent risk factor for cognitive decline, which is commonly 
associated with increased age and greater vascular events (Cao, Pokorney, Hayden, Welsh-
Bohmer, & Newby, 2015; Flaker et al., 2010; Hui, Morley, & Mikolajczak, 2015).  
In Canada, AF affects approximately 1 to 2% of the population, and about 6% of older 
adults aged 65 and over (Canadian Stroke Prevention Intervention Network, 2014; Franken, Rosa, 
& Santos, 2012; Ganz, 2015). The prevalence of AF is rising with age, indicating that the elderly 
population has the greatest risk of AF-related stroke (Bereznicki et al., 2006; Ciervo et al., 2012; 
Wolf et al., 1987).  The proportion of AF-related stroke steadily increased from 6.7% for ages 50-
59, to 36.2% for ages 80-89 (Wolf et al., 1987). The median age of AF occurrence is 75 years, and 
it affects about 10% of the population that is more than 80 years of age, a cohort that is expected 
to double by 2026. Notably, aging results in greater vulnerability to health stressors, making older 
persons more vulnerable to AF, thromboembolic events and bleeding risks (Foody, 2017; Lubitz 
et al., 2013). Not only that, but older age is often associated with frailty syndrome which ensues a 
myriad of complex issues, such as comorbidities, polypharmacy, non-adherence, risk of falls, 
cognitive impairment, mobility issues, nutritional status, swallowing disorders, and so on 
(Granziera, Cohen, Nante, Manzato, & Sergi, 2015). An epidemiological study published that 5% 
of older persons over the age of 65 had AF and at least three chronic conditions (Barnett et al., 
2012). A recent review of the literature found significant physical and mental impairments 
affecting quality of life in older adults with AF compared to the general population (Zhang, 




from AF, morbidity and mortality compared to their younger counterparts (Bereznicki et al., 2006; 
Hobbs et al., 2016).  Based on these needs, chronic AF management programs should specifically 
target the frail elderly as a population to reduce their higher risk of preventable stroke as compared 
to the general population (Barnett et al., 2012; Bereznicki et al., 2006; Ciervo et al., 2012).  
The long-standing standard of care in Canada for persons with chronic non-valvular AF is 
to provide long term oral anticoagulation therapy (OAT) with an inexpensive drug called warfarin, 
a vitamin K antagonist (VKA) to reduce blood clots and prevent stroke (Bereznicki et al., 2006; 
Skanes et al., 2012; Young et al., 2011) . Warfarin has been used as the main therapeutic option 
for its widespread availability and long-term efficacy in stroke prevention for persons with non-
valvular AF, reducing the risk of stroke by two-thirds (Bereznicki et al., 2006; Ciervo et al., 2012; 
Phillips & Ansell, 2008). Warfarin use has been steadily increasing up to about 10% per year due 
to an aging population and the increasing prevalence of AF (Bereznicki et al., 2006; Ciervo et al., 
2012). Typically, older persons with AF have a higher risk of stroke and bleeding, and when 
coupled with frailty, geriatric assessments are required before prescribing warfarin therapy 
(Uchmanowicz et al., 2015). Studies have shown that frail elderly persons were less likely to 
receive anticoagulation therapy despite the clear indication of AF (Chen et al., 2012; Maes et al., 
2014; Perera, Bajorek, Matthews, & Hilmer, 2009). Chen et al. (2012) identified that frail older 
adults who had difficulty obtaining necessary health care were less likely to receive anticoagulant 
therapy. Maes et al. (2014) discovered that the use of aspirin by frail older adults with AF was the 
strongest predictor of warfarin underuse, regardless of the risk of stroke and bleeding. The authors 
suspected that patients were using aspirin to prevent AF-related stroke or “underlying 
cardiovascular ischemic disease,” despite the evidence that long-term OAT was more effective. 




therapy in older adults (Maes et al., 2014). Perera et al. (2009) speculated that OACs were not 
recommended to frail older persons with AF because of potential issues with cognition and daily 
activities to control INR values (Perera et al., 2009).  
Another study revealed that poor compliance and suboptimal clinical condition, such as a 
history of hemorrhages, a risk of falls, physical disabilities and dementia, contributed to the 
decreased use of oral anticoagulation (OAC) as a treatment option in the very elderly (Lotze et al., 
2010). This high risk population, as seen in one study, had a 70% rate for the use of anticoagulants, 
compared to other studies that ranged from 35-65%; it also revealed potential barriers of 
prescribing OAC to elderly patients aged 80 years and older, including risk of stroke, bleeding and 
frailty  (Lefebvre et al., 2015). A recent observational study further reported that the myriad of 
medical and functional disabilities in the frail elderly with AF was a negative predictor of 
adherence to anticoagulation therapy, rather than mild cognitive impairment (Horstmann et al., 
2015).  However, a position paper by an expert panel for optimal stroke prevention in the geriatric 
patient agreed that OAT should be recommended, despite the fear of adverse events due to the 
complex patient profile, such as comorbidities, polypharmacy and bleeding events from falls 
(Bahrmann et al., 2015). The risk of falls in elderly people is usually perceived as a 
contraindication to warfarin therapy, despite evidence that the benefits outweigh the risks (Cheng 
& Fung, 2007; Heckman & Braceland, 2015). Persons aged 65 and older would have to fall 295 
times per year to make OAT riskier than beneficial to this high-risk population (Cheng & Fung, 
2007). In determining treatment for older people, clinicians should do comprehensive assessments, 
such as the CHADS2 and HAS-BLED scores for stroke and bleeding risks, as well as the Mini 
Mental State Examination for cognitive decline to determine appropriateness of warfarin therapy 




Comprehensive assessments for therapy are important because of warfarin’s high risk-
benefit profile. Warfarin is difficult to manage because of its variable dosing regimen to meet a 
narrow therapeutic range; its complications arising from interactions with diet, co-morbidities, age, 
and other factors; and poor patient-provider communication during therapy (Ciervo et al., 2012; 
Fang et al., 2009; Phillips & Ansell, 2008). A recent study revealed further risks for older patients 
with AF treated with long-term warfarin therapy because of their higher rates of all dementia types, 
including Alzheimer’s disease than older patients with other indications (Bunch et al., 2016). 
Having high quality OAT management makes the difference in reducing these risks. In routine 
medical care, OAT management is led by physicians, and often described as inconvenient and 
time-consuming. Usual care requires regular doctor visits, a time lag between INR laboratory 
testing and follow-ups, and frequent ad-hoc dose adjustments to prevent adverse outcomes. These 
are challenges that can affect older patients more often than their younger counterparts (Bereznicki 
et al., 2006; Decker et al., 2012; Young et al., 2011).  As a result, such relatively disjointed 
management leads to INR levels that deviate from the therapeutic range, suboptimal 
anticoagulation and an increased risk of hemorrhage and stroke (Ciervo et al., 2012; Fang et al., 
2009).   
As a result of these complications, new oral anticoagulants (NOACs) with fixed doses have 
been developed and appear to offer more convenience than warfarin with similar efficacy in 
reducing clinical outcomes for older adults with AF (Grander & Armaganijan, 2012; Hart et al., 
2012). NOACs require significantly less monitoring because they have fewer interactions with 
other drugs, a faster mechanism of action, and more predictable pharmacokinetics and 
pharmacodynamics than warfarin (Bauer, 2013). However, questions remain about whether 




achieved during high quality anticoagulation management (Trusler, 2014). NOACs are costly and 
clinically proven antidotes for overdose are still difficult to access, which may cause major 
hemorrhages, whereas warfarin overdose is easily reversed with Vitamin K (Bauer, 2013; Trusler, 
2014). Recently, the U.S. Food and Drug Administration approved Praxbind as the first reversal 
agent for Dabigatran, a NOAC which acts as a direct thrombin inhibitor (FDA, 2015); however, 
that still brings into question the safety of using other NOACs, i.e., direct factor Xa inhibitors: 
Rivaroxaban, Apixaban and Edoxaban, that were approved for therapeutic use without clinically 
proven antidotes (Project On Government Oversight, 2015). There is currently no effective 
antidote to reverse the effects of anticoagulation by direct factor Xa inhibitors because studies have 
not yet found a reliable pathway to neutralize the anticoagulant activity of these NOACs (Sarich 
et al., 2015).  
Although clinical studies on reversal agents for the remaining NOACs are underway, the 
current use of NOACs without an effective reversal agent can increase morbidity and possibly 
mortality, especially if there is an expected risk of bleeding (Bauer, 2013; Harper, 2012). A cohort 
study showed that dabigatran use was associated with a higher risk of major lower gastrointestinal 
bleeding than warfarin use in clinical care (Villines et al., 2015). Other concerns for NOAC use in 
elderly persons with AF include the unknown interactions with foods and drugs (Stollberger & 
Finsterer, 2013).  Further concerns for NOAC dosing are in special populations, such as frail 
persons with multiple conditions such as renal dysfunction, causing drug accumulation; persons 
with extremes of body weights, such as morbid obesity or very low body weight; and medication 
non-adherence, especially in the absence of routine coagulation monitoring (Bauer, 2013; 
Bauersachs, 2012). As a result, Granziera et al. (2015) suggested an algorithm that focused on 




example, frail elderly patients with AF who have high adherence and severe renal/liver impairment 
would benefit from VKAs, whereas those with a risk of falls, mobility issues and polypharmacy 
would benefit from NOAC use (Granziera et al., 2015).  A recent retrospective study showed that 
dabigatran use in elderly patients with non-valvular AF and a history of fractures had a 
significantly lower risk of osteoporotic fractures than warfarin (Lau et al., 2017). However, this 
significant risk of osteoporotic fractures was not true for older adults with AF and without a history 
of fractures (Lau et al., 2017; Misra et al., 2014). Dependent on the clinical situation, tailored oral 
anticoagulation regimens using either VKAs or NOACs can prevent stroke and bleeding risks in 
the frail elderly population. However, there are still concerns over the long-term effects of NOAC 
use because they are not as well studied as warfarin,, which have been widely prescribed over 50 
years with an approved reversal agent and little long term effects on organs and physiological 
systems (Bauer, 2013).  
Despite warfarin’s high risk-benefit ratio, the complications are mitigated by optimal 
management and delivery of OAT (J. E. Ansell, 2009) . Optimal management of OAT can be 
provided to patients through specialized anticoagulation management services (AMS) in 
outpatient settings, such as FHTs and community pharmacies (J. E. Ansell, 2009).  It has been 
shown that pharmacist-led AMS clinics were as effective or better than usual care led by GPs 
(Canadian Agency for Drugs and Technologies in Health, 2012). AMS programs in primary care 
settings follow a multi-disciplinary and collaborative approach, which  has been shown to 
improve health outcomes for patients with chronic diseases such as AF (Wagner et al., 2001). 
Wider implementation across community-based AMS settings requires a coordinated, systematic 




Specifically, Garcia et al. (2008) established a practical consensus-based guideline of 9 
key recommendations to optimize delivery of OAT in all outpatient settings: (1) Qualifications 
of Personnel, (2) Supervision, (3) Care Management and Coordination, (4) Documentation, (5) 
Patient Education, (6) Patient Selection and Assessment, (7) Laboratory Monitoring, (8) 
Initiation and Stabilization of Warfarin Therapy, and (9) Maintenance of Therapy. Garcia et al.’s 
(2008) recommendations for optimal OAT delivery can provide more consistent care for patients 
with AF, particularly the elderly who have specific characteristics that make them more 
vulnerable to adverse events and complications (Bereznicki et al., 2006; Heckman & Braceland, 
2015).  The elderly are at higher risk for AF-related stroke, bleeding, but also of frailty 
syndrome, the latter of which in turn reduces their likelihood of receiving OAT (Lefebvre et al., 
2015). Therefore, chronic OAT management should be delivered systematically in wider 
community settings and target frail elderly with AF to make services accessible, coordinated and 
consistent.  
Although these recommendations are identified in the literature, their implementation in 
community practice remains a challenge. In order to inform future implementation research, this 
study will first explore the clinicians’ perceptions on implementing such recommendations in 
community practice. Then other studies may use this assessment of how various factors affect 
implementation and consider intervention in actual practice. To date, there is limited qualitative 
research on these perceptions for implementation, especially in the community and in the context 
of a frail elderly population. This study will, therefore, use a theoretical framework to explore the 
clinicians’ perceptions on how different factors influence the implementation of the 




on a theory-based assessment of clinicians’ perceptions of the implementation process, which will 
help inform future studies on interventions of a wider and more uniform approach to OAT.   
1.2 Research Objectives  
This qualitative, exploratory study aims to explore and describe the perceptions of 
pharmacists and nurses on the uptake or not of Garcia et al.’s (2008) nine key recommendations 
in AMS clinics within the WWLHIN community for a frail elderly population. Specifically, the 
research objective is to use Michie et al.’s psychological theory:  
(1) To explore and describe how existing intrinsic and extrinsic factors hindered or 
supported the delivery of optimal OAT management, per the Garcia et al.’s (2008) clinical 
guideline, in a frail elderly population.   
 (2) To discover, describe and identify how behavioural changes facilitate the delivery of 




2  CHAPTER 2: LITERATURE REVIEW  
2.1   Oral Anticoagulation Therapy  
 Vitamin K antagonists (VKAs) were discovered in 1939 by Schofield after examining 
spoiled sweet clover consumed by cattle with hemorrhagic disease. In the 1900s, several scientists 
revealed the link between VKAs and oral anticoagulation, and described the prothrombin time 
assay for measuring how blood clots in vitamin K deficient animals; this assay became the 
mainstream method for tracking oral anticoagulation therapy (OAT). Vitamin K was known to aid 
the synthesis of coagulation factors, in which VKAs opposed clotting of the blood (J. E. Ansell, 
2009). In the 1940's, a biochemist named Link investigated the cause of bleeding disorders in these 
cows and then synthesized a class of VKAs called coumarin compounds, specifically dicumarol 
for its first use in humans at the Mayo Clinic. Dicumarol’s pharmacokinetic and pharmacodynamic 
properties could then form a related coumarin compound called warfarin sodium. At this time, 
warfarin became an effective widespread rodenticide. It was not until the 1950s that scientists 
started to perform experiments with warfarin as a suitable oral anticoagulant in humans. After 
President Dwight D. Eisenhower's heart attack in the mid-1950s, warfarin became a more 
widespread human oral anticoagulant in North America to treat thromboembolism in the 
cardiovascular system (J. E. Ansell, 2009). 
2.1.1 Cardiovascular Indications for OAT with Warfarin 
 The most common cardiovascular indications for OAT with warfarin are chronic atrial 
fibrillation (AF), prosthetic heart valves, venous thromboembolism (VTE), and acute myocardial 
infarction (Bereznicki et al., 2006; Canadian Agency for Drugs and Technologies in Health, 2014; 
Hirsh, Fuster, Ansell, & Halperin, 2003). AF is the most common cardiac rhythm disorder, and it 




OAT reduces the risk of thromboembolism related to AF as a primary and secondary prevention 
(Bereznicki et al., 2006; Hirsh et al., 2003). High risk patients with AF show a larger absolute risk 
reduction in stroke rates using adjusted-dose warfarin than aspirin. High risk patients are generally 
defined as those with prior thromboembolism or stroke, hypertension, diabetes mellitus, aged > 65 
years, coronary arterial disease, and poor ventricular function (Bereznicki et al., 2006; Hart & 
Halperin, 1999; Hirsh et al., 2003) . According to the Canadian Cardiovascular Society (CCS) 
guidelines, the CHADS2 scoring schema should be used to estimate stroke risk: Congestive Heart 
Failure, Hypertension, Age, Diabetes, Stroke/Transient Ischemic Attack (2014). Generally, the 
CCS recommends that patients with AF should receive OAT if ≥ 65 years of age or CHADS2 score 
of ≥1 (Verma et al., 2014). Typically, warfarin is adjusted to achieve an optimal INR of 2.0 to 3.0 
for most patients with AF, although low initiation dosing, careful monitoring and education are 
particularly important for elderly patients (Canadian Agency for Drugs and Technologies in 
Health, 2012; Hirsh et al., 2003). Clinical OAT systems should improve to provide patients access 
to better care and health outcomes to balance the high risk/benefit profile of warfarin (J. E. Ansell, 
2009). VTE and AMI are two other cardiac indications for the therapeutic use of warfarin to 
prevent embolic events, and stroke, recurrent infarction or mortality, respectively (Bereznicki et 
al., 2006).  
Although clinicians prescribe OAT for these cardiovascular indications, they need to 
balance the benefits with the risks by administering the appropriate drug intensity to stay within 
the therapeutic range. Warfarin is characterized with a high risk-benefit profile because of these 
characteristics: (1) a narrow therapeutic index, making it difficult to precisely manage medication 
dosage for an accurate therapeutic response; (2) OAT complications influenced by user 




intensity due to poor provider-patient communication during therapy (J. E. Ansell, 2009).  For 
these reasons, health care professionals need to reduce the risk/benefit profile by ensuring the 
quality of OAT and its optimal management for patients.  
2.1.2 Quality of Oral Anticoagulation Therapy   
A study by Phillips and Ansell describes that parameters of high-quality anticoagulation 
management must achieve, and measure efficacy and safety of warfarin therapy. Elements that 
measure efficacy of stroke prevention include appropriate therapy initiation and maintenance of 
therapeutic anticoagulation as measured by time in therapeutic range (TTR); management of 
suboptimal INR scores; and management of peri-operative dosing. A major parameter used to 
assess the efficacy of OAT management is the time in which the international normalized ratio 
(INR) is in the therapeutic range (Phillips & Ansell, 2008). INR scores are based on prothrombin 
time that measures the time that blood takes to clot when added to a mixture of thromboplastin and 
calcium (Medical Advisory Secretariat, 2009). Health care professionals in a variety of settings, 
such as private practice, family health teams or hospitals, need to manage OAC dosages through 
regular blood tests to keep INR scores within the therapeutic range (Trusler, 2014). Patients within 
the INR range of 2.0 to 3.0, for example, takes 2 to 3 times longer for their blood to clot than the 
average healthy person, resulting in less clotting when blood is stagnant in the fibrillating atrium. 
Therefore, the time that a patient is within this target range is ideal in determining anticoagulation 
adequacy, which becomes important because it is inversely related to major patient outcomes of 
hemorrhage, stroke and mortality (Dlott et al., 2014; Trusler, 2014). TTR is calculated using the 
Rosendaal method to measure the percentage of the time that a patient’s INR is within the target 




how close these INR values cluster within the target range, in which a smaller variation results in 
fewer strokes and hemorrhages (Trusler, 2014).   
Furthermore, the safety of warfarin therapy is achieved by proper management of 
suboptimal INR scores and patient education with competent and qualified staff (Phillips & Ansell, 
2008). INR scores outside the therapeutic index may lead to adverse events, such as hemorrhages 
or strokes; therefore, therapeutic intensity must be precisely maintained to accommodate the 
patient characteristics that affect OAT and management (J. E. Ansell, 2009). Another aspect of 
OAT safety is to ensure adequate patient education. Patient education is supported by Fang et al., 
a study that encourages clinicians to have clear public health communication strategies while 
counseling patients who are taking warfarin for stroke prevention; this priority for communication 
can engage and support patients on long-term warfarin therapy to recognize the early signs and 
symptoms of stroke to prevent adverse events (2009). As well, using scales such as the 
SAMeTT2R2 score to measure the likelihood of successful warfarin therapy, along with medical 
details from updated records, and in a setting that promotes  inter-professional communication and 
collaboration, can help determine if a patient should start oral anticoagulation therapy (J. E. Ansell, 
2009; Apostolakis, Sullivan, Olshansky, & Lip, 2013). Ultimately, incorporating elements of high-
quality anticoagulation management is important in achieving efficacy and safety during OAT.  
2.1.3 Optimal Oral Anticoagulation Therapy using AMS vs. Usual Care 
The routine medical care for patients on OAT is usually managed by primary care 
physicians who also attend to other patients in their clinical practices (J. E. Ansell, 2009). Optimal 
management of OAT can be provided to patients through specialized anticoagulation management 
services (AMS), such as anticoagulation clinics in hospitals, primary care settings and community 




This structure provides a practical and coordinated approach with a specialized system to track, 
follow up and educate patients about their care (J. E. Ansell, 2009). Nurses (practical and 
registered), pharmacists and/or physician assistants usually manage OAT under the direction of a 
single physician in the program or a referring primary physician. The basic characteristics of an 
AMS include (1) active management, (2) high competency in OAT as the primary responsibility, 
(3) organized follow-up system, (4) rapid and reliable monitoring of INR scores, and (5) ongoing 
patient education and communication with the provider (J. E. Ansell, 2009).   
These characteristics of an AMS are similar to the principles of a chronic disease 
management (CDM) model. A CDM model comprises of patient-centered care that is multi-
disciplinary, sustainable by the patient, coordinated across networks and providers, and rooted in 
evidence-based care. It relies on the physician’s expertise and leadership in chronic disease care 
(Scott, 2008). Therefore, it thrives in primary care settings, such as family health teams (FHTs) 
because the success is attributed to the fact that majority of patients with chronic diseases receive 
care from their primary care physicians (e.g. 90% of diabetic patients are cared for by their GPs) 
(Rothman & Wagner, 2003). In FHTs, family physicians or pharmacists can provide warfarin 
therapy to patients with AF through usual care (laboratory testing) or a point-of-care testing 
(POCT) model, which is as effective for anticoagulation control as usual care (see section 1.2). 
Clinical pharmacists in FHTs work closely with family physicians to act as the front-line staff to 
the patient's health issues, providing an opportunity to build rapport with patients.  Especially with 
older adults who have more health complexities, there is much to gain with personalized 
knowledge of their social and health patterns to help address potential risk factors that might 
exacerbate warfarin therapy. Evidently, there is the link between the importance of chronic disease 




vulnerable population such as the frail elderly. This is a population that needs the most care due to 
potential for quick decline if a health problem occurs. AMS clinics are essentially applying 
components of the CDM framework which have been tailored for OAT management of patients 
with the chronic disease, AF.  
A systematic review indicates that specialized AMS yield higher TTR than usual care by 
physicians in their practice (Canadian Agency for Drugs and Technologies in Health, 2012). Even 
with the CHEST guidelines for warfarin management, patients managed by usual care were found 
to be sub-optimally treated in a study (Samsa et al., 2000). Therefore, several studies supported 
that a pharmacist-led anticoagulation clinic with evidence-based protocols and venipuncture had 
significantly better INR control than usual care (Young et al., 2011). Another study goes further 
to mention that an interdisciplinary approach between pharmacists and physicians in a primary 
care setting can improve INR control and reduce thromboembolism rates as compared to usual 
care (Bungard et al., 2009).  Ansell (2009) presents evidence on the rates of major hemorrhage and 
thromboembolism from several retrospective and prospective trials of usual care vs. AMS, 
reporting that OAT managed by AMS had better patient outcomes than usual care by physicians. 
Although there were variable results for INR control between pharmacists and physician-led 
anticoagulation management (Young et al., 2011), the advent of technology with a POCT model 
can improve anticoagulation therapy management via convenience for INR testing, follow-up and 
dose adjustments. This model of care enhances patient satisfaction, allows clinicians to make 
timely decisions for care, provides savings to the health care system, and improve clinical 
outcomes (Canadian Agency for Drugs and Technologies in Health, 2014; Davidson, Lindelof, 
Wallen, Lindahl, & Hallert, 2015; Franke, Dickerson, & Carek, 2008; Mifsude, Azzopardi, & 




A POCT model typically includes a hand-held device such as the Coaguchek XS™ for 
rapid and reliable diagnostic testing via a finger prick sample (Medical Advisory Secretariat, 2009; 
Trusler, 2014; Wurster, 2009). INR results are obtained shortly afterward on the device for health 
care provider to manage warfarin dosing; therefore, helping patients to stay within their ideal INR 
range and reduce the onset of hemorrhages or strokes. POCT can also include computerized 
decision support software, such as INR Online™ and Posologic™ that can tabulate INR results 
and calculate TTR to help keep records of patient information and INR readings for future 
assessments and accurate follow-ups (Medical Advisory Secretariat, 2009; Trusler, 2014). INR 
Online™ also has a built-in dosing algorithm for warfarin for clinicians to adjust suboptimal INR 
scores. In a recent audit, it has been shown that clinicians who closely followed the algorithm had 
better anticoagulation control than those who overrode the decision-support software (Harper, 
Harper, & Hill, 2014). Furthermore, the use of a simple algorithm to adjust warfarin dosages in 
the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial predicted better 
TTR and accounted for TTR variations between comparison centers and countries (Spall et al., 
2012). 
It has been shown that POCT is a viable model for improving INR scores in the therapeutic 
range when managed by physicians (Franke et al., 2008). Other studies have shown nurse-led 
anticoagulation management is similar to physician-led care (Davidson et al., 2015; Levine, Shao, 
& Klein, 2012) and slightly better control when led by pharmacists who act under the authorization 
of physicians (Bungard et al., 2009; Young et al., 2011).  Shaw et al. demonstrated a strong support 
by patients and primary care practitioners for a pharmacist-led POC-testing anticoagulation 
management program that requires strong interprofessional relationships in the community for 




communication between health care professionals as a significant contributor to improving 
warfarin management in the community (2007).  
2.1.4 Cost-Effectiveness of Oral Anticoagulation Management Services  
 Experts from the American College of Chest Physicians (ACCP) advise that the delivery 
of OAT be systematic and coordinated with procedures for patient education, communication 
and the INR testing process (J. Ansell et al., 2008).  Anticoagulation management services 
(AMS) allow this type of approach to happen in clinical settings because they are specialized in 
providing oral anticoagulation with key functional features. The literature reveals that the cost-
effectiveness of AMS vs. usual care is rooted in the cost savings from reduced number of 
adverse events and reduced hospitalizations. Eckman and colleagues estimated that the average 
annual cost of hospitalizations for patients using AMS versus usual care was due to a lower 
incidence of adverse events, such as thromboembolism and major bleeding (Eckman, Levine, & 
Pauker, 1995). Similarly, another study performed an economic analysis for 1000 patients of 
atrial fibrillation on warfarin therapy, estimating a cost savings of $0.8 million for patients using 
AMS compared to usual care; the majority of the cost difference was accounted for by the 
reduced incidence of adverse events in the AMS model of care (Campbell, Radensky, & 
Denham, 2000). J. E. Ansell also revealed four studies that showed the cost/benefit ratios of 
AMS vs. usual care, favoring the former model of care (2009). On average, a significant cost 
saving $1000 per patient-year could be achieved from reduced hospital admissions for major 
complications through coordinated care in AMS (J. E. Ansell, 2009).  
2.1.5 Oral Anticoagulation Therapy in Community-Dwelling Frail Elderly 
Frailty is a multidimensional term with no consensus on its definition, but it usually occurs 




stressors to affect physiological systems (Heckman & Braceland, 2015). Frailty is usually 
associated with a higher risk for adverse outcomes, hospitalization and death. The clinical frailty 
scale is commonly used to identify frailty syndrome (Uchmanowicz et al., 2015). As well, frailty 
in older adults with AF is known to reduce the likelihood of being prescribed OAT (Uchmanowicz 
et al., 2015). In an article by Lefebvre et al., octogenarians that received the highest probability of 
anticoagulation therapy were characterized with higher thromboembolism risk, lower bleeding 
risk, and a lower frailty score (2015). Studies have shown the appropriate initiation protocol for 
warfarin therapy in an inpatient and outpatient geriatric population; however, a study reports that 
frailty was a major negative predictor of OAC to AF patients over 70 years of age (Perera et al., 
2009; Uchmanowicz et al., 2015). However, there seems to be a misconception that confounds 
frailty with increased chronological age, which may lead some health care providers to believe 
that all older adults have a complex profile. This confusion about frailty may contribute to OAC 
under-prescription to older adults over the age of 75 (Heckman & Braceland, 2015).  A review of 
the quality indicators for the care of vulnerable elders for stroke and atrial fibrillation supported 
evidence that those with medium to high risk, according to the CHADS2 score of 2 or more, and 
without any contraindications should be recommended warfarin to reduce the risk of 
thromboembolism and bleeding with the INR range of 2.0 to 3.0 (Cheng & Fung, 2007). Although 
intracerebral bleeds after a fall was a long-standing major concern for older adults taking OAC, 
eventually, there was evidence supporting that the risk of falls was not a contraindication for OAC 
use (Heckman & Braceland, 2015). Essentially, there is a disproportionate incidence of AF-related 
stroke for frail elderly persons due to their complex patient profile: increasing age, comorbidities, 
polypharmacy, risk of falls, etc. These aspects make frail older adults more prone to poor oral 




such, chronic disease management interventions, such as coordinated long-term AMS, should be 
tailored for the frail elderly because they need intensive intervention for meaningful outcomes.  
2.2 Preliminary Environmental Scan of Local AMS Clinics  
A preliminary environmental scan (see Appendix A) of AMS clinics in the WWLHIN area 
during the Summer of 2015 revealed three possible areas of improvement in coordinated 
anticoagulation care: (1)  the perceived knowledge gaps in the use of clinical tools to optimize care 
for the frail population, i.e., POCT and dosing algorithms (2) the need for IP relationships, 
collaboration, and communication between health care providers of AMS and primary physicians 
to optimize OAT delivery and management; and (2) the need for system integration.  
The perceived knowledge gaps in the use of clinical tools in AMS vs. usual care for 
warfarin therapy management was also mentioned in the literature. A New Zealand survey 
revealed that patients were more concerned with the pharmacist’s knowledge of POC technology 
to manage warfarin therapy than with the physician’s knowledge to make ad-hoc adjustments  
(Shaw et al., 2014). Despite all pharmacists receiving accreditation prior to the study, patients still 
felt that the pharmacists should have more qualifications.  The study revealed that only 60% of 
pharmacists were confident with the computerized decision support system’s dose 
recommendations, whereas 20% were unsure, and 15% were indifferent. This variation in 
confidence showed that not all pharmacists are experienced in warfarin dosing adjustments using 
POCT, thereby creating gaps in perceived knowledge. Pharmacists’ training qualifications should 
be standardized for OAT management by a single regulatory body. This way, patients will be able 
to trust AMS led by pharmacists with the accreditation because they will have the same standard 
of knowledge and training on the use of POCT for OAT management. Despite the absence of such 




on using POCT to offer OAT management.  In a controlled study by Wilson et al. (2004), 
pharmacists were trained to provide high quality warfarin therapy management using POCT, and 
received satisfied responses from patients and pharmacists; however, as the study mentioned, not 
all comparisons using uncontrolled studies had the same quality of care. This aspect makes it more 
likely that pharmacists without the proper certifications will create distrust or dissatisfaction from 
their patients. Therefore, this knowledge gap on the use of clinical tools for OAT management 
should be addressed.  
Furthermore, inter-professional (IP) relationships and communication were improved with 
a pharmacist-led anticoagulation program as shown in Shaw et al. included relationships between 
providers and patients (2014).  Patients felt that pharmacists were communicating with their 
primary physicians on a regular basis to keep their care up to date. However, this IP relationship 
had to be built on the physician’s confidence in the pharmacist’s skills; if not, physicians were 
hesitant to give up their patients to be managed by pharmacists. General practitioners (GPs) were 
concerned with the accountability and uncertainty of responsibility for their patients’ OAT. All 
GPs mentioned that a good relationship with the pharmacists prior to the study is key to entrusting 
them with their anticoagulation patients (Shaw et al., 2014).  
Lastly, it is speculated that a system-integrated approach is necessary for anticoagulation 
management to have a seamless transition between institutions (e.g. hospitals and convalescence 
homes), and between community clinics (e.g. family health teams, private family doctor offices 
and specialized AMS). A review showed that communication and coordination of care between 
various health care settings (e.g. outpatient to emergency; or acute to long-term care) was essential 
for reducing the risk of stroke or bleeds in patients with AF taking anticoagulants (Deitelzweig, 




documented for appropriate care in transition between health care settings. OAT management 
relies on parameters associated with high-quality anticoagulation management as described by 
Phillips & Ansell (2008).   In order to accomplish this high quality management in the clinical 
setting, a set of recommendations was developed to optimize delivery of OAT (Garcia et al., 2008). 
Hence, the investigators will explore the perceptions of clinicians who work in AMS clinics on the 
effective implementation of these recommendations to improve the delivery of OAT in outpatient 
settings.  
2.3 Recommendations for Delivery of Optimized OAT in all Outpatient Settings  
 Garcia and colleagues provides a practical consensus-based guideline for delivering 
optimized OAT in all outpatient settings, which comprises of health care professionals proficient 
in AMS. The guideline describes 9 key recommendations as a guideline for delivery optimized 
OAT in all outpatient settings, including (1) Qualifications of Personnel, (2) Supervision, (3) Care 
Management and Coordination, (4) Documentation, (5) Patient Education, (6) Patient Selection 
and Assessment, (7) Laboratory Monitoring, (8) Initiation and Stabilization of Warfarin Therapy, 
and (9) Maintenance of Therapy. The following will describe each recommendation in detail. 
(1) Qualifications of Personnel 
Licensed health care professionals (e.g. pharmacist, nurse) who are trained in patient-oriented 
care should receive additional certification from formal anticoagulation management training 
programs (Garcia et al., 2008) . In the United States, the National Certification Board of 
Anticoagulation Providers certifies US health care professionals with expertise in OAT based 
on the core competencies in the following domains: applied physiology and pathophysiology 




applied pharmacology of antithrombotic agents (NCBAP, 2014). Garcia et al. lists 4 other US 
training programs (2008).  
On the contrary, Canada does not have a national board to certify anticoagulation 
providers; however, there are organizations such as the Canadian Council On Continuing 
Education in Pharmacy that provide OAT management for Pharmacists (CCCEP, 2008).  
University of Waterloo in partnership with the School of Pharmacy and the Centre for Family 
Medicine also offers a professional Management of Oral Anticoagulation Therapy (MOAT) 
Primary Care Certification Program for pharmacists, registered nurses and nurse practitioners 
to gain effective competency and management under a medical directive. This program has 
an online component and three site visits with evaluations of the participants by the 
instructor, a pharmacist named Dr. Jeff Nagge (University of Waterloo, 2015).  
(2) Supervision 
A “collaborative practice agreement” outlining administrative details, such as job duties, 
daily responsibilities and accountability is imperative (Garcia et al., 2008). AMS practice 
guidelines are published to guide staffing of AMS providers (Nutescu, Earl, & Oertel, 2009). 
(3) Care Management and Coordination 
Timely care management and coordination with all stakeholders of ACM is dependent on 
clearly established and up-to-date policies and procedures in the organization. The individual 
in charge of the AMS should widely disseminate these approved policies and procedures to 
all individuals involved in the patient’s therapy. These written protocols to deal with typical 
issues during routine visits in the clinic should be available for review by all personnel. Clear 
communication between stakeholders in anticoagulation management can ensure better 




procedures are currently available to all clinicians (Nutescu et al., 2009). CHEST guidelines 
also provide policies and procedures on managing OAT for practical dosing, non-therapeutic 
INRs, invasive procedures, adverse events, models of care and special situations  (J. Ansell et 
al., 2001) 
(4) Documentation 
Documentation in a standardized way is vital for improving quality of data. Computer 
software programs, such as INROnlineTM and PharmaFileTM can document, analyze and 
retrieve patient data. There are other software products, such as DAWN AC, CoagCare, 
CoagClinic, CoaguTrak, etc. There are many benefits of computerized databases: improved 
data storage, tools for data analysis, dosing algorithms, automated interventions, and data 
transfer via electronic interfaces(Oertel, 2009). This record-keeping system tracks patients’ 
information, such as demographic, treatment, communication processes, and miscellaneous 
data (e.g. complications, missed appointments, other laboratory values and invasive 
procedures) (Garcia et al., 2008).  
(5) Patient Education 
Enhancing individualized patient and caregiver education can improve patient safety while 
on warfarin therapy. There are various ways to impart knowledge: audio-visual resources, 
face-to-face interactions and written materials. Knowledge assessment tools can help make 
these sources of knowledge more appropriate for individual patients, e.g. assess written 
materials at the correct reading level, or materials in native language, etc. (Garcia et al., 
2008). Effective patient education needs to be tailored to the diverse patients receiving 
warfarin, giving considerations to potentially low health literacy, limitations from cognitive 




requiring OAT. Examples of patient educational materials are published to improve patient 
understanding of their therapy at baseline visits. These components include knowing the 
medication, importance of adherence, common adverse reactions (i.e. minor bleeding) and 
interactions (e.g. with acute illnesses), diet restrictions (i.e. to avoid foods high in vitamin K 
content and excessive alcohol intake), and disease management of symptoms (Shapiro, 
2009).  
(6) Patient Selection and Assessment 
Clinicians should consider the appropriateness of OAT based on patients’ individual risk and 
benefit profiles. Evidence-based guidelines are published for clinicians to assess and 
periodically reassess the patient’s suitability for OAT (January et al., 2014; Nishimura et al., 
2014; Verma et al., 2014; You et al., 2012). For example, the Canadian Cardiovascular 
Guideline reports that OAT should be recommended to older patients with an appropriate 
indication such as AF.  The CHADS2 (Congestive Heart Failure, Hypertension, Age, 
Diabetes, Stroke/Transient Ischemic Attack) score assesses the yearly risk of 
thromboembolism related to AF, whereas the HAS-BLED (Hypertension, Abnormal liver or 
kidney function, Stroke, Bleeding, Labile INRs, Elderly, Drugs) score assesses the risk of 
bleeding (Verma et al., 2014). Frailty should also be considered in warfarin therapy using 
assessment tools, such as the clinical frailty scale, because older adults with frailty syndrome 
have an increased chance of scoring higher on the CHADS2 and HAS-BLED scales that 
interfere with INR monitoring and thus require closer monitoring (Uchmanowicz et al., 
2015). A comprehensive medical history should also be taken into account at the initial visit 
to assess all risk factors that influence the patient’s therapy: medical, social, psychological, 




(7) Laboratory Monitoring  
Regular monitoring of anticoagulation therapy should be done using prothrombin time 
testing of laboratory plasma samples (venipuncture), or whole blood samples (finger prick) 
on point-of-care devices (Garcia et al., 2008). Both methods of testing are shown to be 
equally acceptable for reporting INR scores  (Plesch et al., 2008; Yelland et al., 2010). A list 
of point-of-care devices available in the market for INR testing is published (Wurster, 2009).  
(8) Initiation and Stabilization of Warfarin Therapy 
Initiation of anticoagulation therapy aims at reaching the lower limit of the therapeutic INR 
range in a timely manner (Wittkowsky, 2009).  Initial dosing should be based on evidence-
based guidelines to reach this range within an appropriate timeframe (ACCP, 2012; J. Ansell 
et al., 2008; Holbrook et al., 2012; Lastoria et al., 2014; Sridhar, Leung, Seymour, & Nagge, 
2014). Patient-specific factors, such as age, weight, height, comorbidities and drug-drug 
interactions should be considered by clinicians who determine starting doses of warfarin 
therapy (Garcia et al., 2008). The recommended initial dose is between 5mg and 10mg daily 
for the first 1-2 days for patients without sensitivity to warfarin, but more recent guidelines 
favors 10mg daily for the first 2 days (J. Ansell et al., 2008; Holbrook et al., 2012). 
Otherwise, it is recommended that initial doses are less than 5mg if there are factors to 
increase sensitivity to warfarin (J. Ansell et al., 2008). Sridhar et al. reported that a safe 
initiation dose of 4mg daily for 3 days could achieve a therapeutic INR range in a timely 
matter (2014). Regardless of the loading dose, INR monitoring should be done after 2 to 3 
initial doses at least 2 to 3 times weekly until INR stabilization (J. Ansell et al., 2004; J. 
Ansell et al., 2008; Wittkowsky, 2009). Depending on the INR response, subsequent dose 




lower limit of the therapeutic range. These dose adjustments can be done empirically or 
through published dosing nomograms (Wittkowsky, 2009).   
(9) Maintenance of Therapy 
Maintenance therapy aims at stabilizing the long term dosage (Wittkowsky, 2009). A 
systematic approach using evidence-based guidelines should be used for the maintenance of 
therapy (J. Ansell et al., 2008; CADTH, 2016; Holbrook et al., 2012).  CADTH outlines a 
structured management plan that considers ongoing patient assessment, dose adjustments and 
follow-up testing (2016).  Patients with consistently stable INRs, i.e., stable for at least 3 
months, are recommended to receive follow-up testing every 4 weeks, but recent guidelines 
recommend patient follow up can occur every 12 weeks instead (Holbrook et al., 2012). 
Validated algorithms for dose adjustments to improve delivery of OAT (Harper et al., 2014), 
but evidence-based guidelines should be used to deal with extreme INR values (Garcia et al., 
2008).  
2.4 Research Addresses Gap in Literature  
The literature depicts limited qualitative research on anticoagulation management as seen 
in table 1 (see Appendix B). The majority of these studies performed interviews without an 
underlying framework, using inductive data analysis to probe health care providers on 
anticoagulation management, patient-provider satisfaction and perceived barriers/ facilitators. This 
type of analysis is useful in obtaining emerging themes from the participants to learn more about 
a less known problem, but it has limitations on exploring a more comprehensive list of factors that, 
for example, are detailed in theories to influence implementation research. For example, Shaw et 
al.’s study on examining the attitudes of a community pharmacist-led anticoagulation management 




POCT based on many of Garcia et al.’s key recommendations in a community setting (2014). 
However, Shaw et al. used inductive methods to create the data collection tools and to analyze the 
data, whereas this study used a deductive method under a theoretical lens to guide systematic data 
collection and analysis. Michie et al.’s psychological theory has 12 domains of behavior change 
that influences implementation of evidence-based practices, which provided a comprehensive 
guide on topic-specific probes during data collection, and influenced data analysis.  
Shaw et al. (2014) also focused on AMS clinics that incorporated many of Garcia et al.’s 
components, but not for a frail elderly population.  Chronic disease interventions, such as AMS 
clinics are expensive and thus, should be run efficiently to be cost-effective. This means that AMS 
clinics should be standardized to follow key components for optimal OAT delivery and tailored 
for those, like the frail, who need intensive intervention to achieve meaningful clinical outcomes. 
As such, this study can contribute knowledge to a limited literature of implementation research 
using theory. Specifically, this study will report the perceptions of pharmacists and nurses on the 
implementation of Garcia et al.’s consensus-based guideline for optimized OAT delivery using a 
theoretical framework, such as psychological theory to systematically understand the factors for 
implementation in practice. These data can contribute to the knowledge of theory-based 
implementation interview techniques to understand the influences on health care professional 
behaviour. The key themes that result from this study can be used to inform further development 
of implementation research by helping clinicians identify, address and improve any issues upon 







2.5 Significance of Research 
The literature shows that AMS is a coordinated, cost effective approach that can reduce 
hospitalizations and other medical expenses related to complications of warfarin therapy (J. E. 
Ansell, 2009). Despite its success, there is limited research on how to integrate a wider and 
systematic approach to OAT management in community AMS clinics. This study sought to 
understand how various factors affected the uptake or not of a clinical guideline to optimize 
OAT management within the WWLHIN community. The region can use this data to consider 
how to develop or refine the components of AMS clinics across the community to successfully 
integrate a wider and more systematic approach to OAT management.   
Wider implementation of standardized AMS clinics can make the government realize the 
potential health care savings on a larger scale, especially for managing chronic AF in vulnerable 
populations like the frail elderly. Cost savings may be gauged through measuring anticoagulation 
benchmarks, such as adverse events and hospitalizations, to show as evidence to secure reliable 
funding. As a result, these AMS clinics may gain more consistent funding from the government to 
continue services in the future. In 2012, the Ontario Ministry of Health and Long Term Care 
recognized the potential benefits of POC INR-testing and funded the one-time cost of POC-
monitoring devices in some Family Health Teams in Ontario; however, medical supplies, 
education and training on how to use the device and the support software were excluded (Ministry 
of Health and Long Term Care, 2012).  Hence, funding opportunities could improve with more 
research on how to systematically apply AMS clinics to its full potential for cost savings to the 
health care system. By leveraging existing resources, reducing barriers and recognizing factors 
that facilitate the implementation of a wider approach to OAT management in AMS clinics, this 




ultimately benefit from improved quality of life via positive health outcomes, and the reduction in 
adverse outcomes and complications through coordinated and timely care. Conducting this study 
is a stepping stone toward achieving the aim of wider implementation and consistent funding for 
community AMS clinics serving frail older persons with AF.  In the next chapter, the methods on 





3 CHAPTER 3: METHODS & STUDY DESIGN 
3.1 Introduction  
This chapter presents the objectives of the research and how they are addressed by a research 
approach. In this study, the qualitative research approach to address the research objectives in this 
particular context with several assumptions that guide the collection, analysis and interpretations 
of data (Creswell, 2009). The investigator made the following assumptions in the study: (1) Garcia 
et al.’s (2008) work is a recent clinical guideline for optimizing the delivery of OAT management 
therapy in community AMS settings; therefore, when the guideline is applied in practice, a more 
systematic approach results; (2) Michie et al.’s (2005) psychological theory domains affect the 
behaviour of clinicians to implement the clinical guideline in practice (see section 3.3); and (3) a 
constructivist worldview because the implementation of the clinical guideline is dependent on the 
particular social context in which it is implemented (see section 3.4). The research objectives 
aimed to explore the clinicians’ perceptions of how various factors affected the implementation of 
a clinical guideline for optimal OAT management a community-dwelling frail elderly population. 
A detailed account of the research objectives, theoretical lens and the philosophical world view 
are described in this chapter, as well as the study design and data analysis. To ensure the 
trustworthiness of the data, potential biases of the analysis and ethical considerations are also 
discussed.   
3.2 Research Purpose & Objectives  
The purpose of this qualitative, explorative study was to explore and describe the 
pharmacists and nurses’ perceptions of the implementation of Garcia et al.’s (2008) guideline for 
optimal OAT management in the WWLHIN community, with a particular lens for a frail elderly 




of OAT management in outpatient AMS settings (see section 2.3). These recommendations are 
available in the literature, yet their implementation in community practice remains a challenge.  
Therefore, this study sought to address the following research objectives using the theoretical 
lens of Michie et al.’s (2005) psychological theory (see section 3.3):   
 (1) To explore and describe how existing intrinsic and extrinsic factors hindered or 
supported the delivery of optimal OAT management, according to Garcia et al.’s (2008) 
guideline, with specific emphasis on frail seniors.   
 (2) To discover, describe and identify how behavioural changes facilitate the delivery of 
optimal OAT management, with specific emphasis on frail seniors.   
A qualitative approach using an exploratory design was selected to study meanings in a 
particular context using emerging methods to collect data and interpret underlying patterns 
(Creswell, 2009). In contrast, a quantitative approach, including mixed methods were not suitable 
for addressing the objectives because quantitative research tests theories by examining 
relationships among variables. Instead, the objectives of this study was to gain insights from 
clinicians on how various factors from Michie et al.’s (2005) psychological theory influenced the 
implementation of Garcia et al.’s (2008) clinical guideline to inform future investigations. 
Therefore, a qualitative, exploratory approach guided by an underlying theoretical lens was 
selected to address the research objectives. The next section describes how Michie et al.’s (2005) 
psychological theory was used as the theoretical lens to guide this research.     
3.3 Theoretical Lens: Michie et al.’s Psychological Theory 
In a qualitative study, a theoretical perspective generally helps the investigator orient the 




(Creswell, 2009). Michie et al.’s (2005) psychological theory was the theoretical lens that shaped 
the research objectives and the questions asked (see section 3.5.3) for this study.  Michie and 
colleagues (2005) from the Center for Outcomes Research and Effectiveness in the Department 
of Psychology at the University College London, U.K. adapted psychological theories relevant to 
behaviour and behaviour change to optimize implementation research of evidence-based 
practices (EBPs). These authors conducted a consensus-based approach of a theoretical 
framework among health psychology theorists, health services researchers and health 
psychologists. This group of experts consolidated psychological constructs and theories in three 
areas (motivational, action and organizational) to identify a list of 12 domainsand corresponding 
interview questions for an “integrative framework for studying the implementation of EBP” 
(Michie et al., 2005).  EBP guidelines need to be effectively implemented in practice to achieve 
the best health outcomes. The implementation process largely depends on these 12 domains, 
comprising of intrinsic and extrinsic factors that modify clinician’s behaviours (Michie et al., 
2005).  Underlined texts represented the necessary and sufficient pre-requisites for the 
performance of a behavior by the health care provider aiming to effectively implement EBPs 
(Michie et al., 2005):   
(1) Knowledge: Implementer’s schemas or procedural knowledge of EBP guidelines  
(2) Skills: Implementer’s competency or skills to provide components of EBP guidelines 
(3) Social/professional role and identity: Compatibility of EBP guidelines with 
implementer’s social or professional standards  
(4) Beliefs about capabilities (self-efficacy): Implementer’s self-empowerment or self-




(5) Beliefs about consequences (anticipated outcomes/ attitude): Implementer’s outcome 
expectancies for applying EBP guidelines   
(6) Motivation and goals (intention):  Implementer’s commitment or goal priority to 
applying EBP guidelines  
(7) Memory, attention and decision processes: Implementer’s cognitive processes 
(memory, attention and decision) to delivering components of EBP guidelines  
(8) Environmental context and resources (environmental constraints): Physical 
resources and context available (or lacking) for implementer to apply EBP guidelines  
(9) Social influences (norms): Social effects, including group dynamics, support and 
conflict that influences the implementer to apply EBP guidelines  
(10) Emotion: Implementer’s positive or negative affect of implementing EBP guidelines  
(11) Behavioural regulation: Implementer’s perception of what preparatory steps or 
procedures were needed to encourage the application of EBP guidelines  
(12) Nature of behaviours: Implementer’s perception of potential behavioural changes that 
facilitates the application of EBP guidelines in the future    
This framework largely reflected Fishbein et al.’s (2001) approach to studying the 
implementation of HIV best practice guidelines. Fishbein and colleagues (2001) created their 
framework through an informal exercise of consolidating psychological theories by leading 
psychologists to promote preventative behaviours for HIV. Michie and colleagues (2005) also 
conducted expert consensus of psychological theories and constructs, but included three expert 
groups using recent literature, resulting in a more comprehensive framework with a total of 12 




Therefore, this study applied these 12 domains by Michie et al. (2005) with component 
constructs and eliciting questions to investigate how these factors affected the implementation of 
Garcia et al.’s (2008)  clinical guideline for optimizing OAT delivery (see table 2, Appendix C). 
For research objective 1, exploring the clinicians’ thoughts on how existing intrinsic factors (i.e., 
explanatory behaviours) and extrinsic factors (i.e., context) supported or countered the 
implementation of the clinical guideline. This inquiry was guided by the constructs from 
domains #1 to 11 of Michie et al.’s (2005) psychological theory, with domains #8 and 9 as 
extrinsic factors, and the remaining as intrinsic factors. For research objective 2, exploring the 
clinicians’ perceptions on how proposed behavioural changes facilitate the implementation of the 
clinical guideline was guided by domain # 12 (Michie et al., 2005).  
Rationale for Theoretical Lens Guiding Research   
Michie et al.’s (2005) psychological theory was the ideal framework to guide the 
development of data collection tools and the data analysis process in this study. The data 
collection tool was a semi-structured interview guide with questions based on Michie et al.’s 
(2005) psychological theory (see Appendix C). The interview guide covered all 12 domains of 
this theory as factors affecting implementation, shaping the types of questions asked. These 
deductive questions also had eliciting probes for inductive themes to emerge from the data, such 
as frailty. This would be an emerging theme because the majority of patients in community-
based AMS clinics were older adults with intensive needs. Therefore, semi-structured interviews 
have both the structure and flexibility to explore existing and emerging themes  (Creswell, 2009; 
Sliverman, 2013).   
In contrast, other  research methods such as surveys, open-ended interviews and focus 




collect deductive data in a quantitative approach, whereas focus groups and open- ended 
interviews collect emerging data using qualitative methods. Both focus groups and open-ended 
interviews encourage participants to talk openly about an issue without structure, allowing 
inductive data to emerge naturally from the interviews (Creswell, 2009). Conversely, semi-
structure interviews conducted without an underlying theory was not as structured as with one.  
As selected for this study, semi-structure interviews guided by theory allows the investigator to 
develop and ask questions to cover all theoretical domains for comprehensiveness, yet the 
flexibility for participants to provide their own input and expand upon their responses (Creswell, 
2009). Limited studies used theory-based implementation interviews to guide the research 
process, which was a strength of this study. 
Firstly, a surveys and open-ended interviews were widely used in previous studies to 
explore factors affecting anticoagulation therapy.  Prior research on anticoagulation management 
described data on health care providers’ perception on anticoagulation management, satisfaction 
on patient-provider relationships and barriers or facilitators for OAT delivery (see Appendix B). 
For example, one study by Bishiop and colleagues described satisfaction of patients and 
physicians with a pharmacist-managed anticoagulation program in a family medicine clinic in St. 
John’s, Newfoundland and Labrador using a self-administered survey (2015). Other studies also 
used surveys as the data collection tool for examining factors that impacted warfarin 
management services, such as Frankel et al. (2015), Lee et al. (2013), and Peterson & Jackson 
(2002). These are examples of a few studies already using surveys to identify barriers and 
facilitators for anticoagulation management, but surveys are limited in that participants cannot 




Other studies such as Shaw et al. (2014) in New Zealand examined pharmacists, nurses, 
practitioners and patients in the community about their attitudes toward a community 
pharmacist-led AMS using both surveys and telephone interviews so that clinicians could expand 
on their responses. Other work also conducted focus groups and semi-structured interviews to 
explore issues related to OAT delivery. For example, Kountz et al. (2015) used focus group 
interviews to explore multiple perspectives on strategies for improving anticoagulation 
management for patients with AF. As well, Bajorek et al. (2007) conducted focus group 
interviews of clinicians, patients and their carers to identify strategies for warfarin management 
in Australia. Chang & Pizzey (2013) used both focus groups and semi-structured interviews to 
collect data from pharmacists and physicians for warfarin management in primary care settings 
in the Kitchener/Waterloo area . Additionally, Decker et al. conducted semi-structured interviews 
to determine the clinicians’ perceptions of barriers for optimal AF management in the United 
States (2012). These studies explored aspects of anticoagulation management for AF in an 
inductive manner, allowing themes to emerge from the participants rather than deductively.  
There are limited studies using theory to guide their research methods. A qualitative 
study by Michie et al. (2007) was useful for this research because it modeled the use of Michie et 
al.’s (2005) psychological theory to explore and measure the implementation process in the 
community. Michie and colleagues (2007) investigated the effectiveness of implementing a 
mental health guideline by identifying barriers influencing its implementation. In semi-structure 
interviews, 20 participants from mental health teams across the United Kingdom were asked 
questions based on 11 theoretical domains of Michie et al.’s (2005) psychological theory to 
explore thoughts, opinions and attitudes. These interviewees’ responses were analyzed based on 




evidence (possible difficulty), and 1=full evidence (no difficulty). This coding system allowed 
the authors to calculate an implementation score in each domain for each participant. Each 
domain was a potential explanatory factor of implementation, so if participants scored low on the 
knowledge domain, the poor application of the mental health guideline could be due to difficulty 
in understanding the guideline. An overall score organized by profession and mental health trust 
location was also calculated; a lower implementation score indicated poor application of the 
mental health guideline as a whole (Michie et al., 2007).  Therefore, Michie et al.’s (2007) study 
and this study were similar in studying the factors that affected the implementation of clinical 
guidelines, yet this study additionally explored how these factors hindered, supported or facilitate 
the delivery of optimal OAT management, as outlined in Garcia et al.’s (2008) clinical guideline. 
After examining the facts, semi-structured interviews guided by theory was the ideal 
research method for this study because it allowed a rigorous process to develop, ask and analyze 
data, while still allowing for new patterns to emerge from guided probes.  Therefore, semi-
structured interviews based on theory was more effective in gathering both deductive and 
inductive data than surveys, focus groups and open ended interviews. This qualitative study was 
also guided by the assumptions of a philosophical world view of the investigator as discussed 
below. 
3.4 Philosophical World View  
The underlying philosophical world view of this research is constructivism. A constructivist 
approach takes into account how reality is fallible and facts are socially constructed in particular 
contexts (Creswell, 2009; Sliverman, 2013). The implementation of an EBP is dependent on the 
particular social context in which it is implemented. Prior to this study, the investigator visited 




which clinicians were working. This environmental scan allowed the investigator to better interpret 
the data collected within the context of community-based AMS settings, which fits into a 
constructivist approach of understanding contexts for interpretation of data. This philosophical 
world view recognizes that the working context influences clinicians’ circumstances and thus, their 
perceptions of what affects the implementation process.  
In detail, this world view that the investigator endorses was used to interpret the data from 
semi-structured interviews through her life experiences. The investigator acknowledged that she 
used her own background and experiences to interpret meanings in that specific context. The 
investigator came from a health studies background, studying at the University of Waterloo, and 
is a volunteer at the Hospital Elder Life Program who has connected with many patients who used 
anticoagulation services. She also has a personal connection with a close friend who experienced 
difficulties from poor anticoagulation management in the community to understand better 
understand the patient’s perspective. She has also met and spoken with experts in the field, and 
observed OAT delivery from the clinician’s perspective.  Keeping in mind both perspectives, it 
helped the investigator describe her interpretation of the clinicians’ responses; for example, when 
clinicians talked about the convenience of AMS for patients, the investigator understood the 
impact on patients. This is especially important in the constructivist approach because the 
interpretation is dependent on the context in which clinicians were working and in which the 
investigator was doing research about how existing factors affected the implementation of the 
clinical recommendations.  
3.5 Study Design 
This section describes the study design, including the study population, setting, and the 




criteria (see section 3.5.1) were key informants of this study. They were interviewed in semi-
structured interviews because it had both the structure and flexibility to guide purposeful 
interactions (Creswell, 2009; Sliverman, 2013). The semi-structured interview guide was based 
on the eliciting questions from Michie et al.’s (2005) psychological theory framework (see 
Appendix C), shaping deductive questions that covered all12 domains as factors affecting the 
implementation of the clinical guideline. There were also probes to direct key informants to 
elaborate upon their responses, allowing inductive themes to emerge from the data.  
During the process of interviewing, key informants chose to speak about the 
recommendations from the clinical guideline that resonated with them the most.. The investigator 
acknowledged that the interview guide was not a “one-size fits all” data collection tool, so a 
flexible approach was adopted to guide a purposeful interaction. Not all questions in the 
interview guide were asked of every key informant. As stated by the constructivist approach, as 
long as the same broad questions were asked in each interview,  then every key informant had 
the chance to construct responses relevant to their experience and context (Creswell, 2009).  All 
key informants were asked the same general questions related to skills, intention and 
environmental resources, all of which were necessary for health care providers to implement 
clinical guidelines in practice (Michie et al., 2005).   
The investigator’s role was to collect this information and interpret the key informant’s 
meanings (Creswell, 2009). When needed, further explorative questions were asked if (a) the 
questions were relevant to the selected recommendations; and (b) the key informant had 
additional insight on the topic being asked. Overall, the flexibility of a semi-structured interview 
approach helped to focus the conversation, but allowed adaptability to gather new information 




purposive sample. Interviews lasted approximately 30-40 minutes and were audio-recorded, 
transcribed and analyzed for data analysis. The results of this analysis addressed the research 
objectives of this study. These components are described in detailed in the section below.    
3.5.1 Study Population & Setting    
The study population included pharmacists and trained registered nurses who worked in 
outpatient AMS clinics in family health teams and community pharmacies within the WWLHIN 
community: Waterloo-Kitchener, Cambridge and Guelph. Only pharmacists and nurses were 
chosen in the purposive sample because they represented care providers in community-based 
AMS clinics (more details in section 3.5.2). The study sample consisted of key informants who 
met the following inclusion criteria: (1) Registered as a pharmacist with the Ontario College of 
Pharmacists, or nurse (RPN or BScN with the College of Nurses of Ontario); (2) Aged 18 and 
over; (3) Employed at an AMS clinic using POCT, i.e., INR testing devices and software, for at 
least 6 months to arbitrarily represent “experienced” clinics; and (4) Be located within the 
WWLHIN community. The 6-month mark was chosen arbitrarily as the cut-off for the length of 
time that a clinician working in an AMS clinic; this study sought to study the perspectives of 
relatively experienced key informants.   Key informants were not qualified if they met any of 
these exclusion criteria: (1) Provided laboratory testing in routine medical care; and (2) 
Employed at AMS clinics within hospitals. Clinicians who were employed in hospital-based 
AMS clinics were excluded because the research interest was in a regional, not hospital-based 
model.  
3.5.2 Recruitment  
Key informants were primarily identified during the prior environmental scan of AMS 




WWLHIN community expressed an interest in participation. In purposive sampling, the 
investigator aimed to recruit key informants of each profession from different study sites.  The 
investigator sent a recruitment email (see Appendix G) to these seven pharmacists and additional 
eligible key informants. The email explained the details of the study and how to participate. A 
follow up email was sent within one week of the initial recruitment email for non-respondents 
(see Appendix I).  
Upon expressing interest, the investigator sent a confirmation email to key informants to 
confirm time, date and location of the interview (see Appendix H), and attached two documents 
for the participant to read in advance: the information and consent form (see Appendix D), and 
Garcia et al.’s (2008) clinical guidelines. The information and consent form explained the 
research, interview process and how confidential information will be handled, asking for the key 
informant’s permission to proceed with the interview. Key informants completed the interviews 
either during normal working hours of the clinic or after hours. During working hours, the 
investigator conducted the interview during a 30-minute slot when no patients were scheduled in.  
The alternative was to conduct the interview after hours if the clinic was fully booked. The 
investigator collected the data following the procedures outlined below.   
Recruitment resulted in one pharmacist from each study site and two nurses from one 
site. This small sample size affected the transferability because it generated a non-probability 
sample that cannot claim generalizability to the study population. The point of saturation may be 
prematurely reached if key informants provided only ‘status-quo’ responses. This could be 
resolved if the sampling frame was widened and included at least one or more key informant of 
each profession to capture a variety of new information. In this study, the sampling frame was 




data to capture more diverse information. This narrow sampling frame reduced transferability of 
the data to a larger population, but this study can still add value to a larger project, which can 
include more nurses for a richer study.  
3.5.3 Data Collection  
The data collection instruments included the information and consent forms (see 
Appendix D) for a key informant semi-structured interview guide (see Appendix E). Justification 
of the questions with probes is found in table 3 (see Appendix F). Outlined below was the 
procedure for conducting semi-structured interviews:  
1. At the start of the interview, the key informant was given the information and consent 
form to sign, as well as Garcia et al.’s recommendation guidelines to reference during the 
interview.   
2. The investigator prompted the key informant for any questions or concerns, then 
proceeded to collect the consent form and set up the audio recorder on the table if the key 
informant had fully consented.  
3. Closing remarks were made and the audio recorder was turned off with all materials 
being re-collected and placed into a secure filing cabinet in an office. The feedback letter 
(see Appendix J) was subsequently emailed to thank the participant for their time. 
4. At the end of each interview, the investigator immediately made field notes in a reflexive 
journal to reduce interviewer bias, since no note taker was present. 
Field notes were kept by the investigator on overall impressions and thoughts about the 
key informant’s responses and the interview, including any strategies to improve the interview 
process. These notes helped to optimize the process of subsequent interviews. For instance, in 




investigator learnt to re-direct questions. As well, the investigator needed to provide more 
prompts without leading key informants to a particular answer.   
Additionally, the investigator noticed that the interview went more smoothly when the 
key informants were asked to discuss topics based on a case study. All relevant factors related to 
Michie et al.’s (2005) 12 domains came up when the key informant discussed how the clinic was 
run, or what happened in a specific patient case. During the interviews, the investigator modified 
the semi-structured interview guides to ask about examples in the form of patient cases. For 
instance, the question about care management and coordination was framed as a patient case 
example: “If a frail older adult with atrial fibrillation was a patient in the family health team, how 
would they be referred into the anti-coagulation clinic?” As key informants answered this 
question, the investigator probed about any existing policies and procedures for Warfarin therapy 
management and coordination in the clinic. After these interviews were completed, data analysis 
was performed on the transcripts as outlined below.  
3.4 Qualitative Data Analysis  
Interviews were transcribed verbatim onto Microsoft Word. Transcripts were de-
identified using a code and uploaded on NVIVO Pro 11 software. The transcribed data were first 
characterized as cases based on the type of clinic and profession (tables 5-6 in Chapter 4). Next, 
the investigator performed a thematic analysis of each transcript using both deductive and 
inductive codes. The investigator started by deductively identifying data that fit into the 
appropriate domain from Michie et al.’s (2005) psychological theory. Deductive coding used the 
investigator’s interpretation of the definitions from Michie et al. (2005). Codes were also 
attached to Garcia et al.’s (2008) recommendations to put the domains into context when the 




to emerge from the data, the investigator looked for recurrent patterns in the data to code, such as 
frailty. As thematic analyses were being conducted, the nodes were compared, contrasted and 
condensed into a codebook to code all interviews.  
 After this round of coding, the coded data and codebook was sent to a second coder with 
qualitative data analysis experience. She performed the second coding analysis and compared 
nodes and consolidated them into a single codebook in a manual comparison to refine the themes 
line-by-line (see Appendix K).  Conflict in themes were refined either by coding to additional 
nodes or un-coding unnecessary nodes. This review and refinement was done using NVIVO Pro 
11’s side-by-side view of the nodes coded to each line. A list of coding issues and assumptions 
discussed between the investigator and the second coder is available (see Appendix L).   
Next in the data analysis, the investigator created a compilation of similarly coded blocks 
of texts across all interviews. After all texts were coded, this analysis provided the investigator 
with the number of references to particular nodes from all key informants. The ‘query wizard’ 
function in NVIVO Pro 11 was used to ‘search for content based on how it is coded’ by selecting 
‘search for content coded at all of these nodes’ using terms seen in the rows of table 4 (see 
Appendix M). Each row consists of the emergent concept or the Garcia et al.’s recommendation 
AND Michie et al.’s domain AND benefit or barrier to further differentiate how each domain 
contributed to the implementation. For example, there was one reference coded at all these 
nodes: Qualifications AND Knowledge AND Barrier to help interpret coded data as a lack of 
knowledge about the qualifications of personnel. This output (i.e. block of text) was saved as a 
query result with the actual quote in NVIVO and the number of references (i.e., in this case, one) 
was recorded in table 4 (see Appendix M). The compilation of the output of similarly coded texts 




themes mentioned in the study. For example, there were 32 references related to the nodes: Care 
management and coordination AND Environmental Context and Resources AND Barriers 
suggesting that the environment was mentioned as a barrier 32 times for optimizing the care 
management and coordination recommendation in warfarin therapy.  
3.5 Trustworthiness of Data 
Generally, the trustworthiness of a qualitative study is assessed by looking at the 
dependability (reliability), credibility (internal validity), transferability (external validity), and 
confirmability (objectivity) of the study (Shenton, 2004). Dependability is the reliability of the 
study design, demonstrating the consistency in which other investigators are able to repeat the 
study. In this study, the data collection tool was a semi-structured interview guided by an 
underlying theory. This theory-guided approach allowed the investigator to ask general questions 
about Garcia et al.’s (2008) clinical recommendations based on the 12 domains of Michie et al.’s 
(2005) psychological theory. These theory-guided questions allowed for some consistency in 
responses between interviewees (i.e. similar themes to come up with each question) for 
potentially reliable data if other investigators choose to repeat the study.  However, there could 
be variations in the data collected since the investigator conducted a semi-structured interview 
where new information emerged from the data. Therefore, in this qualitative inquiry, it was 
important to verify meanings, interpretations and assumptions between key informants and 
within key informants, then explain the thinking process. A reflexive journal (see Appendix N) 
was kept to document the investigator’s thought processes and decisions, which enables other 
investigators to repeat the study more reliably (Shenton, 2004). In this journal, the investigator 




and analysis to explain the way interpretations were reached. This reflexive journaling allowed 
other investigators to review the activities taken by the investigator during the study. 
Secondly, credibility of data is the process of demonstrating that a true representation of 
the phenomenon is being presented (i.e. the data analysis actually captures the key informant’s 
responses on how various factors affected the implementation of the clinical guideline). In this 
study, the investigator strived to obtain accurate details of the interview based on the 
participant’s responses by recognizing any assumptions when interpreting the meanings of data. 
The investigator also employed techniques to establish internal validity to verify data, including 
triangulation of different sources by comparing the transcripts with audio files and field notes 
(Corbett, 2015; Creswell, 2009; Shenton, 2004). The investigator re-listened to the audio files 
before categorizing and coding the text in the transcripts. Then, a peer reviewed and compared 
the transcripts with the audio files to doubled check the interpretation of the raw data during 
transcription and coding. This process was done to confirm what was said and how it was said 
(inflection and tone) to improve credibility of the data.  
Furthermore, thick descriptions of the context of the fieldwork provide sufficient details 
for other investigators to determine if the findings are applicable to other settings for to improve 
transferability standards (Corbett, 2015; Shenton, 2004). Elaborate descriptions of the key 
informants’ behaviours in the study’s context were noted after each interview, such as personal 
impressions, characteristics and thoughts. For example, the majority of key informants in this 
study were pharmacists who were knowledgeable and keen to participate in the study. Most of 
them wanted to provide quality data for this research and asked several times if they provided 
enough information. They had clear knowledge about AMS and were all formally trained at the 




reading the guidelines and usually elaborated on their responses without prompts.  In 
comparison, the sample of nurses in the study was small, so their responses may be biased. Both 
nurses had extensive clinical experience in the community AMS clinics, which was involved in 
ongoing research and learning. They tend to provide rich data when given a case or example to 
explain a concept. Complex or multiple questions were difficult for them to elaborate more on, 
so interpretative probes helped to guide the conversation.  
Finally, confirmability of the study was demonstrated when findings emerged from the 
data and not from the investigator’s predisposed ideas to bias the study. Since the data collection 
tools and procedure were dependent on human skills, there was a possibility of bias. The 
investigator improved objectivity by emphasizing triangulation to reduce interviewer bias, which 
used different sources to verify the data, as stated earlier,  to trace the course by which the results 
were drawn from the data (Shenton, 2004).  
3.6 Ethical Considerations  
This study received ethics clearance through a University of Waterloo Research Ethics 
Committee.  All key informants voluntarily agreed to participate in the study without 
remuneration, and after fully understanding the purpose of the study via information and consent 
forms (see Appendix D) and verbal clarifications. All confidential information obtained from the 
interviews, including all field notes and audio-tapes, was kept in a securely locked cabinet in the 
investigator’s office. All information identifying the participant was removed upon transcription 







3.7 Practical Insights  
Overall, there is practical insight on exploring how various existing factors hindered or 
supported, and how behavioural factors can facilitate the implementation of the clinical 
guideline. Lessons learned from this study may be portable to other LHINs that plan, integrate 
and fund local health care in communities for improved access to patients (Ontario's LHIN, 
2016).  Additionally, acknowledgement of this existing work may also promote the usefulness 
and validity of psychological explanations to behaviour change for the implementation for EBP. 
This qualitative study guided by theory can help shape future research and development of best-
practice guidelines for the optimal delivery of OAT in a frail elderly population. Therefore, the 








CHAPTER 4: RESULTS 
4.1 Introduction  
This chapter presents the results of the study, including the characteristics of the study sites 
and key informants. Although there was a wide range of themes (see Appendix M), the 
investigator focused on those that addressed the research objectives. For the purpose of this 
Master’s thesis, the key results reported here are how existing intrinsic and extrinsic factors 
hindered or supported, and how behavioural changes facilitate the delivery of optimal OAT 
management, according to Garcia et al. (2008), in AMS clinics within the WWLHIN 
community: Kitchener-Waterloo, Cambridge and Guelph. 
4.2 Characteristics of Study Sites  
Firstly, the results were gathered from six AMS clinics or study sites that participated in 
the study with the same proportion of family health teams and community pharmacies. Table 5 
shows the characteristics of these study sites. The majority of clinics had a sizable patient base of 
50 or more patients, either only for only rostered members in family health teams or community 
members in pharmacies. In family health teams, there was a mix of registered nurses and 
pharmacists providing care, compared to just pharmacists in pharmacies. Regardless, all OAT 
management in these clinics was headed by pharmacists, per the inclusion criteria for this study.   
Table 5. Characteristics of Study Sites  
Type of Outpatient Setting Type of Patients Type of Trained Staff 
Family Health Team Rostered in community RNs & CPs 
Community Pharmacy 
 








4.3 Characteristics of Key Informants 
In these clinics, there were a total of eight key informants:  six pharmacists and two 
registered nurses (see table 6). Key informants had at least one-year of experience in OAT 
management within a community setting , and met inclusion and exclusion criteria of this study 
(see section 3.5.1). All key informants received some type of formal training, either through a 
course at University of Waterloo (School of Pharmacy) or a workshop from Roche 
CoaguChekTM. After examining these characteristics, the most salient themes are presented to 
address research objectives 1 and 2.  
Table 6. Characteristics of Key Informants
Key Informant Code Job Title 






KI 2 5 
KI 3 2 
KI 4 1.5 
KI 5 6 
KI 6 8 
KI 7 3 
KI 8 3 
 
4.4 Themes for Research Objective 1   
In order to address research objective 1, key informants revealed three important themes 
that described how existing intrinsic and extrinsic factors counteracted or supported the 
implementation of the clinical guideline for optimal OAT management in community AMS 







Table 7. Themes for Research Objective 1 
Research Objective 1: To explore how existing intrinsic or extrinsic factors hindered or 
supported the implementation of Garcia et al.’s (2008) clinical guideline for optimal OAT 
management.  
Hindered implementation 
Theme 1: Inadequate reimbursement for logistical 
operation of AMS clinics    
Supported implementation 
Theme 2: Clinicians’ awareness of how to apply 
knowledge to support practice  
Theme 3: Tailored organizational supports for the frail 
elderly  
In table 7, theme 1 shows how inadequate reimbursement for operating AMS clinics 
(extrinsic factor of environment) counteracted the implementation of the clinical guideline. The 
clinical guideline portrayed key recommendations for the optimal delivery of OAT management, 
so there needed to be an infrastructure to support this practice. Clinicians in these AMS clinics 
were not sufficiently compensated for their resources and services rendered, which jeopardized 
the long-term sustainability of the infrastructure of AMS clinics. As a result, consistent funding 
was needed to support AMS clinics for clinicians to apply the recommendations. On the 
contrary, themes 2 and 3 were about how existing intrinsic and extrinsic factors supported the 
implementation in practice. Theme 2 showed how the implementation of the clinical guideline 
depended on the clinicians’ awareness to apply the knowledge of the recommendations to 
support practice (intrinsic factors of knowledge and skills). Clinicians generally knew how each 
element in the clinical guideline was applied to start a community AMS clinic; however, there 
were some issues related to an incomplete frailty assessment among key informants. Whereas, 
theme 3 described how tailored organizational supports for the frail elderly, such as physical 
tools, face-to-face interactions and home visits (extrinsic factor of environment) helped with the 
implementation of the clinical guideline for the optimal delivery of OAT management in the 




Theme 1: Inadequate Reimbursement for Logistical Operation of AMS Clinics  
 For the first of three themes, the most prominent was how inadequate reimbursement for 
logistical operation of AMS clinics hindered the delivery of optimal OAT management. Because 
of funding issues, there was insufficient compensation for materials and services rendered for 
therapeutic activities in AMS clinics. AMS clinics procured overhead costs related to equipment 
(hand-held POC-INR testing device and strips) and salary. An inadequate reimbursement model 
compromised the delivery of optimal OAT management within AMS clinics in both FHTs and 
community pharmacies. For example, it seemed that FHTs had a problem with the allocation of 
funds for AMS clinics when this key informant said:  
“Funding for any type of clinic like this is difficult. Um...within the family health team 
model, it has been especially difficult to get the Ministry to specifically fund the INR 
clinics so every single year we're worried about whether or not we're able to continue 
with the program because other priorities within the family health team may take away 
funding from our program.”- KI 6    
As funding was unpredictable from year-to-year, it threatened the long-term sustainability of the 
clinic, which was the infrastructure supporting the delivery of optimal OAT management. These 
clinics continued to operate as long as FHTs funded them. Funding issues were more severe in 
community pharmacies with inadequate funding from the government:      
“Actually, it'll be awesome if ODB [Ontario Drug Benefit] initiated the MedsCheck 
program that was seventeen to eighteen dollars that was meant specifically for 
management of a disease. So they have one for diabetes, it's seventy-five bucks for the 
first one and twenty-five dollars thereafter. Why can't they do one for Warfarin that's just 
18 bucks per INR tests with certain criteria of when you can bill it and when you can't. 
You're maintaining somebody at therapeutic dose, you do their INR monitoring, you don't 
get reimbursed. If you have to make a change in therapy, that would make sense to be 
reimbursed as a follow up MedChek in any regard or as a pharmaceutical opinion, but 
most of the Warfarin clinics that are run by pharmacists are done by medical directives, 
which therefore excludes you from billing for a pharmaceutical opinion. In order for a 
pharmaceutical opinion, you need to have a doctor sign off on your dose 




As demonstrated, community pharmacists were not paid for the majority of therapeutic activities, 
such as maintaining and monitoring INR values. The only way for reimbursement was through a 
physician-signed pharmaceutical opinion during therapeutic dose changes. This reimbursement 
model jeopardized the long-term sustainability of AMS clinics because it meant pharmacists 
were not being paid unless there was a therapeutic change approved by a physician. Without the 
means to keep up with overhead costs over the long term, clinicians were not well supported to 
deliver the clinical guideline. Instead, community pharmacies had to compensate for the cost of 
operating AMS clinics in other ways:   
“....there's really no billing, there's no good billing way in the community, for 
pharmacists in the community. I think that they justify it by the patient being a client in 
other ways, so they spend money in the pharmacy and their other prescriptions come to 
them. Um, so that's how they balance it.” – KI 3 
Since patients were using other services in the pharmacies, these AMS clinics were able to stay 
in operation; however, this was not a viable long-term solution for reimbursing AMS clinics that 
were expected to provide chronic disease management. This inadequate funding issue caused a 
dilemma for pharmacists who wanted to stay in operation and manage optimal standards, but 
struggled to do so:  
“...I mean I can cancel my clinics and let them go back to labs if I wanted to, but it's just 
not something we're prepared to do at this time. But it is scary, you know, when we hear 
about other pharmacies that have been billing for the service. To me personal opinion, 
it's reasonable to bill but then you hear that they've been audited and you're like okay 
well, why am I putting myself out there for these potential repercussions if all I'm trying 
to do is taking care of my patients?” – KI 1 
As seen above, this key informant had financial concerns to continue operating and could not 
effectively focus on delivering optimal OAT management for patients. There were concerns 
about how to balance the optimal delivery of OAT management using limited financial 




services. An advocacy letter by a community pharmacist to the government showed how 
important funding was to the operation of AMS clinics to support OAT:  
“Well, we proposed that a nominal fee be set up specifically for this work. Like this 
activity that you're doing, we should be reimbursed for it, we said between $10-$15. 
Right now, you know we're doing a lot of other things in these INR appointments as well 
which helps cover some of the funding, but you should be paid for what you do and it's 
...so hopefully [laughs]… And we calculate how much drug therapy problems we saw on 
top of Warfarin issues during our clinic appointments and we had about 15 a month. So if 
you think of how much money that saves the government if each drug therapy problem is, 
you know the x amount of dollars. So, hm...we're including all of this in our advocacy 
letter!”  -KI 5 
They advocated for the government to set up a reasonable fee to help sustain the foundation of 
the AMS clinic. There was inadequate funding for FHTs and community pharmacies to maintain 
the infrastructures of these AMS clinics, which counteracted the implementation of the clinical 
guideline for the optimal delivery of OAT management in the community. Yet, for those AMS 
clinics that stayed in operation despite the inadequate funding, there were other existing factors 
that supported the delivery of optimal OAT management.  
Theme 2: Awareness of how to apply knowledge to support practice  
 In order for clinicians to apply the clinical guidelines, there should be knowledge and 
skills to do so. In sum, there should be an awareness of how to use that knowledge to support 
practice.  That is what was portrayed in theme 2, which showed how recommendations from the 
clinical guideline were well known and applied by the majority of key informants. The 
awareness of the clinical guideline as a whole was apparent for pharmacists in both FHTs and 
community pharmacies. An example of this is described here:   
“So if like first you would need medical directives and everyone to buy in to whoever's 
managing it. Everyone would have to have a comfort level of the people who have been 
trained to do it and I think it works the best when the people managing it are the only 
ones managing it and they have the medical directives to make the changes on the spot 




response because there is sometimes urgency to making a decision and managing it. So I 
think it's good if full medical directive is in place to give that person a full scope of 
managing. Um...and then once that step is in place, I think if you've been trained, you 
should have the knowledge of what patient education is necessarily, how to monitor, 
how to start, what influences or impacts INRs and what barriers patients have to 
maintaining INRs, including older age and frailty and where extra support is needed.” 
– KI 3 
There was a general understanding of how to apply the key elements for optimal OAT 
management in participating AMS clinics. As shown above, the key informant identified the 
need for qualified individuals who understood the terms for supervision of team, care 
coordination with physicians, OAT management and patient education, as well as the concept of 
frailty for care in this context. Having this awareness of how to apply knowledge is the first step 
to the implementation of these recommendations in practice.  Clinicians were also aware of how 
to apply their knowledge of each recommendation in this clinical guideline to support practice. 
These results did not report on the fourth and seventh recommendations of documentation and 
laboratory monitoring of the clinical guideline because they were in the inclusion criteria; AMS 
clinics had to use computerized software for documentation, and POCT to test whole blood 
capillary samples for INR values.  
 Among the nine recommendations of the clinical guideline, the first two were 
qualifications of personnel and supervision of team. These recommendations were implemented 
to support how different professions involved in OAT management organized themselves to 
ensure that patients’ needs were met:   
“Um, no, I think we are very fortunate that um we had been given such free reign […] we 
go to the docs when we are over 4, if we have an issue we, you know, we let the docs 
know this is what we are doing […]. But other than that, that's you know, we have our 
outline of what our protocols are, we follow them and we are very fortunate that we have 
a physician who overlooks us if they’re not here” – KI 7 
As this key informant described, the team dynamics of qualified team members in the clinic 




understanding was also foundational to the delivery of other recommendations in the clinical 
guideline.   
 Among the other recommendations, the third is care management and coordination. 
Clinicians knew how to apply the procedures for managing and coordinating care processes, such 
as those expressed by this key informant:  
“We have templates. Yeah, of specific letters, like for the first INR appointment, we use 
the same thing every time. We have a checklist for that. When a patient discharges from 
the hospital, we can't really use a template for that, but we have a template in terms of 
discharges for all patients that we send the providers what was changed, what was new, 
same would apply to our Warfarin patients when there's a surgery again, we have a 
template for requesting or denying bridging like we talk about discussing bridging and 
duration of anti-coagulation, when it should be started or stopped, and when it should be 
restarted. We kind of have all the same format.” – KI 5 
Having these templates and checklists for initial appointments, follow ups and bridging showed 
that this key informant understood how to apply established care procedures to support practice. 
The awareness to apply knowledge of care management and coordination protocols allowed key 
informants to implement this component of the clinical guideline. Note that documentation, the 
fourth recommendation of Garcia et al.’s (2008) clinical guideline, was not reported because it 
was an inclusion criterion for key informants to know how to use computerized software for 
OAT management documentation.  
 Furthermore, the fifth recommendation is patient education. Clinicians were aware of 
how to provide tailored education to individual patients, as this key informant portrayed:     
“[…]spread[ing] out our education in some ways because it can be information 
overload, so we try and provide the necessary information upfront and then education 
along the way, like you said, as issues come up. We try and explain how important 
adherence is for this medication because it will tend to, you'll see it in the INRs. We 
explain things like if you, if they have a low INR today, like for example they had a 1.8, 
letting them know that if you've missed a dose in the last week or the last few days, that 
could be an indication of why it's low today. So they can kind of connect that and then 




happens then we will probably want to see them back sooner so it kind of gives them 
more reason to try and be diligent with their medications” –KI 3 
 
As demonstrated, this key informant explained the information in “chunks” and guided patients 
through the practical aspects of therapy, the lows and highs of the INR value and what the 
changes in values meant. The key informant was delivering the information to meet the patient’s 
educational needs, showing that clinicians’ awareness of how to apply this knowledge supported 
the implementation of the clinical guideline for optimal OAT management.   
 Subsequently, the sixth recommendation of this guideline refers to the patient selection 
and assessment for therapy.  It recommended that clinicians need to have a comprehensive 
history of medical, social, lifestyle, psychological and employment profiles to determine the 
appropriateness of therapy for patients. In this study, clinicians were aware of how to select and 
assess patients for OAT management to support practice, as shown when this key informant 
described:   
 “I can't again stress the importance of getting a good clinical history and doing a proper 
cardiovascular risk assessment in terms of clot assessment, bleed assessment, frailty 
assessment, nutritional status assessment, compliance assessment. Is this person a good 
candidate for anti-coagulation, period? Does the benefit outweigh the risk? And 
compliance needs to be part of that initial assessment, it's absolutely key, and it's not say 
that if there's poor compliance that Warfarin is not a good option, what I'm saying is that 
if the initial assessment is done.” – KI 2 
In considering these elements, it showed that  awareness of how to apply the knowledge of a 
comprehensive selection and assessment process supported the uptake of this recommendation. 
Although key informants had a comprehensive list of elements to assess and select patients on, 
there were issues with the frailty assessment. Despite having an adequate understanding of the 
concept of frailty, the frailty assessment was incomplete, as described by this participant:    
“It's usually everyone that's seventy-five and older, we screen them using gait, grip 
strength, um...falls and we screen nutrition, and then based on a combination of those 
things we would go and define them as frail. So, some of our patients are frail and some 




As shown, patients who were older often received a frailty assessment using the gait, grip 
strength and nutritional status evaluations. Screening by chronological age showed that this 
frailty assessment was ad-hoc and not standardized based on evidence. It has been shown that 
chronological age is not a good indicator of frailty (Heckman & Braceland, 2015), but at least the 
key informant considered frailty in the assessment and selection for warfarin therapy. Even 
though the assessment of frailty was not standardized, the general awareness of how to apply 
knowledge of a comprehensive patient assessment and selection for therapy supported the uptake 
of this recommendation in the clinical guideline.   
 Another aspect of the clinical guideline for optimal OAT management is initiation and 
stabilization of therapy. The majority of key informants knew how to apply a systematic, 
validated process for the initiation and stabilization of therapy, as shown when this key 
informant expressed:  
“So using dosing nomograms for initiation that have been validated are very important. 
But what's equally and arguable more important is frequent testing in that first month.” –
KI 2 
 
“Well, there's a nomogram for 4mg that's well studied with Dr. X who published it, 4 mgs 
in elderly people, then there's a 5 and 10mg start.” – KI 5 
 
Validated dosing nomograms were used to start and stabilize a patient’s therapy to reach the 
lower limit of the therapeutic range in a timely fashion, as recommended by the clinical guideline 
(Garcia et al., 2008). When therapy was initiated and stabilized promptly following evidence-
based guidelines, such as the 4 mg initiation for older persons with AF (Siguret et al., 2005; 
Sridhar et al., 2014), the clinicians’ awareness of how to apply this knowledge supported the 




 Finally, the ninth and last therapeutic recommendation is maintenance of therapy. 
Clinicians knew how to systematically maintain longitudinal therapy, as shown when this key 
informant revealed:   
“In our older population, the four milligram initiation nomogram has had good 
predictability for maintenance dosing. I believe it's about 72 or about 75% predictive of 
the maintenance dosage so that's a very useful tool if it's followed correctly.” –KI 2 
As shown above, the maintenance dosage was determined by the previously established 
evidence-based initiation dosing nomogram. When INR values are fluctuating, there was also a 
systematic process to determine the issues during longitudinal follow-ups:  
“Yeah! So if there's a low dose, we ask them a list of questions that I can give you about 
why the dose is low. We review all these things: Is there a med change? Is there a change 
in their diet? Is there a change to their medical conditions? How are you feeling today? 
Did you miss any meds? There's a list of questions we ask.” – KI 5 
As shown above, this key informant knew how to use a standard procedure for long-term follow 
up assessments, dose adjustments and monitoring of adverse events. All of these activities using 
standardized protocols helped to optimize OAT management per the clinical guideline.  Overall, 
the awareness of how to apply this knowledge supported the implementation of the clinical 
guideline, but there were also external factors that supported this implementation in practice.   
Theme 3: Tailored organizational supports for the frail elderly 
 Theme 3 described how tailored organizational supports for the frail elderly supported the 
optimal delivery of OAT management. This theme illustrated how the environmental resources 
such as blister packs, calendars and written reminders; the context of face-to-face interactions; 
and home visits tailored for the frail elderly supported the uptake of the clinical guideline as a 
whole.  Patients who are frail, elderly and have AF are vulnerable, requiring vigilant care and 
attention from clinicians in AMS clinics to optimize OAT management. One of these initiatives 




support the optimal delivery of OAT management by reducing non-adherence to therapy. This 
helped the frail elderly population as portrayed by this key informant:   
“And if it's an adherence issue, we deal with that by introducing the idea of blister packs. 
Sometimes we need to dispense one at a time. We actually have one guy, he's frail and he 
has a language barrier and we actually fill up the dosettes with him with just Warfarin 
every time he comes.” – KI 5 
 As seen above, the use of blister packs was a physical tool used to support the delivery of 
optimal OAT management in the frail elderly. Additionally, the use of other resources was also 
useful to improve adherence in this population:  
“We have seen trends that there's been unidentified cognitive impairment but then once 
they have started on Warfarin, which is a complex medication that requires strict 
adherence, cognitive issues will come out, so ...and then steps have to be taken to manage 
that too. But we'll just put in place lots of support initially for the patient and back up 
support so that we know that there are some safeguards if there are difficulties. But we 
use lots of tools to help all of our patients, not just our frail older patients, but written 
calendars, verbal instructions, written instructions and reminders, um...” –KI 3 
As detailed above, written calendars and instructions were used as reminders particularly for the 
frail elderly with cognitive issues. The use of these resources helped clinicians to deliver OAT 
for this population that would otherwise not be able to receive care if these tools did not exist. 
The clinical guideline recommended having standardized protocols for delivering therapy, so the 
systematic use of these physical tools to manage compliance in the frail elderly was one way that 
organizational supports encouraged the implementation of the clinical guideline as a whole.  
 As with these physical tools, the environmental context of AMS clinics also provided 
support for optimal OAT management, such as face-to-face interactions and home visits. In face-
to-face interactions, clinicians did longitudinal patient assessments, dose adjustments and health 
monitoring for other conditions such as frailty. The benefits of a face-to-face interaction were 
described by this key informant:    
 “However, what tends to happen is, I would say that offering an in-person point of care 




especially in your older, more frail populations, right? Because what it is, is a face-to-
face opportunity to address and screen and monitor all the other co-morbidities that they 
are currently dealing with. When you've got that face-to-face contact with them routinely, 
whether it be once a month or once every six weeks, you know in that neighbourhood, in 
terms of that time frame, you have a very unique and valuable opportunity to address 
everything else right? You can see if they are becoming more frail.”- KI 2 
 
This key informant had the opportunity to monitor adverse events and frailty markers to 
promptly resolve any interacting conditions during these face-to-face interactions. This context 
allowed for face-to-face interactions in AMS clinics, which enabled key informants to deliver 
therapeutic activities as recommended by the clinical guideline.  
 In addition, another organizational support was having home visits for patients who were 
frailer and who notably needed the service the most. Having home visits reduced the complexity 
of therapy and supported the ability for clinicians to provide optimal OAT, as stated by this key 
informant:     
“We do home visits. We take as much out of their hands as we can without taking away 
the sense of empowerment just to make it simple and easier for them. Just a way of 
simplifying regimens… If that's what's needed, yeahh... You do whatever's gotta be done. 
(laughs)”  – KI 4 
 The point of organizing these home visits was to support the delivery of OAT 
management for this specific population who tend to be more frail, which was typically 
characterized as having multiple co-morbidities, polypharmacy and loss of independence 
(Heckman & Braceland, 2015). Essentially, the AMS approach provides tailored organizational 
supports, such as blister packs, written calendars, face-to-face interactions and home visits for 
the frail elderly to monitor adherence and complete follow-up assessments and measurements in 
a more systematic manner.  Therefore, these tailored organizational supports allowed key 
informants to deliver optimal OAT management through the deliberate implementation of the 




Summary: Themes for Research Objective 1 
 Ultimately, three themes illustrated how existing intrinsic and extrinsic factors played a 
role in the uptake of the clinical guideline for optimal OAT management in community AMS 
clinics. Firstly, theme 1 showed inadequate reimbursement for logistical operation of AMS 
clinics as an environmental constraint (Michie et al.’s (2005) domain #8) that hindered the 
delivery of optimal OAT management recommendations. There was an unstable reimbursement 
model for sustaining the infrastructure of AMS clinics in the long term so the recommendations 
were not effectively implemented in practice. For clinics with unstable financial support, 
clinicians’ awareness of how to apply the knowledge of key recommendations of the clinical 
guideline (domains #1 and 2) supported practice. Key informants generally knew about how to 
apply these recommendations as a whole for the optimal delivery of OAT in practice. Despite 
that, there were concerns for specific recommendations of the clinical guideline, specifically with 
ad-hoc assessments of frailty based on chronological age, rather than standardized methods using 
evidence. Furthermore, the environmental resources of tailored organizational supports for the 
frail elderly, such as blister packs, reminders, and the context of face-to-face interactions and 
home visits helped key informants to deliver optimal OAT management by moving toward a 
systematic method of adherence monitoring and follow up assessments in this context. All in all, 
these three themes addressed how existing intrinsic and extrinsic factors counteracted or 








4.5 Themes for Research Objective 2 
Themes 4 and 5 described how behavioural changes can facilitate the implementation of 
Garcia et al.’s clinical guideline for the optimal delivery of OAT management in community 
AMS clinics (see table 8).  
Table 8. Themes for Research Objective 2 
Research Objective 2: To discover, describe and identify how behavioural changes facilitate 
the implementation of Garcia et al.’s (2008) clinical guideline for optimal OAT management. 
Facilitates Implementation 
Theme 4: Engage efforts to improve interprofessional 
communication and collaboration  




As seen in table 8, theme 4 showed how clinicians can engage in efforts to improve 
interprofessional communication and collaboration to facilitate the optimal delivery of OAT via 
hiring a nurse navigator and social networking with other clinicians.  These opportunities can 
help change clinicians’ behaviours from working in isolation to working together.  Furthermore, 
theme 2 described another behavioural change, showing how clinicians can take action to use 
compatible software platforms for documentation of OAT management.  In essence, both themes 
described how behavioural changes can facilitate the implementation of the clinical guideline for 
optimal OAT management in the WWLHIN community. Each theme is elaborated below.  
Theme 4: Engage Efforts to Improve Interprofessional Communication and Collaboration  
The fourth theme was for clinicians to engage in opportunities to improve 
interprofessional communication and collaboration efforts. The clinical guideline for optimal 
OAT management had recommendations that advised how care procedures and protocols should 




behaviours from working in isolation to effectively communicating and collaborating in teams, 
this change can facilitate the implementation of the clinical guideline. There was a need for 
pharmacists and nurses to develop these strong interprofessional communication and 
collaboration skills to facilitate care processes, especially during transitions of care. This was 
reinforced by this key informant:     
 “It's gotta be about collaboration. Um...nobody's doing this in a silo and you can't fully 
function without that integration […] So it's true collaboration, it's building those 
relationships so that there's trust amongst different practitioners. And building bridges 
with other community partners like the hospitals and making sure that people are doing 
things in a similar fashion [...]”-KI 6 
As a pre-requisite for building trust and efficiency, true communication and collaboration 
between providers was a necessary factor to facilitate the implementation of the clinical 
guideline for optimal OAT management. Firstly, the opportunity to connect with others was 
limited in community pharmacies compared to family health teams, as described by this key 
informant:   
“[…] it takes a lot of collaboration and coordination between professionals. […]So I 
don't know if I would consider it easy in our system if you're outside a family health team 
because you can probably tell we have a lot of people that are helping us maintain all 
these standards including our nursing team, our physician buy-in and the support of 
experts. “ –KI 3 
In this situation, it was easier for key informants to communicate and work with other providers 
in family health teams than community pharmacies because of the dedicated nursing team, trust 
from physicians and so on. Even with these available resources, clinicians in family health teams 
struggled with communication with other providers outside the organization such as hospitals. 
The following scenario illustrated the need for improvements in interprofessional communication 





 “There was so many things that could go wrong, so if any one of them has taken a 
moment picked up the phone and said “please keep an eye on this person” you know, 
thankfully, Person X noted the end review when she got the discharge summary and 
thankfully the surgeon sent off a quick discharge summary of all you know, not all 
discharge summaries come quickly um disaster was adverted. But some discharge 
summaries don't come until like weeks or two later um there could've been some serious 
problems […]” –KI 7 
As demonstrated, this key informant revealed that provide interprofessional communication was 
not always consistent during transitions of care. Since interprofessional practice was not 
consistent, providers clearly needed to engage their efforts to improve communication to prevent 
disastrous consequences during therapy. One such effort could be to institute a new position as a 
contextual prompt to behaviour change, as suggested by this key informant:  
“The-there needs to be a nurse navigator that sort of works through that either at the 
hospital end or at the doctor's office or maybe at the booking office or something like 
that.” – KI 7 
This  “nurse navigator” could be the channel of communication to connect health care providers 
for seamless transitions. Having a “nurse navigator” could be a prompt for behaviour change in 
this context, allowing for clinicians to improve interprofessional communication and 
collaboration efforts. As a result of improved communication, health care providers could 
facilitate improvements of all aspects of therapy as recommended by the clinical guideline, 
facilitating its implementation in practice. However, financial considerations for an additional 
health care role of a “nurse navigator” were not considered.  
 Another effort for clinicians to improve interprofessional collaboration was to create 
more opportunities for social networking with experts and other clinicians. The clinical guideline 
for optimal OAT management recommended having a systematic approach to therapy. Clinicians 
who engage in interprofessional collaboration efforts could promote this systematic approach 




connect with experts in the local region to learn more about and improve anticoagulation 
systems, as suggested by this key informant:   
“And we're very lucky to have the McMaster so close. They do a thrombosis and 
hemostasis conference every year so we go to that and the physicians there are 
remarkably approachable so you just walk up and ask them a question, they're happy to 
help! Send them emails, they always respond pretty darn quickly so that's another bridge 
that's making sure you're maintaining that competency is key!” – KI 6 
As clinicians network, this opportunity would maintain competencies in OAT management, help 
clinicians connect to experts in the field and start a conversation on how to create a broader 
approach to therapy. Secondly, creating connections with clinicians in other regions can facilitate 
the implementation of the clinical guideline, as was suggested by this key informant:   
“[…] looking to other regions that are already doing this and doing this very, very well. 
And so the folks in Edmonton are doing this very, very well. The Germans, the Swedes, 
they are doing this very, very well. And we need to be looking more broadly to apply 
those successes here. And it's about system integration, that's what it boils down to. The 
systems need to be integrated, the communication needs to be seamless and the patients 
need to be well-informed and move towards becoming self-managers when appropriate.” 
–KI 2 
Interprofessional collaboration between clinicians can help generate ideas and broaden their 
perspectives on how to have an integrated and systematic approach to therapy. In turn, this social 
networking opportunity can facilitate the systemic implementation of the clinical guideline for 
the optimal delivery of OAT management. Ultimately, creating the new position of a “nurse 
navigator” and social networking opportunities are two ways to engage clinicians to improve 
interprofessional communication and collaboration, a behavioural change which ultimately 
facilitates the uptake of the clinical guideline in community-based AMS clinics. The next theme 
describes the other behavioural change that clinicians can make to facilitate the implementation 





Theme 5:  Use of Compatible Software Platforms for OAT documentation 
The fifth and last theme illustrated how clinicians can use compatible software platforms 
for OAT documentation to facilitate the implementation of the clinical guideline for optimal 
OAT management. The clinical guideline generally recommended that documentation of OAT 
should be done on a computer software program for timely record-keeping, tracking and retrieval 
of “accurate and easily accessible” information (Garcia et al., 2008). All participating clinics 
used computer software programs, albeit not on the same platform, as this key informant 
described:    
“Um, no, only that where we need to move more broadly is connecting the INR clinics 
together. So right now they seem to operate as silos which is hard to overcome but we 
need to address that and put in strategies of communication to kind of break down those 
silo barriers. It seems a bit counterproductive for such as large population being 
managed in community pharmacies, Family Health Teams, by their solo practice 
physicians and then of course our self-managers, it seems a bit strange that this patient 
population is not more well connected and the clinicians managing them are not more 
well connected. So I think we need to think more broadly about creating databases, 
right?” –KI 2  
 
As demonstrated, clinicians in the community were operating in silos (isolation) rather than in 
unity. An integrative approach via compatible for OAT management was one way to facilitate 
the implementation of documentation standards. This standardized, integrated  approach via 
compatible systems would make the same patient information, such as demographics, treatment 
details, patient education materials and so on, more accessible to all clinicians in the community 
for enhanced patient safety, as was suggested by this key informant:  
“ […]So perhaps it makes more sense for everyone to pick a tool, whether it'd be 
INROnline or DonAC or PharmaFile or whatever it may be, there are different tools out 
there and they are online based. It would make more sense that we all use the same one 
so that the databases could be combined, the information could be shared, the INR clinic 
leads could collaborate with each other much more easily and patients could get more 
support, patient education materials and then with that, we can get a much better sense 




improve their outcomes and improve safety and move towards patients becoming self-
managers.” –KI 2 
  
Patient information and therapy elements can be streamlined across the community AMS clinics 
if clinicians change their behaviour to adopt compatible software platforms for documentation of 
OAT. All software platforms should be interoperable to combine standardized patient 
information for anticoagulation management. For example, the key informant mentioned that a 
combined system can provide shared information, such as patient educational materials to 
support them in therapy. Clinicians can then make informed decisions about OAT management 
with the use compatible software platforms because documented information would be up-to-
date and available to all of those involved. .  
Furthermore, the use compatible software platforms for documentation was already 
implemented in one region with much success, although it was not widespread in the WWLHIN 
community. As this key informant said:  
“[…] So everybody is working on a very similar system and with the plans to integrate 
all the physicians who are not part of the [organization], that's gonna make it that much 
better. So the ability for system integration has really been helpful for us but I could see 
where it could be a huge barrier in community where they don't have the processes set up 
for that to happen.” KI 6 
 
From this case, other clinicians can learn about the benefits of a compatible software platform, 
although there was still much to do to create a truly integrative system.  These key informants 
made it clear that a behavioural change to using a compatible software platform can facilitate the 
implementation of the clinical guideline in other regions of the WWLHIN community. This 
behavioural change would not only encourage the documentation standards in the clinical 
guideline, but it can also facilitate the uptake of other recommendations that focus on having a 




all patient information accessible to other clinicians in different care settings for an integrated 
and systematic approach to OAT management. 
Summary: Themes for Research Objective 2 
 Ultimately, themes 4 and 5 addressed research objective 2 by depicting how behavioural 
changes facilitate the implementation of the clinical guideline for optimal OAT management. 
This clinical guideline recommended a systematic approach to OAT management in all aspects, 
so when clinicians change their behaviours to promote this approach, it would lead to the optimal 
delivery of OAT management. The first behavioural change was described in theme 4, which 
showed how clinicians can engage in efforts to improve interprofessional communication and 
collaboration to facilitate the optimal delivery of OAT management. A “nurse navigator” could 
act as a contextual prompt to behavioural change of clinicians working in isolation to effectively 
communicating with one another. In addition, social networking with experts and clinicians in 
other regions can prompt interprofessional collaboration.  So, when clinicians engage in these 
two efforts to improve inter-professional communication and communication, this behavioural 
change facilitates the uptake of the clinical guideline as a whole.  Furthermore, theme 5 
illustrated how using compatible software platforms to document OAT can encourage the uptake 
of the clinical guideline. Clinicians who change their behaviour to uniformly document elements 
of OAT management in a compatible software platform can promote the standardized approach 
to therapy and encourage the uptake of the clinical guideline in practice. Essentially, these two 
themes showed how behavioural changes could facilitate the optimal delivery of OAT 






4.6 Conclusion  
This chapter summarizes the key findings of the data analysis. The study had six AMS 
clinics with a total of eight key informants. The most salient themes addressing research 
objectives 1 and 2 sought to explore how existing intrinsic and extrinsic factors hindered or 
supported, and how behavioural changes facilitate the implementation of the clinical guideline 
for optimal OAT management. The end of sections 4.4 and 4.5 summarized these themes for 
research objectives 1 and 2 respectively.  The next chapter presents the discussion of these key 




5 CHAPTER 5: DISCUSSION 
 
5.1 Introduction 
Community-based AMS clinics offer a practical and coordinated approach for chronic OAT 
management, particularly for frail older persons with AF (J. E. Ansell, 2009; Heckman & 
Braceland, 2015). AMS clinics are more cost-effective than usual care, because of improved 
patient outcomes and reduced hospitalizations (J. E. Ansell, 2009; Campbell et al., 2000; Eckman 
et al., 1995). There are, however, challenges for an integrative and systematic approach to OAT 
management in AMS clinics. To address this need, clinicians can apply Garcia et al.’s (2008) 
clinical guideline to deliver optimal OAT management in outpatient AMS settings, but there is 
limited research on how to go about implementing a regional program. The findings of this study 
provide insight on how  various factors counteract, support and facilitate the potential  uptake of 
the clinical guideline in community AMS clinics for a frail elderly population.  This chapter 
compares the findings with existing work in order to highlight the contributions of this study to 
the literature. In closing, limitations of qualitative studies and directions for further research are 
also outlined.    
5.2 Key Themes for Research Objective 1 
The findings of the study revealed three key themes related to research objective 1, which 
described how various factors counteracted or supported the implementation of Garcia et al.’s 
(2008) clinical guideline in AMS settings for a frail elderly population.   
Theme 1: Inadequate Reimbursement for Logistical Operation of AMS Clinics  
In determining that inadequate funding was a key barrier to implementation, the finding 




management per the clinical guideline. This sentiment was shared by more than half of the 
community pharmacists providing INR monitoring for older people in a New Zealand study, who 
claimed that services could not continue without appropriate funding (Tordoff, Chang, & Norris, 
2012).  There is currently no coverage of services and materials for OAT management by 
pharmacists and nurses in Canada, except for Quebec (Coaguchek, 2016).  
Starting in 2014, Quebec has been covering test strips for patient self-testing and 
management using a POC INR device, and allowing pharmacists to bill for OAT management 
services (Coaguchek, 2016; Régie de l’assurance maladie du Québec (RAMQ), 2014). Medicare 
Part B in the United States of America also covers the cost of test strips, as well as devices for 
patient self-testing and management, but still does not allow pharmacists to bill for OAT 
management services (Medicare, 2017). In contrast, Ontario’s Ministry of Health and Long Term 
Care does not allow the billing of POC-INR devices, test strips or OAT management services by 
both patients and non-physicians. Instead, community-based pharmacists  previously relied on 
the Pharmaceutical Opinion Program to partially recover costs for OAT management services, 
but only  when  INR values change sufficiently to require a change in OAC dose and this change 
is approved by a physician (Ontario Ministry of Health and Long Term Care, 2008). In 
comparison, FHTs receive funding from the Ministry of Health and Long Term Care to sustain 
initiatives of interprofessional primary care, such as chronic disease management programs. 
Specifically in 2016, the Government of Ontario invested $85 million to recruit and retain non-
physician health care staff in FHTs (Association of Family Health Teams of Ontario, 2017), but 
even so the allocation of funds to AMS programs are not guaranteed. The findings suggest that 




from year to year. Therefore, such inequitable funding goes against principals of care delivery 
elaborated by the Ministry of Health and Long-Term Care.  
In light of these findings, there needs to be appropriate and assured funding for community 
AMS to continue their valuable services. Pharmacist-led AMS clinics have been shown to be 
superior and safer than usual care (Bungard et al., 2009; Canadian Agency for Drugs and 
Technologies in Health, 2012; Poon, Brown, & Braun, 2007). These services are especially 
important for the frail elderly who may benefit the most from pharmacist-led AMS (Heckman & 
Braceland, 2015; Poon et al., 2007). Poon et al. (2007) found that older veterans had reduced 
thromboembolic events from pharmacist-led OAT management compared to usual care. 
Targeting frail seniors can potentially be cost-saving because they have the most to lose from 
poor care, although the benefits of well-managed AMS also extend to a variety of other 
stakeholders, including physicians, pharmacists and caregivers (Bishop, Young, Twells, Dilon, & 
Hawboldt, 2015; Shaw et al., 2014; Thompson, Ragucci, Fermo, & Whitley, 2009).   
Despite many benefits, a study by Schulman et al. (2010) revealed the Ministry of Health’s 
perspective on the high costs of long-term warfarin therapy management in Canada. It showed 
that OAT management using warfarin was 10 times the lowest cost of the drug. However, the 
cost analysis was based on only three models of care: hospital-based sites (physician-led and 
pharmacist-led) and community sites led by physicians. The cost analysis was incomplete 
because the authors did not have enough data to analyze the cost for a pharmacist-led community 
site and the potential benefits on the management of other conditions, especially for frail seniors 
in this setting. Despite that, the study still suggested that the cost analysis be used to compare 
with newer anticoagulants (Schulman et al., 2010). There were potential conflicts of interest 




In light of the evidence, the Ministry of Health should consider how to optimize warfarin therapy 
instead of replacing it. Warfarin is not as expensive as NOACs and has a more reliable history of 
use, efficacy and safety (Bauer, 2013). Analyses have shown that clinic-based POC INR testing 
is more cost-effective than usual care led by physicians (J. E. Ansell, 2009; Campbell et al., 
2000; Eckman et al., 1995). The government should focus their funding on community 
pharmacist-led AMS that aim to optimize OAT management.  However, laboratory INR testing 
for usual care continues to be covered by the Ministry of Health (Ontario Health Insurance Plan, 
1999). If inadequate billing models for pharmacist-led AMS persist, OAT management may fall 
back to usual care, causing negative effects to patients. A study established a significant decline 
in the quality and satisfaction of OAT management for patients transitioning from pharmacist to 
physician-managed care (Garwood, Dumno, Baringhaus, & Laban, 2008). Therefore, the finding 
suggests that it is important for community AMS clinics to receive consistent funding for 
logistical operation. That way, clinicians can cover costs for their services and work toward 
optimizing OAT management in the community, especially for frail older persons.  
Theme 2: Awareness of how to apply knowledge to support practice  
The finding that key informants knew how to apply general knowledge of the clinical 
guideline to support practice is consistent with other findings.  An Albertan study developed a 
three-phase approach to establish community-based AMS clinics for optimal OAT management 
(Bungard, Hamilton, & Tymcak, 2006).  In phase one, they developed a core AMS program to 
create, test and establish key components for the anticoagulation program, such as policies and 
procedures, and teaching modules. In the second year, phase two proceeded to teach these key 
components to pharmacists through three ways: (i) a web-based educational module to provide 




self-directed component with therapeutic discussions to integrate knowledge with practice. These 
modules were created to teach pharmacists about OAT management in AMS settings. Finally, in 
the third phase, they successfully applied their knowledge and skills to establish AMS clinics at 
their own practices (Bungard et al., 2006). As a result, it showed that pharmacists understood 
how to implement key components to run AMS clinics, which was consistent with the finding of 
this study that being aware of the general knowledge and skills supported the implementation of 
the clinical guideline for optimal OAT management.  
This finding is also consistent with a review that highlighted key features to consider to 
implement anticoagulation clinics (Bounda, Ngarambe, Hong, & Feng, 2013). The review found 
strategies for delivering effective OAT management in anticoagulation clinics, including the 
importance of team composition, pharmacist education and competencies for OAT management 
(Bounda et al., 2013). It showed the importance of learning how to apply components for optimal 
OAT management, which further supports the finding that awareness of the knowledge and skills 
were important for delivering optimal OAT management per Garcia et al.’s (2008) clinical 
guideline.  
Furthermore, the finding that it was important for key informants to be aware of how to 
organize themselves to meet patients’ needs to deliver optimal OAT management is consistent 
with other work.  A New Zealand study of community pharmacists who provided a range of 
services, including INR monitoring, revealed that working cooperatively with other health care 
providers, such as nursing staff, was important for developing programs (Tordoff et al., 2012). 
These community pharmacists knew that working cooperatively within their roles supported the 




the qualifications of personnel and supervision supported the implementation of the clinical 
guideline for optimal OAT management.  
Secondly, the finding that it was important for key informants to know about care 
management and coordination standards to support practice is also seen in other studies. Bungard 
et al.’s (2006) core AMS clinic developed and refined policies and procedures that adhered to 
national and local standards, which helped to engage physicians and pharmacists to run the clinic 
efficiently. Later, pharmacists in that study successfully adapted these policies and procedures to 
their own practices (Bungard et al., 2006). As such, those results endorsed the finding of this 
study that clinicians’ awareness of established policies and procedures supported the delivery of 
optimal OAT management.  
Thirdly, the finding that key informants were aware of tailoring patient education to 
support practice is consistent with other studies. One review article found that the pharmacist’s 
ability to communicate, provide patient education and counseling was important to developing 
an anticoagulation clinic (Bounda et al., 2013), and to optimizing patient outcomes (Burke et al., 
2008). One German study showed that standardized patient education was effective for 
improving knowledge and patient safety during anticoagulation (Vormfelde et al., 2014). Reports 
also indicated that strategies such as standardizing educational content, focusing on topics of 
patient safety, and using effective delivery methods optimized OAT management (Wofford, 
Wells, & Singh, 2008).  As shown in that study key informants of this study utilized some of 
these methods, such as delivering relevant information in small “chunks” to accommodate for 
individual patients’ educational needs. Hence, key informants showed an awareness to apply 
patient education standards to support practices of optimal OAT management, according to 




Fourthly, the findings suggest that key informants were aware of the standards for patient 
selection and assessment of therapy and were applying them to practice as best as they can. This 
finding supported implementation of the clinical guideline and is consistent with other findings. 
One study showed health professionals, including pharmacists and nurses, viewed 
comprehensive assessment as necessary for stroke prevention in AF (Wang & Bajorek, 2016). 
Experienced pharmacists and nurses who managed OAT emphasized the medication safety and 
management aspects of antithrombotic use, such as the cognitive function, lifestyle factors, 
polypharmacy issues and adherence in patients (Wang & Bajorek, 2016). This closely resembled 
the finding of this study where the majority of key informants in this study knew how to select 
and assess patients using these same factors, except for some discrepancies in the frailty 
assessment.  
Other work supported the finding that key informants had an incomplete assessment of 
frailty. One review reported that the diagnosis of frailty syndrome was often based on 
chronological age, leading to an inadequate risk assessment (Uchmanowicz et al., 2015). Instead, 
clinicians should focus on frailty, which is reflects biological age better than chronological age 
(Heckman & Braceland, 2015). Despite that, the findings indicate that key informants knew 
which components of frailty to assess in patients. A recent study on stroke prevention in frail 
elderly patients proposed a practical algorithm for tailored anticoagulation therapy to guide 
clinicians on selecting appropriate VKAs or NOACs (Granziera et al., 2015).  Granziera et al. 
(2015) created a diagram to show all aspects of frailty, which were components mentioned by 
key informants in this study. The finding showed that key informants were aware that assessment 
and selection of frail older patients with AF depended on their nutritional status, cognitive issues, 




the assessment and selection process supported the implementation of the clinical guideline in 
practice. However, the currently ad-hoc assessment of frailty needs to be more standardized and 
rigorous to systematically determine who in particular is frail and needs additional intervention 
or supports.  
Moreover, the finding that key informants’ awareness of how to systematically apply 
therapeutic knowledge during initiation, stabilization and maintenance of therapy supported 
implementation is consistent with other findings. Studies have shown that the 4mg regimen was 
effective for initiating elderly patients with non-valvular AF on warfarin therapy to stabilize 
them in the therapeutic range (Siguret et al., 2005; Sridhar et al., 2014). This evidence has been 
established for optimal OAT management for the frail elderly with AF and was used by key 
informants in this study to support optimal practices of OAT management, as outlined by Garcia 
et al. (2008).  
Lastly, in determining that key informants were aware of how to apply a systematic 
process for maintenance dosing and follow-ups, the finding supported the implementation of the 
clinical guideline and is consistent with other studies. CADTH endorsed a systematic plan for 
managing long-term assessment, dose adjustments and follow-up testing for optimal OAT 
management (2016), a conclusion that resonated with Garcia et al.’s (2008) clinical guideline. 
Other work also supported a systematic approach to maintenance therapy using evidence-based 
guidelines (J. Ansell et al., 2008; CADTH, 2016; Holbrook et al., 2012), and validated 
algorithms for dose adjustments to improve delivery of OAT management (Harper et al., 2014). 
This systematic approach was used by key informants to maintain therapy showing that they 
were aware of the knowledge to support practice. Furthermore, one implementation study 




consistent with the finding of this study that key informants had the knowledge and skills to 
maintain therapy and thus, supported the implementation of the clinical guideline for optimal 
OAT management.   
Theme 3: Tailored organizational supports for the frail elderly 
Although there needs to be a more rigorous way to assess for frailty, key informants 
knew how to apply an ad-hoc assessment of frailty to determine who in particular needs 
additional attention. Once identified, the findings suggest that tailored organizational resources 
for the frail elderly supported the delivery of optimal OAT management in community AMS 
clinics. Organizational supports, such as physical tools, face to face interactions, and home visits 
optimized therapeutic activities in AMS clinics by improving medication adherence and health 
monitoring. A study of pharmacists in New Zealand demonstrated that compliance packaging, 
repeat prescription reminder services, home deliveries and home visits improved medication 
adherence and safety for older patients, especially with cognitive issues in a range of services 
including INR monitoring in community pharmacies (Tordoff et al., 2012). Patients also felt 
more involved in their treatment when they had printouts to remind them of their next dose and 
test date, as shown in a pilot study of a pharmacist-led AMS clinic (Shaw et al., 2014).  New 
warfarin patients were also empowered to adhere to treatment in post-discharge home visitations 
(Stafford et al., 2011). For patients who can attend clinics, pharmacists in a study by Tordoff et 
al. (2012) found that face-to-face counseling were helpful for improving patients’ knowledge or 
understanding of their medications  (Tordoff et al., 2012). In person counseling was particularly 
important for medication adherence in older adults who tend to take on average seven 




Another study also showed that frequent face-to-face counseling in pharmacist-managed 
anticoagulation clinics helped patients (mean age of 58.2) to improve their overall health by 
monitoring health issues not related to anticoagulation management (Hicho, Rybarczyk, & 
Boros, 2016). Pharmacists managed the majority of older patient’s overall health through 
interventions, such as promoting continuity of care, assessing and triaging health concerns to 
other providers, acquiring necessary diagnostic tests, reconciling medications, modifying therapy 
and providing drug information and counseling (Hicho et al., 2016). Similar findings were found 
in another study of pharmacists in Veterans Health Administration (VHA) anticoagulation clinics 
(McCullough et al., 2016). This study further supported the value of frequent face-to-face 
interactions, point-of-care or telephone visits in the pharmacist-patient relationship, helping 
pharmacists to manage warfarin therapy more effectively. Pharmacists took a more active role to 
identify unmet needs, such as underlying mental and health conditions, then connected them to 
appropriate health care providers as needed (McCullough et al., 2016). These studies 
corroborated the finding that tailored organizational supports for the frail elderly, such as 
physical tools (blister packaging and verbal or written reminders), face-to-face interactions and 
home visits, supported the implementation of the clinical guideline through improving 
medication adherence and monitoring of other health issues.  
5.3 Key Themes for Research Objective 2 
The findings of the study revealed two major themes related to research objective 2, which 
described how various factors facilitate the delivery of optimal OAT management, according to 






Theme 4: Engage Efforts to Improve Interprofessional Communication and Collaboration  
The finding that clinicians’ engagement in interprofessional communication and 
collaboration facilitates implementation of optimal OAT management is consistent with other 
work. Bounda et al. (2013) found that effective communication with other health care providers 
was vital for establishing successful anticoagulation clinics. A pilot study of a community 
pharmacist-led AMS clinic in New Zealand showed the importance of strong collaboration 
between health care professionals in wider implementation, especially with general practitioners 
to support the role of community pharmacists and nurses (Shaw et al., 2014). Although general 
practitioners (GPs) were hesitant about pharmacists taking on clinical activities, studies showed 
that the pharmacist-GP relationship improved through building trust and confidence in the 
pharmacist as a ‘warfarin expert’ who communicated with and worked closely with GPs (Hatah, 
Braund, Duffull, & Tordoff, 2012; Shaw et al., 2014).  In a later study by Bishop et al. (2015), 
pharmacists were shown to be supported in their role in OAT management within a multi-family 
medicine clinic.  
  One particular area of interest is during transitions of care between the community and 
hospitals. A study of clinicians’ perceptions further confirmed that a breakdown in 
communication between health care providers in primary care and hospitals was perceived as a 
key barrier to optimal anticoagulation (Decker et al., 2012). This corroborates the finding that 
interprofessional communication and collaboration during care transitions facilitates optimal 
OAT management. One American study emphasized effective communication and collaboration 
between clinicians for safe care transitions of anticoagulated patients with AF, particularly for 
elderly patients moving from the hospital back into the community (Deitelzweig, 2013). 




findings suggest that community pharmacies had limited opportunity to connect with other 
providers compared to family health teams. One study found that post-discharge communication 
between hospitals and pharmacies for medication reconciliation was inconsistent and jeopardized 
patient safety (Urban, Paloumpi, Rana, & Morgan, 2013).  Although FHTs function on a 
collaborative model of multidisciplinary teams of providers (Ontario Ministry of Health and 
Long Term Care, 2016) with commitments to patient-centered care, a qualitative study showed 
that there were still challenges for patient’s transition of care when FHTs were not notified 
(Brown, Ryan, & Thorpe, 2016). This was consistent with the finding that FHTs still faced 
challenges during patient discharges when there was a lack of communication and close 
collaboration between providers in the community and hospitals. With this care transition issue, 
the finding suggests that having the additional role of a ‘nurse navigator’ can prompt 
interprofessional communication and collaboration. However, the financial implications of 
introducing this additional role needs to be considered.   
One report outlined that nurse navigators were advocates who educated, guided and 
coordinated services for patients, families and care providers (McMurray & Cooper, 2016).  Like 
studies have shown, nurse navigators can act as liaisons to multidisciplinary teams of care 
providers while they manage patient cases, functioning as both case managers and care 
coordinators (McMurray & Cooper, 2016; Watts & Lucatorto, 2014). One report showed that 
nurse navigators in primary care settings were instrumental to service integration and 
interprofessional collaboration during transitions of acute, post-acute and community care , 
especially for underserved populations who experience fragmented care (McMurray & Cooper, 
2016). Another review of a chronic disease management program for diabetes revealed that 




program (Watts & Lucatorto, 2014). This review showed that there were cost savings and 
benefits from nurse contact with patients and clinicians that still have to be examined. However, 
several of these reviewed studies did not have a formal cost analysis of having registered case 
managers in a chronic disease management program for diabetes (Watts & Lucatorto, 2014).  
Additional costs are expected when introducing “nurse navigators” to the health care system.    
Another solution could be to significantly redesign  the role of nurses in primary care 
settings (Anderson, St. Hilaire, & Flinter, 2012). Existing nurses could either take on the role of 
a “pod nurse” who would attend to the daily medical and administrative needs of the primary 
care clinic, or a “coordination nurse” who would work as a case manager, helping primary care 
providers manage care for complex patients. They proposed that sufficient funding would still be 
required to support the redesign of nursing roles and incentivize coordination of complex 
patients. (Anderson et al., 2012). There needs to be further investigation on whether or not 
redesigning staff roles are effective in prompting care coordination.  
An alternative to introducing a new role is for existing pharmacists and nurses to expand 
their scope of practice to methodically provide care coordination in community-based AMS 
settings. Anderson et al. (2012) reported that care coordination was often done “as needed” 
rather than deliberately. McMaster University provides busy clinicians with educational modules 
to integrate interprofessional education in practice (2013). One module outlined how guided 
discussion of case studies can become real life opportunities for teaching and learning 
interprofessional education. Going through this series of modules can help clinicians reach the 
goals of working and communicating better with other providers to reach patient-centered goals 
(McMaster University, 2013). As a result, pharmacists and nurses can develop interprofessional 




systematic and coordinated approach to OAT management, facilitating the delivery of optimal 
OAT management in AMS settings. In turn, integrating interprofessional education in practice 
appears to be a more feasible effort than introducing an additional nurse navigator in the health 
care system to prompt better interprofessional communication and coordination.  
Lastly, the finding that social networking among anticoagulation experts in the local and 
wider regions provides the opportunity for interprofessional collaboration is consistent with other 
work. The World Health Organization’s work on transforming education in health professionals 
included interprofessional education as one of six themes. The Canadian Interprofessional 
Collaborative connects world leaders on interprofessional practice and education through hosting 
conferences and events (2010). Providers, researchers and students exhibit proposals and 
abstracts to further interprofessional practice and opportunities (Canadian Interprofessional 
Health Collaborative, 2010). A New Zealand study of community pharmacists providing 
services, such as INR monitoring to older people, presented peer support from other pharmacists 
across the country and professional institutions as integral to facilitating services in their clinics 
(Tordoff et al., 2012). Care providers, such as pharmacists have the responsibility to share their 
knowledge with students and other colleagues (World Health Organization, 1997), which helps 
existing and new pharmacists to maintain competencies and gain new knowledge (Bounda et al., 
2013).   Therefore, other work is consistent with the finding that suggests collaborative efforts 
from social networking with experts can facilitate the adoption of an integrated and coordinated 







Theme 5:  Use of Compatible Software Platforms for OAT documentation 
 Last but not least, the finding that a compatible software for OAT documentation was a 
facilitator for implementation is consistent with other work. Optimal OAT management is rooted 
in evidence-based care, requiring standardized and integrative documentation practices to ensure 
patient-centered care, a practice that prioritizes continuity and coordination of care. 
Standardization of the data collection and retrieval process is also necessary for consistent 
documentation over time during wider implementation of optimal OAT management (Oertel, 
2009).  
With the advent of dedicated computerized software for anticoagulation management, 
there are various applications available to collect vast amount of data. However, there are 
inherent disadvantages with the use of multiple software applications across community AMS 
clinics, including interface incompatibility, and unorganized, non-standardized data. Efficiency 
of data collection and retrieval is compromised with incompatible software applications across 
clinics, making performance reviews of benchmarks and the implementation of coordinated and 
timely care more difficult (Oertel, 2009). Therefore, clinicians should select software that are 
interoperable with other data systems, especially hospital-based information systems to create 
opportunities for information exchange. Benefits in timely care for AMS patients during care 
transitions, such as admittance and discharge from hospitals can foster continuity and 
coordination of care. AMS software should also create interfaces with laboratory databases for 
INR values to be readily available to clinicians not using POC technology (Oertel, 2009).  
Another solution is to use web-based software applications, which make it possible to 
achieve systematic documentation standards across care settings. However, the reality is that the 




including the compatibility of the software’s basic features, functionality, interoperability, user 
support and financial implications to the AMS clinic. There are a variety of dedicated software 
applications for OAT management created by different vendors with varying needs (Oertel, 
2009). Depending on individual clinic’s needs, it may be difficult for all community AMS to 
have interoperable software to be a part of a compatible platform for OAT management. 
Literature on the implications of using compatible software platforms for OAT management is 
limited and needs further investigation.  
5.4 Limitations  
 Selection bias may influence the findings of the study. Only interested pharmacists and 
nurses participated in the interviews, and may not have captured implementation difficulties seen 
in smaller clinics that are not as well run or have closed down. As well, the sampling frame of this 
study may not be wide enough to capture diverse information because only two nurses were 
interviewed. Although sampling until the point of saturation was achieved from six interviews 
with pharmacists, there may be incomplete data from the small sample of nurses. However, it was 
feasible to combine the perceptions of pharmacists and nurses because they were both care 
providers in AMS community-based settings who provided the same underlying OAT 
management. Rather than claim generalizability, it is more important for this research to contribute 
to a larger project that may include more nurses and pharmacists in its sample. A larger sample 
size of pharmacists, nurses, doctors and patients in the WWLHIN community, including those in 
institutional settings should also be investigated to understand care transitions better.  
Another limitation was that the kappa coefficient was not calculated due to coding software 
incompatibility, but the percent agreement between the two coders should be calculated for inter-




transcript, the investigator could have recorded the percent agreement in coding from each 
transcript. A simple chart to document the coder’s agreement could be done for each variable of 
interest (McHugh, 2012). The chart would have column one as variable (line), two as coder’s 
themes, and three as agreement (Yes= 0; No= 1) to calculate the percent agreement for each 
transcript (number of zeros/total lines), aiming for an 80% agreement (Lombard, Snyder-Duch, & 
Bracken, 2002).  
However, reaching consensus in coding may be difficult if the second coder does not have 
an understanding of the context. For example, a quote could clearly be related to environmental 
constraints as a barrier, but regardless of these difficulties, the circumstances may suggest that 
key informants may still have the intention to continue services to support implementation.  
However, that element would be missed by a second coder who does not know the context well.  
There are more difficulties in coding because Michie et al.'s (2005) psychology theory domains 
represent distinct factors, rather than an interconnected model. From the underlying theory, 
Michie and colleagues (2005) mentioned that not all factors were required for successful 
implementation, but mainly three factors: skills, intention, and environmental resources for the 
performance of a behaviour. The investigator acknowledged that environmental factors and skills 
explicitly showed up as key themes in this study, but not intention. Although it was not a key 
theme, it was interpreted implicitly through inflection and tone of speech during interviews. 
Intention to continue services was strongly present in key informants who participated in the 
study hoping to standardize and rigorously advance OAT management systems. In order to 
prevent isolating factors that affect implementation, Michie et al. (2005) could work toward a 





5.5 Directions for Further Research  
OAT management for persons with AF needs to be optimized especially for vulnerable 
populations, such as the frail elderly who tend to move in and out from the community. There 
should be a broad and uniform approach to managing OAT across facilities in the region to 
maintain the quality of care. There needs to be continued research to validate optimal practices of 
OAT management across community AMS settings.  In the following section, directions for further 
research related to each key finding are presented. For each area of focus, further exploratory 
studies would help gain insights on the problems for further investigation. A summary of research 
questions for further studies that expand on the study’s key findings are shown below in table 9.  
Table 9. Summary of further studies     
Key Findings Research Questions  
1. Inadequate reimbursement for logistical 
operation of AMS clinics 
 
 
Before looking at the cost-effectiveness of 
long-term warfarin therapy, what are the 
perceptions of other stakeholders in adopting 
a regional approach to therapy in pharmacist-
managed AMS settings in Canada?  
 
2. Awareness of how to apply the knowledge 
to support optimal delivery of OAT 
management  
What are clinicians’ perceptions of adopting 
clinical tools for frailty assessment of patients 
with AF during OAT management in 
community-based AMS settings?  
 
3. Tailored organizational supports for the 
frail elderly 
What are the additional benefits and barriers 
that could exist by having a pharmacist or 
nurse regularly review patients with chronic 
non-valvular AF?  
  
4. Create new opportunities for 
interprofessional communication and 
collaboration to facilitate efficient care 
processes  
Instead of adding an additional role in the 
health care system, further studies should 
focus on how physicians, pharmacists and 
nurses can collaborate more effectively?  
 
What are the implications of improved 
interprofessional communication and 






5. Use of compatible software platform for 
documentation of OAT to facilitate an 
integrated, systematic approach to 
management  
 
What are the perceived benefits and barriers 
for transitioning to compatible software 
platforms for OAT management?  
Further studies should focus on gathering more qualitative data using the study’s 
methods, but from other stakeholders on their perceptions of adopting optimal practices across a 
wider community setting. Other stakeholders include general practitioners, specialists, nurses, 
physician assistants, caregivers, frail elderly patients, and so on. To expand upon the finding of 
incomplete frailty assessments,  one area of focus could be on stakeholders’ perceptions of 
adopting clinical frailty tools for selection and assessment for therapy. Conducting an 
exploratory study would help stakeholders, including policy makers and clinicians, gain insights 
on the issues around frailty tools and their use in practice. Secondly, to further explore the 
finding that tailored organizational supports for the frail elderly supported practice, another area 
of focus could be on exploring the additional benefits and barriers of regular review of patients 
with AF. As corroborated by McCullough et al. (2016), there were many additional supports 
such as face-to-face counselling to help pharmacists to manage warfarin therapy more effectively 
at the Veterans Health Administration anticoagulation clinics, but there still needs to be further 
studies in the Canadian context. The pharmacist-patient relationship in community AMS settings 
was important to delivering optimal OAT management, and for patient compliance.  
Not only that, but gaining interprofessional opportunities was a key finding to facilitate 
optimal practices in this study. Further work should also focus on how pharmacists, nurses and 
physicians can make a community-wide effort to work better together, especially during care 
transitions for patients with chronic AF. Then, further studies could look at the implications of 
improved interprofessional opportunities in the community, including safer transitions of care 




improved documentation standards on interoperable software. Then, research on the clinicians’ 
perceptions of compatible software platforms for documentation of OAT management should be 
further explored.  
After acquiring deeper insights and community-wide recognition on these research 
problems, future studies could then focus on the cost-effectiveness of long-term warfarin therapy 
in pharmacist-managed AMS settings to compare upfront costs with long-term benefits.  A cost-
effectiveness analysis will not only consider the immediate costs and benefits, but also the long-
term outputs of the program such as cost per case prevented. This is why it is important to first 
gather more qualitative data on the benefits offered in community-wide AMS clinics, such as 
additional supports for the frail elderly during regular therapeutic reviews.  As such, a systems 
approach will be useful in considering all these elements influencing patient care and health in 
pharmacist-managed AMS settings. With these studies, the Ministry of Health can make 
informed decisions to fund community AMS clinics or not. However, this is a considerably long 
path without ongoing evidence to show support from several stakeholders in the community for a 
regional approach to OAT management in the community.   
In conclusion, further studies inspired by key findings in this study can help optimize OAT 
management for efficient and quality care across the community to improve health outcomes. As 
Bungard et al. (2006) conducted a province wide study in Alberta using the health innovation fund 
for early adoption of community AMS clinics, a similar study should be conducted in Ontario. 
Further studies on validating optimal practices across community networks can lead to a more 
complete understanding of the benefits of pharmacist-managed AMS clinics. Initiatives to achieve 
a wider, integrative approach to OAT management in the community can improve the quality of 




5.6 Implications of Study  
As a theory-based assessment of factors affecting implementation, this study provides 
strategies for interventions working toward an integrative, regional approach to OAT systems. 
Insights into how intrinsic and extrinsic factors help, hinder or facilitate the implementation of 
optimal OAT management in community AMS settings can be useful for clinicians and 
policymakers. Clinicians can start to bridge gaps within their own clinics by applying these 
strategies, such as adding tailored organizational supports, improving awareness of the clinical 
guideline components, or taking initiatives for interprofessional communication and 
collaboration. Policy makers can consider issues systematic issues of funding and documentation 
software as logistical barriers to optimal practices of OAT management in community AMS 
settings. A warfarin registry, like the one conducted by Quebec, could be created for Ontario to 
assess the optimization of use (Quebec Drug Research Network, 2017). Pharmacist-led AMS 
clinics in communities across Ontario could join in the initiative to standardize documentation of 
patient data, as outlined by Garcia et al.’s (2008) clinical guideline. Then, make a combined 
effort to collate standardized data into a warfarin registry, which can be useful to clinicians and 
policymakers for monitoring clinical outcomes and performance measures.  
5.7 Conclusion  
This chapter summarizes the key findings in comparison with other work and gaps in the 
literature, as well as the limitations, directions for further research and implications of the study. 
In essence, the key findings addressed the research objectives 1 and 2 (see section 3.2), which 
was guided by the underlying theoretical lens, Michie et al.’s (2005) psychological theory. Table 




domains (i.e. factors) in the underlying theory that affected implementation of the clinical 
guideline in this study.  
Table 10. Linking key themes with research objectives and domains 
Research Objectives  Key Themes Domains of psychological 
theory 
(1) To explore and describe 
how existing intrinsic and 
extrinsic factors hindered or 
supported the delivery of 
optimal OAT management, 
according to Garcia et al.’s 
(2008) guideline, with specific 








(8) Environmental Constraints  
2. Awareness of how to 
apply the knowledge to 
support optimal delivery 
of OAT management  
(1) Knowledge  
(2) Skills  
3. Tailored organizational 
supports for the frail 
elderly 
(8) Environmental Resources 
and Context  
(2) To discover, describe and 
identify how behavioural 
changes facilitate the delivery 
of optimal OAT management, 
with specific emphasis on frail 
seniors 




collaboration to facilitate 
efficient care processes  
(9) Social Influences  
(12) Nature of Behaviours  
5. Use of compatible 
software platforms for 
documentation of OAT to 
facilitate an integrated, 
systematic approach to 
management  
 
(12) Nature of Behaviours  
 
In conclusion, linking key themes to the domains of Michie et al.’s (2005) psychological 
that influenced the implementation of the clinical guideline: (1) Inadequate reimbursement for 
logistical operation of AMS clinics was an environmental constraint; (2) Clinicians’ awareness 
of how to apply knowledge to support practices was having the knowledge and skills; (3) 
Tailored organizational supports for the frail elderly were environmental resources within their 




collaboration was using social influences to prompt behavioural changes; and (5) Use of 
compatible software platforms for documentation was a proposed system to change the nature of 
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APPENDIX A- Environmental Scan Report 
Field Visits 
A list of 12 potential clinics, including family health teams (FHTs) and community 
pharmacies within the WWLHIN were compiled with the help of key stakeholders, such as 
pharmacists in the community for the field visits. I contacted the pharmacists at each of the 
12 clinics to explain the purpose of my visit, but in the end, only 7 clinics were appropriate 
for observations (i.e. regular flow of anticoagulation patients). 
I also created a worksheet titled “Practicum Observations” as an observation/interview 
guideline to use at each visit in order to compare the similarities and differences later on. This 
worksheet was created out of the brainstorming of “Questions/Topics to Explore” (see 
appendix Figure 2) to include final questions about the POCT, feasibility in operating the 
INR-testing site, quality control, barriers/challenges and facilitators. 
 
List of Clinics Visited 
    Family Health Teams 
o FHT 1, Clinical Pharmacist 
o FHT 2, Clinical Pharmacist  
o FHT 3, Clinical Pharmacist 
o FHT 4, Clinical Pharmacist 
 
    Community Pharmacies 
o Community Pharmacy 1, Clinical Pharmacist 
o Community Pharmacy 2, Clinical Pharmacists 






1.   FHT 
G.HECKMAN | HSG 641 | SPRING 2015 
Name of HCP: Clinical Pharmacist                                          Date: June 1st, 2015 
OBJECTIVE: To understand the current processes of INR testing and to identify gaps in real life 
practice within different health care settings as compared to the literature. 
TASK DONE 
POC TECHNOLOGY 
POC Device: CoaguChek XS (Roche Canada) 
Software to track? Posologic (formerly PharmaFile) includes data on… 
- Name of patient and physician 
- CHADs Score, diagnosis, other medications, tablet strength 
- INR range, history of INR scores and notes on adjustments, current period for new dosage (mg), next appointment 
date 
- TTR (+/- 10% range, Rosendaal method) and point-prevalence (% days within INR range = days within INR 
range/ total days that INR scores were taken) 
Patient base? FHT patients only. Drop-in basis M/R mornings at Location 1; alternate W afternoons at Location 
2. Patient has a calendar booklet with dosage to take for each day until the next INR test. 
Adjustments? Clinical judgement based on principle taught in Jeff Nagge’s Pharmacist-led anti-coagulation 
course (i.e. considering all risk factors, including CHADs score) 
- 5-10% increase on their maintenance dose if patient has low INR not due to missed dosages 
-diet interactions: 1 mg of kale, parsley, and cooked spinach to get to antidote level to affect warfarin 
-medication interactions, i.e. Tylenol 1300mg for 3 or more days on average will affect INR reading 
-questions on medical/non-medical factors to assess any further adjustments 
-principle taught based on validated McMaster’s nomogram; but pharmacists don’t use algorithm during clinic. 
TTR Calculation? >75% via Rosendaal method for average TTR every quarter for reporting to MoHLTC 
Cost/ Billing? Software covered by the FHT discretionary funding for operation of clinic; device covered by 
research funding. INR strips covered by physician code billed to OHIP. 
☒ 
FEASIBILITY IN OPERATING INR 
TESTING SITE How you started? 
Program History started 9y ago using DON AC software (English program costing $8/patient) 
-patient management system is imperative 
-English dosing system where daily dosage was the same, so needed to override system if days altered in doses 
-device needed to be checked for quality at the start of every clinic session 









How do you get a medical directive? 
- Procedure 
o Doctor from the FHT issues a medical directive from the doctor to manage warfarin therapy; initiate, maintain 
and adjust the dosage. 
o  Nurse performs the test using the device and strips 
o An INR reading is inputted into the software, and adjustments are made based on the pharmacist’s knowledge 
based on past history of INR scores and follow-up medical/ non-medical questions to determine why INR is low 
or high (i.e. interactions with other medications or with lifestyle factors –diet, exercise, stress, etc.) 
o  Nurses sometimes cover for the pharmacist in-charge 
o Pharmacist fill in the calendar booklet for the patient, advise them of the maintenance dosage if changed and 
make next appointment based on their judgement based on training/experience 
      Dosage in booklets are written in mg or tabs depending on patient’s preference 
Trust in technology by MDs? Yes, due to evidence in the literature. Also trusts Jeff as the pharmacist managing their 
patients. 
Networks within Community? How do you deal with special cases? “Go-to” Resources? 
-Physician or other colleagues such as the local hematologist 
-Course material from training program 
-Encouraged to make links in the community on their own; there is no platform for communication between HCPs 
offering clinics in the area. 
 
QUALITY CONTROL 
Device: Quality of device tested every year by One World Accuracy (formerly Digital PT) 
o  Otherwise, no need to match to lab-test because they are not the gold standard 
o  Over-estimates INR between 3 and 4 
INR Training/Mentorship:Training program at UW School of Pharmacy and trained nurses at the FHT to cover his 
shifts. 
- Pharmacy school anticoagulation program 
o  6 weeks online + 40 readings with 60h coursework + 5 case studies + online exam 
o  Mentorship includes 3 clinics 
o  Trained 165-170 people- including pharmacists, nurses, residents and other HCPs 
Availability of trained staff: Clinical pharmacist, several trained nurses 
☒ 
CHALLENGES/ BARRIERS? 
-Why do you think POC technology is limited in use in Canada? Funding issues with the INR strips. Need 
trained and experienced HCPs running the clinic. 
-Trust issues between Doctor-Pharmacist? Minimal in FHT because Jeff is a well-known advocate and professor for INR 
testing clinic. Doctor trusts his management skills. 
-Collaboration with other HCPs for continuity of patient care (i.e. past INR reading, meds, if patient moves, etc)? 
Cardiologist, Hematologist, other colleagues including pharmacists in other cities/ regions in case patient moves. 
☒ 
WHAT WORKS? 
-Rapport with patients 
-Asking the right questions (medical and non-medical) to adjust warfarin 















2.   Community Pharmacy 
G.HECKMAN | HSG 641 | SPRING 2015 
Name of HCP: Clinical Pharmacist                                                             Date: June 11, 2015 
TASK DONE 
POC TECHNOLOGY 
POC Device: CoaguChek XS (Roche Canada) 
Software to track? Posologic (formerly PharmaFile) includes questions/prompts on the program 
Patient base? Patients in the community; 60-70% of patient base is valve; # patients. Does home visits for non-
mobile patients. 
Adjustments? Manual based on clinical judgement based on Jeff Nagge’s principle of +/- 10% 
TTR Calculation? 70% skewed down because of new patients who are not yet stable; 80% for long-term patients. 
Cost/ Billing? MedsCheck ($25 follow up); Site pays for program and device. 
☒ 
FEASIBILITY IN OPERATING INR TESTING SITE 
How you started? January 2015 after taking Jeff’s program. 
Trust in technology? Yes. 
How do you get a medical directive? Authorization per patient; fax with information sheet and fax every result 
and follow up plan to MD. 
Trust in technology by MDs? Cardiologists prefer NOACs; Pharmacist has to explain and reassure MDs of his program 
and skills. 
Networks within Community? How do you deal with special cases? “Go-to” 
Resources? Colleagues, Jeff Nagge, Course notes, physicians 
☒ 
QUALITY CONTROL 
Device? Quality Control done at initiation of program; still too new to consider another quality test. 
INR Training/Mentorship: Anticoagulation Course 









-Why do you think POC technology is limited in use in Canada? 
o  unawareness 
o  billing issue 
o  pharmacist: cost of being trained in the anticoagulation course 
o  MDs are conservative and don’t trust pharmacists that they don’t know to manage their patients just in case 
an adverse event occurs, which would be the responsibility of the primary physician 
-Any perverse billing incentives? 
X community pharmacy was being audited for the MEDSCHECK program by the ODB 
-Trust issues between HCPs? Doc-pharm? Pharm-patient? Pharm-pharm (transfers)? 
If the doctor doesn’t know the pharmacist, they don’t give their authorization. 
Through other services provided by the pharmacist, the doctor can come to trust the pharmacist’s abilities. 
Patients are on board and trust the pharmacist. 
 
 
-Collaboration with other HCPs for continuity of patient care (i.e. past INR reading, meds, if patient 
moves, etc)? No problem if pharmacist knows where the patient is moving to. 
☒ 
WHAT WORKS? Rapport with patients Trust from MDs 
Training and experience from anticoagulation program 
Initiative from pharmacist 





3.   FHT 
G.HECKMAN | HSG 641 | SPRING 2015 
Name of HCP: Clinical Pharmacist    Date: June 15, 2015 
TASK DONE 
POC TECHNOLOGY 
POC Device: CoaguChek XS (Roche Canada) 
Software to track? INROnline and Telus EMR (documents on separate spreadsheet) 
Patient base?  Patients; majority 65+ 
Adjustments? Clinical judgement based on principle taught in Jeff’s program: +/- 10%. Claims that INROnline 
adjustments are 
overestimations of the actual INR so they use clinical judgement first, then refer to program’s adjustment as support 
TTR Calculation? Average TTR = 70% ; no individual TTR’s 
Cost/ Billing? OHIP service 
☒ 
FEASIBILITY IN OPERATING INR TESTING SITE 
How you started? Person X started the anticoagulation clinic after training with Jeff. 
Trust in technology? Yes, literature to support it. 
How do you get a medical directive? FHT physicians authorize pharmacists to see all their warfarin patients. 
Trust in technology by MDs? Yes, because doctor knows/ trust FHT pharmacist 
Networks within Community? How do you deal with special cases? “Go-
to” Resources? Physicians in FHT, Jeff Nagge, referral to emergency if 
cannot reach physician 
☒ 
QUALITY CONTROL 
Device: Calibrated 3x/year for quality control 
INR Training/Mentorship: Jeff’s anticoagulation course 
Availability of trained staff: Nurses and Clinical Pharmacist 
☒ 
CHALLENGES/ BARRIERS? 
-Why do you think POC technology is limited in 
use in Canada? Funding, billing 
-Any perverse billing incentives? 
None for FHT because they allocate the funds to the program. Not billed directly to OHIP or ODB. 
-Collaboration with other HCPs for continuity of patient care (i.e. past INR reading, meds, if patient moves, etc)? 
Jeff Nagge, course notes, physician, nurses, community pharmacist if need to clarify other medications, other 
colleagues (not so much the cardiologist) 
 







4.   Community Pharmacy 
G.HECKMAN | HSG 641 | SPRING 2015 
Name of HCP:  Clinical Pharmacists    Date: June 25, 2015 
TASK DONE 
POC TECHNOLOGY 
POC Device: CoaguChek XS (Roche Canada) 
Software to track? Posologic (formerly PharmaFile) 
Patient base? Patients in the community and from the adjacent doctor’s offices; drop-in basis; majority of 
their patients fill their prescriptions here.  
Adjustments? Clinical judgement based on Jeff’s principles and teachings. INROnline doesn’t adjust for 
special situations, so clinical judgement is used first. 
TTR Calculation? 78% built in TTR calculator. 
Cost/ Billing? Medscheck; government is not allowing pharmacists to bill if INR adjustments are stable and 
needs no changes. Need to do an annual meds review, papers to sign by patient to submit to ODB. 
☒ 
FEASIBILITY IN OPERATING INR TESTING SITE 
How you started? 5-6y ago after training in Jeff’s anticoagulation program 
Trust in technology? Assessed variability between lab and POCT device 
How do you get a medical directive? Dr. offices surrounding the pharmacy. Knowing the doctors and having a 
good relationship with them so they can trust their skills. 
Trust in technology by MDs? At first, it was new, but as they started using them, the doctors warmed up and 
started becoming familiar with the new technology. Although Cardiologists prefer NOACs because there is no 
need to monitor their patients— sometimes they have no time. It was actually protocol to offer NOACS e.g. 
Xarelto at one clinic but no evidence it’s effective, and apixaban at another which is the best NOAC with 62% 
TTR. Doctors usually gave authorization if their patient’s INR is equal to or less than 5. 
Networks within Community? How do you deal with special cases? “Go-
to” Resources? Jeff Nagge, Physicians , Other Colleagues 
☒ 
QUALITY CONTROL  
INR Training/Mentorship: Anticoagulation program 









-Why do you think POC technology is limited in use in Canada? 
Billing Medscheck only if INR needs adjustment. Cost of POCT ($25test, $7 strips) vs. lab-test ($18) but without the 
long wait and pharmacists can provide patient counselling. Patient interaction about missed dosages, mixed up tablet 
strengths and catch any mistakes before they get worse at consistent meetings. 
-Any perverse billing incentives? 
ODB Medscheck: requirements are narrow (seniors/social assistance are eligible but need >3 medications) 
-skills-set of pharmacy; “counter” medscheck is trying to capitalize on the reimbursement 
-But it is meant to incentivize the pharmacist to provide service to patients 
-Trust issues between HCPs? Doc-pharm? Pharm-patient? Pharm-pharm (transfers)? 
Not a problem for those who know the doctor well enough. 
Patient doesn’t always disclose all medications if not a client at the pharmacy  unnecessary liability for both parties 
Switching pharmacists- dispensing all medications to prevent drug-drug interactions but it may cause friction between 
pharmacists in the community if they think Pharmacy is “stealing their business” 
-Collaboration with other HCPs for continuity of patient care (i.e. past INR reading, meds, if patient moves, etc)? 
Dispense all medications at Pharmacy so they know other medications patients are taking 
Doctor next door or have contact via phone/fax 
 
 
-Others: Since NOACs are out, there has been a shrinking patient base. Apixaban is okay and some patients may 
benefit from NOACs if not appropriate for warfarin. POC contraindications: Lupus and INR greater or equal to 8. Need 




-Rapport with patients, trust and easy access to pharmacists 
-Professional Opinion and Intervention for patient advocacy 
-Urge and engage patients for treatment to manage co-morbidities 
-Privacy in professional setting 
-Time for patients to express concerns 
-Clinician to question and give advice to patients 
 
-Compliance and adherence management 
 






5.   Community Pharmacy 
G.HECKMAN | HSG 641 | SPRING 2015 




POC Device: CoaguChek XS (Roche Canada) 
Software to track? Posologic (formerly PharmaFile) 
Patient base? Referral based from the community; total of # patients with # doctors on board. Patients mostly 65+ 
Adjustments? Clinical judgement based on Jeff’s principle. 
TTR Calculation? 71% two years ago. 
Cost/ Billing? Medscheck requested by Physician. Some patients don’t qualify so it’s $20/test. Narrow requirements by 
ODB: check out website to see. 
☒ 
FEASIBILITY IN OPERATING INR TESTING SITE 
How you started? 3 years ago; introduced to anticoagulation clinic by Clinical Pharmacist at FHT 
Trust in technology? Yes, validated by studies in the literature 
How do you get a medical directive? Community doctors, referral based. 40 doctors authorized by doctor to 
treat all their anticoagulation patients. 
Trust in technology by MDs? Yes, via successful clinical studies for CoaguChek XS and additional references. 
Networks within Community? How do you deal with special cases? “Go-to” Resources? 
☒ 
QUALITY CONTROL 
Device:  Quality check yearly 
INR Training/Mentorship: Anticoagulation Program 
Availability of trained staff: 2 pharmacists on site 
☒ 
CHALLENGES/ BARRIERS? 
-Why do you think POC technology is limited in use in 
Canada? Funding issues. 












-Trust issues between HCPs? Doc-pharm? Pharm-patient? Pharm-pharm (transfers)? 
1.Minimal trust issues if rapport with doctors and have other doctors backing the program up. 
2. Don't want to mess with patient's relationship with their current pharmacist so patients do not need to 
switch to their pharmacy to access the clinic; however, they are required to pay $100 to start. 
3. Pharmacist has rapport with doctors and there are some doctors advocating for the program 
4.Hospital referrals too. 
5. Patients sometimes do not disclose all meds used such as antibiotics, which is especially difficult if it's due to 
memory issues/cognitive issues  need to refer to CCAC 
-Collaboration with other HCPs for continuity of patient care (i.e. past INR reading, meds, if patient moves, 
etc)? Collaborate with doctors advocating for program, other pharmacists for up-to-date meds for patients, 
physicians giving 
authorization if INRs are too high or low, other colleagues 
-Others 
If pharmacist working for FHT and own pharmacy, there could be a conflict of interest if sharing EMRs and patient info. 
 
WHAT WORKS? 
- Close rapport with doctors and patients 
-Long-standing relationships 
- M/W INR clinic days by appointment in the office 
-Medscheck at the same time 






6.    FHT 
G.HECKMAN | HSG 641 | SPRING 2015 
Name of HCP: Clinical Pharmacist                                                          Date: July 22nd, 2015 
TASK DONE 
POC TECHNOLOGY 
POC Device: CoaguChek XS (Roche Canada) 
Software to track? Practice Solutions - Telus EMR only system includes INR score range (In/out of therapeutic 
range) 
Patient base? FHT patients ~# total; 60% are older adults with AF; all physicians sign one directive for all their 
patients. 
Adjustments? University of Wisconsin- validated algorithm (nomogram) 
TTR Calculation? Point prevalence 
Cost/ Billing? FHT discretionary funds for POCT (device and all program related costs) 
☒ 
FEASIBILITY IN OPERATING INR TESTING SITE 
How you started? Pharmacist initiated through "gap analysis" to see who would benefit from one-on-one staff 
attention. 
Trust in technology? Yes. Studies to show effectiveness. 
How do you get a medical directive? Authorization from FHT doctors. Program in the FHT so doctors get 
involved. 
Trust in technology by MDs?  Yes. Studies to show effectiveness. 
Networks within Community? How do you deal with special cases? “Go-to” Resources? 
Doctor in the FHT, course notes, nurses etc for DVT duration 
☒ 
QUALITY CONTROL  
INR Training/Mentorship:  BC anticoagulation program for 5 days then it became outdated so they still use the 
philosophy to 
train other nurses 
Availability of trained staff: Three; Clinical pharmacist, nurses 
☒ 
CHALLENGES/ BARRIERS? 
-Why do you think POC technology is limited in use in Canada? 
1.Managers- accountability issues in the FHT 
2.No comparison for POC vs. lab? [Shows gap in knowledge to action! That's why there's trouble with funding!] 









4.Cost of strips - unsure about funding each fiscal year 
-Any perverse billing incentives? 
None since FHT funds them.  Controversy if funds not used efficiently. 
-Trust issues between HCPs? Doc-pharm? Pharm-patient? Pharm-pharm (transfers)? 
All involved in FHT so there is minimal issue as long as it's a FHT pharmacist doing a program. 
-Collaboration with other HCPs for continuity of patient care (i.e. past INR reading, meds, if patient moves, 
etc)? 
*EMR messaging system with doctors or face-face interaction; barely contact Cardiologist. 
*Community pharmacies have no communication with FHTs if they don't fill a prescription 
1.Need documentation 
2.Infers with trust of pharmacies with the FHTs 
3.Nurse education to document properly but also workload issues 
* Assess bridging for patients into surgery  heparin needles 
Others: 
-Each FHT operates differently and has its own work routines and related issues 
-Low risk guidelines for bridging warfarin before surgery not available? [gap in knowledge: need to see CHESS 
guidelines!] 
-Not using software for adjustments and using their own clinical judgement based on the nomogram; 
but not standardized protocol each time. 
 
WHAT WORKS? 
-Education sessions for nurses for critical thinking when receiving INR form lab (to ask questions before 
dose adjustments on the phone when doing it the usual care way) 







7.   FHT 
G.HECKMAN | HSG 641 | SPRING 2015 
Name of HCP: Clinical Pharmacist         Date: August 13, 2015 
TASK DONE 
POC TECHNOLOGY 
POC Device: CoaguChek XS (Roche Canada) 
Software to track? Posologic (formerly PharmaFile) + EMR (Telus) 
Patient base? #  patients (~# physicians in the FHT) 
Adjustments? Clinical judgment using algorithm based on a combination of CHESS guidelines, Jeff's prinicple, 
PharmaLearn at 
University of AB 
TTR Calculation? Pharmacy co-op students make a excel worksheet to calculate TTR every 4 months. TTR= 70-
75% all patients 
Cost/ Billing? FHT Global budget (L/G physician codes ceased); report #counts to MoLTC but they aren't 
really checking so they stopped doing it. 
☒ 
FEASIBILITY IN OPERATING INR TESTING SITE 
How you started? August 200# first project to start this clinic; first clinic in Jan 2008 
Trust in technology? Yes, there are clinical studies on the device. 
How do you get a medical directive? Pharmacist goes around and recruits doctors from the FHT. Every 
2 years, pharmacist renews the directive. 
Trust in technology by MDs? Ok--there are many physicians on board. 
Networks within Community? How do you deal with special cases? “Go-to” Resources? 
-Physicians 
-Bridging letter for surgeons; oral surgeon will automatically refer patients to the clinic and GI surgeons 
write note for patients to be managed in clinic 






Device: Quality control yearly with 3 samples 
from 1WorldAccuracy 
INR Training/Mentorship: 
* Pharmacist and Nurse initially took Anticoagulation Course with 1-2d mentorship (longer if needed), then 
other nurses would get the PharmaLearn certification with case presentations - valid up to 2012 since CHESS 
guidelines changed since then. They still use the thought process to guide HCPs. 
*As of June 2015: reading package, INR clinic time with certified HCP, 11 cases to present and discuss before 
they are qualified 
 
☒ 
Availability of trained staff: Two HCPs (pharmacist/student and nurse) always present in 2 rooms for INR clinic.  
CHALLENGES/ BARRIERS? 
-Why do you think POC technology is limited in use in Canada? 
*Documentation and communication 
-difficulty faxing lots of information 
-access to all information including new meds, conditions, lifestyle 
-in order to run it on this level, you need to collaborate and communicate 
*Funding to buy strips is the biggest expense 
*Expenses for full time nurse, point nurse and pharmacist for 2 full days is expensive 
(POCT is $18 vs. lab is $21 per test) 
*Hospital cannot do just POCT because they need to take blood to test for other conditions as well. So it's not 
efficient to use 
POCT for just warfarin management. 
-Any perverse billing incentives? 
-Trust issues between HCPs? Doc-pharm? Pharm-patient? Pharm-pharm (transfers)? 
-Collaboration with other HCPs for continuity of patient care (i.e. past INR reading, meds, if patient moves, 
etc)? 
-Communication with specialists is frustrating 
-Close communication with community pharmacist 
-Others: 
-Does Roche give away devices to FHTs willing to buy strips from them? They do replace devices for free…check 
this out! 
-Wants to turn program into an anticoagulation clinic for all anticoagulants including NOACs (should 






-Implement CHAD2 scores and ECHO especially if patient is older 
-Seamless EMR between all sites involved with the FHT 
-Clinical pharmacist allowed to refill and plan warfarin dosing regime 
-3.6 pharmacists per FHT site; so they work closely with doctors and build a rapport/trust with them 
-Patients bring up other issues besides anticoagulation such as issues with physician relationship, other 
conditions, compliance issues 
-Patient was in hospital and had to wait in frustration for hospital to do lab testing and result so 






Potential Gaps Identified during Environmental Scan 
Reflecting on this practicum course, I observed 7 clinics within the WWLHIN that are 
operating anticoagulation clinics for warfarin management. I met key stakeholders in the 
community, such as pharmacists at FHTs, Grand River Hospital and UW’s School of Pharmacy as 
additional supports for my thesis research. As such, we began to discuss and compare what was 
shown in the literature and reality to identify potential gaps for my thesis research. 
In the literature, there are data to suggest that pharmacist-led anticoagulation clinics are 
superior to physician or nurse-led anticoagulation in terms of reducing clinical outcomes and 
improving INR control. The implementation of POC-INR clinics in local FHTs and 
community pharmacists reflect this knowledge in the literature. The data also suggests that 
using validated algorithms for warfarin dosing adjustments resulted in a better time in 
therapeutic range (TTR), a surrogate outcome for anticoagulation adequacy, and a reduction in 
total bleeds. Despite what's shown in the literature, a gap exists between this knowledge and 
action in reality because clinics using validated algorithms for dose adjustments varied. 
Although most of them were certified through the anticoagulation program at the School of 
Pharmacy, they were using their experience, clinical judgement and the principle taught in the 
program rather than a validated nomogram for initiation and maintenance dose adjustments. 
Furthermore, quality control of the CoaguChek XS device and collection of data such as 
TTRs also varied between the clinics.  This poses as another barrier to make it difficult to compare 
and contrast the anticoagulation adequacy. There needs to be improvement in the standardization of 
protocols for anticoagulation clinics, as well as the making it more available to all patients 
requiring warfarin management. Currently, an eligible patient would have to either find a 
participating community pharmacy or be enrolled in a FHT to receive anticoagulation services. 
This may be due to barriers such as a lack of inter-professional communication and collaboration 
between pharmacists and physicians, especially in community pharmacies. Accountability of 
patient outcomes is another issue because the primary physician has the defaulted responsibility of 
the managing the patient care; therefore, pharmacists must gain the trust of physicians to manage 
their patients. This is often difficult for most physicians who are more conservative and/or who 
don’t know the pharmacist well enough to assess their clinical skills to manage their patients. 
Ultimately, through conducting the preliminary scoping review and field visits, I believe this 





APPENDIX B- Summary of Articles on AMS 
Table 1. Research and review articles on anticoagulation management services (n=16) 
Study Purpose  Methods Conclusions 
(Bishop et al., 
2015) 
To describe the 
satisfaction of patients 
and physicians with a 
pharmacist-managed 
anticoagulation program 
in a family medicine 




survey of 94 patients 







management by the 
pharmacist  
Patients and family 
physicians were 





program with clear 
instructions on dosing 
and INR testing. All 
physicians 
recommended the 
program continue to 
other clinics.  
(Kountz et al., 
2015) 
To explore multiple 
perspectives on 
strategies for improved 
management of AF   
Focus groups of 
health care 
stakeholders were 
conducted by a 
moderator and note 
taker on topics such 
as preliminary data 




and their impact on 
clinical and 
economic outcomes, 
and strategies for 
optimizing treatment. 




three groups: patients/ 
caregivers, physicians 
and payers. They 
recognized the need to 
understand the reasons 
for under-prescription 
and non-adherence for 
anticoagulation 
therapy. As well, a 
concerted effort 
between the three 
stakeholders using 
evidence and outcome 
based data are required 
to address the gaps and 
optimize 
anticoagulation therapy 





To examine the impact 
of stroke on patients with 
AF and caregivers, 
knowledge gaps, 
perceptions of physicians 
A survey of patients 
with AF, caregivers 
and physicians were 
conducted online or 
via telephone 
The impact of stroke 
on patients with AF 
can be improved with 
better decision making 




and patients, and barriers 
to optimal 
anticoagulation therapy 
management   
management of care, 








expressed the desire to 
learn, receive more 
information and take 
action to reduce their 
risk of stroke, despite 
overwhelmed and 
socially isolated. In 
spite of this, physicians 
underestimate the 
patient compliance and 
willingness to take 
anticoagulants.   
 
(Barra & Fynn, 
2015) 
To examine the barriers 
of prescribing 
anticoagulation in 
patients with atrial 
fibrillation (AF) and how 
to overcome them in the 
United Kingdom  
Review article of the 
epidemiology of AF, 
economic analysis of 
AF, the use of 
warfarin in managing 




patient age, multiple 
conditions, insufficient 
risk stratification based 
on the CHADS2 or 
CHA2DS2-VASc 
scores, perceived falls 
and bleeding risk, and 
complexity of 
achieving a stable INR 
for patients using 
warfarin  
(Nicholls et al., 
2014) 
To survey Canadian 
physicians on the 
treatment of patients 
with AF and barriers to 
the prescription of 
anticoagulants  
A cross-sectional 




specialists had 1032 
who were contactable 
and 335 who 
completed the survey 
about the frequency 
of patients with AF 
Physician groups had 
similar prescribing 
practices and reported 
seeing at least 1 patient 
with AF. Cited barriers 
of prescription were 
falls risk, hemorrhage 
risk, and poor patient 
adherence. Physicians 
were more likely to 





practices and barriers 
to prescription of 
warfarin. The survey 
was developed 
through a narrative 
review of the 
literature for 
previously identified 
data on the topics 
asked in this study.  
patients with prior 
stroke while not on 
warfarin, even with a 
risk of falls.    
(Shaw et al., 
2014) 









GPs, practice nurses, 
pharmacists) who 
were all surveyed and 
some of which were 
also interviewed on 
the telephone about 
their attitudes on a 
variety of attributes 
related to CPAMS, 
such as accessibility, 
convenience, etc. 














some of Garcia et al.’s 
key components for 
optimized OAT, but 
program was for 
general population. 
(Lee, Tam, 
Yan, Yu, & 
Yat, 2013) 
To explore the 
perceptions of doctors 
and patients on stroke 
prevention management 
in Hong Kong  
A prospective survey 
of 62 physicians and  






knowledge of AF and 
warfarin therapy     
Barriers of stroke 
prevention 
management were 
related to physicians 
and patients’ 
knowledge, which 
were lower than their 
international 
comparison groups. 
Majority of physicians 








knowledge on AF and 




To describe the 
perceptions of 
pharmacists and 
physicians for warfarin 
management in primary 
care settings in 
Kitchener/Waterloo area  
Focus groups and 
semi-structured 




rate from pharmacists 
and physicians (42, 
16.8%). Basic 
demographics were 
also collected.  
Pharmacists favoured 
POCT in community 
pharmacies more than 
physicians, who were 
more hesitant about 
inaccurate results even 
with more training. 
Both practitioners 
suggest that additional 
training, funding for 






(Decker et al., 
2012) 
To determine the 
clinicians’ perceptions of 
barriers for optimal atrial 
fibrillation (AF) 
management in warfarin 
treatment at Kansas City, 




and internal medicine 
physicians who are 
responsible for 
anticoagulation 
management for AF. 
Semi-structured 
interviews were 
conducted on 27 
clinicians from two 
different clinics until 
point of saturation 
Many challenges to 
warfarin treatment 
were identified by 
clinicians. 5 major 
themes of barriers 









These social and 
lifestyle factors were 
pertinent to warfarin 
treatment. This 
exploratory, qualitative 
study has limitations in 
non-generalizability 





(Pugh, Pugh, & 
Mead, 2011) 
To determine the 
attitudes of physicians 
A systematic review 
of 1375 citations 
Physicians are 




and identify the reasons 
for the under-
prescription of warfarin 
for patients with AF  
from 5 databases 
from an electronic 
search of MEDLINE, 
EMBASE, CINAHL, 
PsycINFO and Web 
of Knowledge 
warfarin therapy to 
elderly patients with 
AF with risk of falls 
and hemorrhaging as 
highly cited barriers to 
warfarin prescription. 
Despite the greater 
benefits of 
anticoagulation in the 
elderly over younger 
patients, these 
perceived barriers were 
seen by physicians. 
Further investigation 




therapy.   
(Thompson et 
al., 2009) 
To examine the clinical 
outcomes and views of 
patients using warfarin 
and managed by a 
pharmacist in an 
anticoagulation clinic 
using point-of-care 
testing (POCT) device 
vs. venipuncture in 
outpatient care clinics in 
the United States 
Enrolled 145 patients 
using warfarin who 
had anticoagulation 
services managed by 
clinical pharmacists 
at the MUSC Family 
Medicine Centre and 
University 
Diagnostic Center. 
Patients were asked 
to fill out a 
satisfaction survey, 
and had these data 





% of time in the INR 
therapeutic range for 
6 months before and 
after the use of 
POCT device 
41% of patients were 
taking warfarin for 
atrial fibrillation. 59% 
of patients completed 
satisfaction surveys, 
which revealed 
preference of POCT 
device over 
venipuncture due to 
more face-to-face 
interaction, shorter 
wait time, more 
convenience in INR 
testing and faster 
results. No significant 
differences were found 
in the clinical 
outcomes before and 
after the use of POCT 
device. Concluded that 
patients were more 
satisfied with POCT 
than venipuncture but 
difference in clinical 
outcomes were limited.   
(Garwood et 
al., 2008) 
To assess the changes in 
the quality and 
Enrolled 40 patients 







anticoagulation  care for 
patients in a transition 
from a  pharmacist-
managed anticoagulation 
clinic to a physician-
managed care clinic after 
stabilization of warfarin 
in Detroit, Michigan    
therapy to measure 




including % of INR 
in target range, 
anticoagulation-
related health care 
visits, and responses 
to satisfaction 
surveys  
services resulted in a 
significant decrease in 
the quality and 
satisfaction of 
anticoagulation care 
after the stabilization 





To identify perspectives 
of clinicians, allied 
health professionals, 
older patients and their 
carers on the strategies 
for the use and 
management  of warfarin 
in Australia  
Focus group 
interviews of 14 
patients with atrial 
fibrillation aged 65 
and older taking 
warfarin, 3 carers, 12 
specialists, 8 general 
practitioners (GPs), 6 
community 
pharmacists and 11 
nurses recruited in 




required to support the 
use and management 
of warfarin by health 
care professionals and 
patients. Several issues 
were identified in the 
study, such as ways to 
improve decision 
making processes, and 
dissemination of 
practical information to 




recognized that allied 
health professionals 
need to take 
responsibility in 
warfarin therapy as a 
major step to 
improving the service 
in the community.  
(Ford & Close, 
2007) 
Editorial  
To criticize Bajorek et 
al. on the time of dose 
and point-of-care testing 
that may affect 
compliance for the 
management of patients 
with atrial fibrillation 
taking warfarin in the 
community 
To the editor:  
Criticizes that 
warfarin dosing in 
the evening is a 
practice to allow dose 
adjustment on the 
day of testing in a 
hospital that flowed 
into community 
In reply: Time of 
warfarin dosing is due 
to medication safety 
protocol in the hospital 
so that the main 
treatment team can 
review the patient’s 
blood test and adjust 





taking warfarin as 








warfarin therapy.  
The authors recognized 
that this timing may 
not be optimal for 
patients discharged in 
the community, and 
should be at a time that 
is most convenient for 
patients to comply to 
warfarin therapy. 
Point-of-care testing 
was not expanded in 
the study due to word 
limits, but it was 
recognized as a service 
in outpatient settings. 




frameworks of care, 
including mobile 
services.  
(Wilson et al., 
2004) 
To assess the quality of 
anticoagulation using a 
pharmacist-led point-of-
care testing model of 
care under the 
supervision of an 
Anticoagulation clinic at 
a specialized hospital in 
Halifax, Nova Scotia.   
Enrolled 19 patients 
receiving long-term 
warfarin therapy for 
at least 3 months in 
the hospital 
anticoagulation clinic 
or the designated 
pharmacy. The 
primary outcome 
measured was the 
proportion of time for 
INR within the 
therapeutic range for 
2 groups (patients 
managed in the 
community pharmacy 
and historical 
controls managed in 
the hospital clinic). 
Secondary outcomes 
were the rates of 
thromboembolic and 
major bleeding 
The two groups had 
similar warfarin 
management measured 
by the primary 
endpoint of INR level 
in the therapeutic 
range. No adverse 
events occurred in any 
participants, and there 
was no difference in 
the patient satisfaction 
surveys between the 








& Vial, 2002) 
To investigate doctors’ 
attitudes on the use and 
lack-of prescription of 
warfarin therapy for 
stroke prophylaxis in 










knowledge on current 
guidelines of 
therapeutic 
management of AF 
and attitudes on 
potential barriers on 
the prescription and 
use of warfarin.  
There is room for 
improvement of 
doctors’ knowledge 
about the suitable use 
of warfarin therapy and 
the results of recent 
clinical trials. Major 
barriers to warfarin use 
in patients with AF 
were identified. 
Strategies were listed 
to target these barriers 
to improve warfarin 
prescription: (1) create 
and disseminate clear 
guidelines on whether 
to anticoagulated 
patients or not, (2) 
education on other risk 
factors in patients with 




APPENDIX C- Michie et al.’s Psychological Theory Domains 
Table 2. Theoretical domains adapted from Michie et al. (2005) to investigating clinicians’ 
perceptions of implementing the recommendations for optimized OAT  
Domains* Constructs Interview questions  
(1) Knowledge Knowledge about components of the guidelines for 
optimized OAT 
Schemas+mindsets+illness representations  
Procedural knowledge 
Do they know about the 
guideline?  
What do they think the guideline 
says?  
What do they think the evidence 
is?  
Do they know they should be 
doing x?  
Do they know why they should 
be doing x?  
(2) Skills  Skills to provide components for optimized OAT 
Competence/ability/ skill assessment of personnel   
Practice/ skills development 
Interpersonal skills  
Coping strategies  
Do they know how to do x?  
How easy or difficult do they 
find performing x to the required 
standard in the required context?  
(3) Social/ Professional 
role and identity  
Identity 
Professional identity/boundaries/ role 
Group/social identity 
Social/group norms  
Alienation/organizational commitment  
What is the purpose of the 
guidelines? 
What do they think about the 
credibility of the source, e.g. 
consensus-based on the 
anticoagulation forum?  
Do they think guidelines should 
determine their behaviour?  
Is doing x compatible or in 
conflict with professional 
standards/ identity? (prompts: 
moral/ ethical issues, limits to 
autonomy) 
Would this be true for all 
professional groups involved 
(e.g. GPs, cardiologists)  




Control—of behaviour and material and social 
environment  
Perceived competence  
Self-confidence/ professional confidence 
Empowerment 
Self-esteem 
Perceived behavioural control 
Optimism/ pessimism 
How difficult or easy is it for 
them to do x? (prompt re. 
internal and external 
capabilities/ constraints) 
What problems have they 
encountered?  
What would help them?  
How confident are they that they 
can do x despite the difficulties?  
How capable are they of 
maintaining x?  
How well equipped/ comfortable 
do they feel to do x?  








What do they think will happen 
if they do x? (prompt re 
themselves, patients, colleagues, 









Unrealistic optimism  
Salient events/ sensitisation/critical incidents 
Characteristics of outcome expectancies—physical, 
social, emotional 
Sanctions/rewards, proximal/distal, valued/not 
valued, probable/improbable, salient/not salient, 
perceived risk/threat 
and negative, short term and 
long term consequences)  
What are the costs of x and what 
are the costs of the 
consequences of x?  
What do they think will happen 
if they do not do x? (prompts) 
Do benefits of doing x outweigh 
the costs?  
How will they feel if they 
do/don’t do x? (prompts) 
Does the evidence suggest that 
doing x is a good thing?  
(6) Motivation and 
goals (intention) 
Intention; stability of intention/ certainty of 
intention  
Goals (autonomous, controlled)  




Distal and proximal goals  
Transtheoretical model and stages of change   
How much do they want to do 
x?  
How much do they feel they 
need to do x?  
Are there other things they want 
to do or achieve that might 
interfere with x?  
Does the guideline conflict with 
others?  
Are there incentives to do x?  
(7) Memory, attention 




Decision making  
Is x something they usually do?  
Will they think to do x?  
How much attention will they 
have to pay to do x?  
Will they remember to do x? 
How?  
Might they decide not to do x? 
Why? (prompt: competing tasks, 
time constraints) 
(8) Environmental 
context and resources 
(environmental 
constraints)  
Resources/ material resources (availability and 
management) 
Environmental stressors 
Person x environment interaction 
Knowledge of task environment  
To what extent do physical or 
resource factors facilitate or 
hinder x?  
Are there competing tasks and 
time constraints?  
Are the necessary resources 
available to those expected to 
undertake x?  






Team working  





Management commitment  
Supervision 
Inter-group conflict  
Champions  
Social comparisons 
Identity; group/social identity 
To what extent do social 
influences facilitate or hinder x? 
(prompts: peers, managers, other 
professional groups, patients, 
relatives) 
Will they observe others doing x 






Conflict—competing demands, conflicting roles  
Change management 
Crew resource management  
Negotiation  
Social support: personal/ professional/ 
organizational, intra/interpersonal, 
society/community 
Social/group norms: subjective, descriptive, 
injunctive norms 















Does doing x evoke an 
emotional response? If so, what?  
To what extent do emotional 
factors facilitate or hinder x?  




Implementation intention  
Action planning 
Self-monitoring  
Goal priority  
Generating alternatives 
Feedback 
Moderators of intention-behaviour gap 
Project management  
Barriers and facilitators of delivery of optimized 
OAT 
What preparatory steps are 
needed to do x? (prompt re 
individual and organizational)  
Are there procedures or ways of 
working that encourage x?  




Direct experience/past behaviour  
Representation of tasks  
Stages of change model  
What is the proposed behaviour? 
(e.g. systematic approach in 
patient selection, initiation and 
management of OAT; provider 
education and training; etc.) 
Who needs to do what 
differently when, where, how, 
how often and with whom?  
How do they know whether the 
behaviour has happened?  
What do they currently do?  
Is this a new behaviour or an 
existing behaviour that needs to 
become a habit?  
Can the context be used to 
prompt the new behaviour? 




equipment) e.g. reminder posters 
on the wall  
How long are changes going to 
take?  
Are there systems for 
maintaining long term change?  





APPENDIX D- Information and Consent Forms 
Key Informant Information Sheet 
Faculty Supervisor: Dr. George Heckman (ggheckma@uwaterloo.ca) 
Student Investigator: Brenda Trinh (b2trinh@uwaterloo.ca) 
Organization: University of Waterloo, School of Public Health and Health Systems 
Study: “Clinical pharmacists and nurses’ perceptions on implementing anticoagulation therapy 
recommendations for the frail elderly: An exploratory study based on psychological theory” 
 
Introduction 
My name is Brenda Trinh, a MSc. student at the University of Waterloo working under the supervision 
of Dr. George Heckman in the School of Public Health and Health Systems Department in the faculty 
of Applied Health Sciences. This information letter will explain my research and your involvement in 
this study as a participant. Our research focuses on understanding the perceptions of pharmacists and 
nurses on the implementation of the guideline recommendations for the delivery of optimized oral 
anticoagulation therapy (OAT) by Garcia et al. (2008). The target population is the frail elderly with 
atrial fibrillation (AF) who live in the community.  
As a participant, you will be interviewed as a key informant to help us understand your perceptions on 
why the guideline for optimal OAT delivery is implemented or not. These interviews will help us create 
a list of the benefits, barriers and facilitators for effective implementation. We hope that this 
information will be a vital for informing how a coordinated, regional approach to OAT is possible in 
the Waterloo-Wellington LHIN (WWLHIN) community. You do not have to make a decision to 
participate or not today, but before you decide, you can feel free to talk about this research with anyone. 
I encourage you to ask any questions or express any concerns that you may have after reading this 
information sheet. 
Background & Aim of Research  
AF is a significant contributor to stroke at all ages and the prevalence of AF rises with age. In 
Canada, stroke is the leading cause of mortality and disability. The standard of care for persons with 
chronic non-valvular AF is to provide long term oral anticoagulation therapy (OAT) with warfarin, 
which reduces blood clots and the risk of stroke by two-thirds. Research has shown that pharmacist 
or nurse-led anticoagulation management service (AMS) clinics are comparable or better than routine 
medical care by physicians, in terms of cost-effectiveness and patient outcomes.  Poor OAT 
management often results in an increased risk of major hemorrhage and stroke. These risks are 
further complicated for people with AF who are older, frail, and have multiple co-morbidities and 
polypharmacy. Hence, a coordinated, regional approach is required to optimize OAT management for 
the frail elderly to offset complications and improve outcomes.  
The first step to achieving this goal is to understand why implementation of key elements in a 
systematic approach to OAT delivery are implemented or not. Then, a list of the benefits, barriers and 
facilitators can be generated from this data to help inform the wider implementation of an integrated 
OAT system within the WWLHIN region. The investigator will conduct this research by first 
inquiring the clinician on which of the 9 guideline recommendations he or she feels requires the most 




skills and other factors that influence the uptake or not of the selected guideline recommendations. 
This way, clinicians and policymakers in the region can start a conversation about what worked, 
didn’t work and will work in the wider implementation of a coordinated approach to OAT. 
 
Participant Selection 
You are being invited to take part in this research because we feel that you are a key informant for this 
study. Key informants are pharmacists and nurses with the following criteria:  
- Possess the proper certifications to work at AMS clinics within the WWLHIN community: 
Waterloo-Kitchener, Cambridge and Guelph;  
- Involved in a AMS clinic using point-of-care technology (i.e., hand-held INR testing device and 
software) within a Family Health Team or community pharmacy; and  
- Have worked for at least 6 months.  
Excluded key informants are clinicians who work in hospitals; provide laboratory testing for routine 
medical care in the community (e.g. physicians who provide venipuncture INR testing); and/or have 
worked less than 6 months at AMS clinics.   
  
Voluntary Participation 
Your participation in this research through key informant interviews is completely voluntary. It is your 
choice on whether or not to participate. If you choose not to participate, there are no consequences. 
You can choose not to answer any questions that you feel uncomfortable with. You may choose to 
participate now and still be able to change your mind later, ending the interview at any time. 
 
Procedures/Duration 
We are inviting you to participate in a 30-minute key informant interview to learn more about your 
perceptions on how different influences affect the uptake or not of the guideline recommendations for 
optimal OAT delivery. The target population we will be talking about is a frail elderly population. If 
you accept, you will be asked ahead of time to review the 9 guideline recommendations by Garcia et 
al. and identify 1 or 2 key recommendations that require improvement in practice. This 7-page journal 
article will typically take less than 30 minutes to read, and will be provided again for your reference 
during the interview. During the interview, questions about your knowledge, opinions and attitudes 
that affect your selected guideline recommendation(s) will be asked. With your permission, the 
interview will be audio-recorded to help facilitate the collection of information and later be transcribed 
for analysis.  
 
Confidential Information 
The interview will be conducted by the investigator, Brenda Trinh, and interviewer notes will be taken 
by a research assistant for the purpose of data triangulation to ensure accuracy during qualitative coding 
and analysis. Your information and the interview you provide, including all notes and audio-tapes, will 
remain confidential and only identified by a code. Nothing will be attributed to your name. All 
information that could identify you, except for your profession and the city in which you work, will be 
removed from the data immediately after transcription by the student investigator or the research 
assistant, and stored separately. All recordings and notes will be maintained for a minimum of seven 




this time period. Only those associated with this study will have access to these records which are 
password protected. It is not possible to withdraw your consent once papers have been submitted to 
publishers. All records will be destroyed according to the University of Waterloo policy.  
 
 
Risks and Benefits 
There may be sensitive or uncomfortable topics about your knowledge, opinions and attitudes that you 
may choose not to answer.  You do not have to provide any explanations for questions left unanswered. 
There will be no direct benefit to you, the participant, but your help in answering the interview 
questions is likely to help us identify the clinicians’ perspective on implementing guidelines for optimal 
OAT   
 
Sharing the Results 
The knowledge we gain from this research will be made available to you before it is made public for 
other interested people to learn from the research. A summary of the results will be emailed to all key 
informants before we publish it.  
 
Right to Refuse or Withdraw 
You do not have to participate in the interview if you choose not to. There are no consequences to 
withdrawing your consent, even if you agreed to participate earlier. You may choose not to participate 
by saying you want to stop the interview. 
 
Who to Contact 
If you have any further questions or concerns, please ask them now or anytime during the 
interview. If you have further questions after the interview, please contact any of the following people: 
Student Investigator-- Brenda Trinh, b2trinh@uwaterloo.ca; Faculty Supervisor – George Heckman, 
ggheckman@uwaterloo.ca 
 
Ethics Statement  
 This study has been reviewed and received ethics clearance through a University of Waterloo 
Research Ethics Committee.  However, the final decision about participation is yours. If you have any 
comments or concerns resulting from your participation in this study, please contact the Chief Ethics 
Officer, Office of Research Ethics, at 1-519-888-4567, ext. 36005 or ore-ceo@uwaterloo.ca. 
 
Key Informant Consent Form 
Study: “Clinical pharmacists and nurses’ perceptions on implementing anticoagulation therapy 
recommendations for the frail elderly: An exploratory study based on psychological theory” 
Project context: A Masters of Science thesis  
 
I have read and fully understood the information sheet provided about this study, so I agree to voluntarily 





 The aim of the research is to identify pharmacists and nurses’ perceptions on what behaviours influence 
the implementation of selected guideline recommendations for optimal OAT delivery in AMS clinics. 
The population of interest is the frail elderly in the WWLHIN community. 
 
 I am a pharmacist or nurse working at a Family Health Team or community pharmacy that uses point-
of-care technology (i.e., hand-held device to check INR and computerized software) for at least 6 
months.  
 
 I will be asked to review the 7-page journal article with guideline recommendations and select 1-2 key 
areas that I feel require improvement in clinical practice before I meet the investigator. Then, I will be 
asked to do a 30-minute interview.  
 
 Questions will be about my knowledge, opinions and attitudes on why different factors influence the 
uptake or not of the selected guideline recommendation(s). I understand that my perceptions will 
contribute a collective list of benefits, barriers, and facilitators for effective implementation across 
community clinics. This study will be a small but vital step to informing the region how we can achieve 
a broader, more uniform approach to OAT.  
 
 At any time, I can refuse to answer or discuss certain questions/ topics, or even end the interview 
without any problems.   
 
 With your permission, the interview will be recorded to facilitate collection of information and later 
transcribed for analysis.  
 
 The interview that I give with its information will be used solely for the purposes defined by the project 
and will remain confidential using a number code to protect my identity. All data will be maintained 
for a minimum of seven years. You can withdraw consent to participate and have your data destroyed 
according to the University of Waterloo policy by contacting us within this time period. Only those 
associated with this study will have access to these records which are password protected.  
 
 For any information about the project, I can contact the investigator, Brenda Trinh at 
b2trinh@uwaterloo.ca or her academic supervisor: George Heckman, ggheckman@uwaterloo.ca 
 
 By indicating my consent, I am not waiving my legal rights or releasing the investigators or involved 
institution from their legal and professional responsibilities.  
 
 This study has been reviewed and received ethics clearance through a University of Waterloo Research 
Ethics Committee.  I was informed that if I have any comments or concerns resulting from my 
participation in this study, I may contact the Chief Ethics Officer, Office of Research Ethics, at 1-519-
888-4567 ext. 36005 or ore-ceo@uwaterloo.ca. 
 
Respondent's signature: _____________________      Date: __________________________ 









Thank-you for meeting with me today to discuss your perceptions as a pharmacist or 
nurse on implementing the recommendations for optimal oral anticoagulation therapy 
(OAT).  
The big picture is to understand how we can go from the status quo to an integrated, 
regional approach to OAT. But first, we must understand why the guidelines, being a 
systematic approach for optimal delivery, are being implemented or not in community 
clinics. 
Before we begin, I want to make sure that you understand what this study involves. 
[Review the forms handed out:   
 Garcia et al. provides us with these 9 key elements or recommendations for 
optimal OAT delivery:  You have chosen _______________ (insert 1 or 2 selected 
recommendations) to focus on in detail.  
 The information and consent forms explain the research and how we are 
conducting it. The purpose is to help you decide whether you want to be 
interviewed or not. 
 The interview will last about 30 minutes and it will be audio recorded with your 
permission. We will talk about what you think are current behaviours or lack of 
behavioural change, and prompts for future changes that influence the uptake 
or not of the selected guideline recommendations within the general scope of 
community practice.  
 You don’t need to answer any question and you can stop the interview at any 
time. 
 We will be using the information from the interview to help us identify a list of 
benefits, barriers and facilitators for effective implementation of the guideline 
recommendations. This will help inform the WWLHIN on the steps to take for a 
broader and more uniform OAT system.  
 Information from this interview will remain confidential. 
 
Collect the Informed Consent Form at the end.] 
 
[Investigator has these general probes for each question:   
 Watch tone of voice and facial expressions  
 Silence  
 Clarification of ambiguous terms (e.g. Can you give me an example of ‘term?’) 
 Encourage more information by asking neutral prompts: What else? Can you 






1.0 Key Informant Characteristics  
(1) Tell me a little about yourself and the clinic.  
- Specific Probes:  
 What is your… 
 Job title (e.g. pharmacist or nurse)?    
 Professional degree designation (PharmD, BScN, etc.)?  
 Employment Status (full time, part time, sessional, etc.)?  
 Experience with anticoagulation?  
 # years working with anticoagulation management 
 POC technology training/experience 
 POCT device and software used?  
 # of active patients in the database?   
 Availability of trained staff in clinic 
 
2.0 Frailty Consideration in Patient Selection and Assessment for OAT 
(2) As we are targeting a vulnerable older population, we tend to see frailty. 
What is your take on frailty and how it influences patient selection and 
assessment for anticoagulation therapy? 
 Reiterate question for clarification:   
- So in other words, what is frailty?  
- Do you know if frailty is assessed in patients with OAT?    
- If so, what is the frailty assessment based on?   
- Do you think it has an effect on anticoagulation therapy 
management?  
- If so, why or why not?  How so?  
 
 
3.0 Internal Influences on the Implementation of Selected 
Recommendation(s)   
Looking at the optimized OAT guidelines, we will ask the following questions in 
regards to your selected recommendation(s): _________ (1 or 2 chosen). Keep in 
mind that OAT is in the context of a frail elderly population.  
 
(3) Knowledge: [Highlight selected recommendations and ask those ones]    
 1. Qualifications of Personnel 
- What certifications are required to work in this AMS clinic?  
 If formal training: Can you describe what the program 
entails?  
 If informal training: Do you think it necessary to obtain 
formal anticoagulation management training programs?  
Why or why not?  
- What do you think the guideline says about optimizing 




 2. Supervision 
- What kind of supervisory agreement is required by referring 
physicians to transfer patient care to AMS clinics?  
 Who is accountable for the patient during therapy?  
- What do you think the guideline says about optimizing practice 
guidelines for AMS providers, in terms of daily job duties, 
responsibilities and accountability?  
- Why do you think it is necessary to obtain a “collaborative practice 
agreement”?  
 3. Care Management and Coordination 
- What policies and procedures are followed for care management 
and coordination for routine visits and continuity of care across 
institutions?     
- What do you think the guideline says about optimal care 
management and coordination?  
- Why is it recommended? How does it affect the patient?  
 4. Documentation 
- What kind of documentation system do you use?  
- What do you think the evidence says about optimizing 
documentation in practice?  
- Why do you think it was recommended?   
 5. Patient Education 
- During a typical visit, how do patients learn more about their 
condition?  
- What do you think the guideline says about optimizing patient 
education?  
- Why do you think the evidence suggests this?  
 6. Patient Selection and Assessment 
- How are patients currently selected and assessed for OAT?  
- What do you think the guideline says about optimizing patient 
selection and assessment procedures?  
- Why do you think this should be done?  
 7. Laboratory Monitoring 
- Based on the POC device you use for regular monitoring; how would 
you describe your trust in the technology?  
- What do you think the evidence is for optimizing laboratory 
monitoring for warfarin therapy?  
- Why do you think this is recommended?  
 8. Initiation and Stabilization of Warfarin Therapy  
- What is initial dosing based on?  
 Is it based on a nomogram?  
 Where from? E.g. CHEST guidelines  
- What do you think the evidence is for optimizing initiation and 
stabilization of warfarin therapy?  




 9. Maintenance of Warfarin Therapy:  
- What is the approach for maintenance therapy to stabilize the long 
term dosage?  
 Is it based on a nomogram?  
 Where from? E.g. CHEST guidelines 
- What do you think the evidence is for optimizing maintenance?  
- Why do you think this should be done?  
 
(4) Skills- How easy or difficult do you find implementing the 
recommendation(s) to the required standard in the context of a frail elderly 
population?  
 Specific probes if topic not mentioned:   
- Reason for difficulty:   
 Why is it easy or difficult for you?  
- Interpersonal skills:  
 How about your experience when collaborating or 
communicating with physicians and other health care 
providers involved in your patient’s therapy?   
- Skills Training & Development   
 If a PD (professional development) workshop such as OAT 
training or mentorship were available, what would you want 
to learn more about?  
- Skills Assessment:  
 What qualifies a clinician to work in the AMS clinic?  
 
 
(5) Social/Professional role and identity- Is applying the guideline 
recommendation(s) compatible or in conflict with professional 
standards/identity?   
 Specific probes if topics not mentioned: 
- Professional Role:  
 What do you think about the credibility of the source, i.e. 
consensus-based anticoagulation forum?  
 Do you think these recommendation(s) should determine your 
behaviour in practice?  
 Are there moral/ethical issues?  
 Are there limits to autonomy?  
- Social norm:  
 Would this be true for all health care professionals involved?  
 
 
(6) Beliefs about capabilities (self-efficacy)- How comfortable do you feel 
about following the selected recommendation(s)?  
 Specific probes if topics not mentioned:  




- What would help you?  
- Despite these difficulties, how confident are you that you can follow 
the recommendation(s)?  
 
(7) Beliefs about consequences (anticipated outcomes/ attitudes) – What do 
you think will happen if you follow the guideline recommendation(s)?  
 Reiterate the question if clarification required:  
- What do you think will happen if you do not follow the guideline 
recommendation(s)?  
- Do benefits of following the guideline outweigh the costs?  
 Specific probes:  
- Regarding patients, colleagues, and the organization 
- Short term and long term consequences 
- How will you feel if you do/don’t follow the guideline(s)? 
 
(8) Motivation and goals (intention)- Do you feel that the implementation of 
the selected recommendation(s) is a goal priority for this clinic?  Why or why 
not?  
 Specific probes:   
- Are there incentives to do so?   
- Or does it conflict with others, i.e. colleagues in the same field 
(nurse or pharmacist), physicians, specialists, etc.?  
- If so, do you feel that it is harder to commit to the implementation?   
 
 
(9) Memory, attention and decision processes – Might you decide not to 
follow the selected recommendation(s)? Why? 
 Specific Probes:  
- Will you usually think to implement the recommendation(s)?  
- How much attention will you have to pay to do it?  
- What if there are competing tasks, or time constraints?  
 
4.0 External Influences on Implementation of Selected 
Recommendation(s) 
 
(10) Environmental context and resources- How does the physical 
environment or resources facilitate or hinder implementation?   
 Specific Probes:  
- 1. Qualifications of Personnel  
  Are there available formal training programs in Canada? 
 How well are these programs managed for students?   
 Are there any competing tasks and/or time constraints to 
obtaining a certification?  




 How do they facilitate or hinder implementation of this 
recommendation?  
- 2. Supervision 
 Are there AMS practice guidelines available?  
 Are trained personnel familiar with the AMS practice 
guidelines?  
 How are AMS staffing guidelines managed for accountability 
of patient care?  
i. Are there times when staffing was short?  
ii. What happens if the main staff take temporary leave, 
i.e. vacation?  
iii. How would the pharmacist or nurse ensure that the 
terms of supervision are satisfied?  
 How would these resources influence the implementation of a 
collaborative practice agreement?   
- 3. Care Management and Coordination 
 Are there opportunities for inter-professional communication 
and collaboration with all involved stakeholders?   
i. Physicians  
ii. Cardiologists/ specialists 
iii. Relatives/ Family Members 
iv. Other pharmacists 
v. Health care providers in long-term, hospitals, etc. 
 How are these inter-professional relationships initiated and 
managed? 
 Are there any time constraints or competing tasks that 
interfere with communication and collaboration processes? 
 How would having this input affect the continuity of care?   
- 4. Documentation:  
 Is there access to information technology (IT), software, and 
the relevant patient data?  
 How is the patient data managed in the system on a regular 
basis? 
 Is there access to shared patient data between health care 
providers?  
i. During transfers into/out of institutions 
ii. Between community providers 
iii. How are paper based records handled?  
 Do you know how to access help from the supplier or other 
resources during IT errors?  
 Is there a competing documentation system?  
 How would these resources influence the implementation of 
documentation software into practice?  




 Is there access to educational resources for providers to give 
to patients? What are they about?  
i. Prompt: In case of a warfarin dosing error 
(over/underdose), how do patients know what to do?  
 Are AMS providers available for face-face interactions if 
patients have questions? How is this done?   
 Is there availability to the knowledge assessment tools to 
customize education materials to the patient population? 
i. What is being done for the frail elderly?  
 How are these resources managed to keep the education 
materials up-to-date? E.g. which data source is used?  
 What strategy do you use to disseminate educational 
materials to patients? Individualized or general? Why?   
 How would these resources influence the implementation of 
patient education?  
- 6. Patient Selection and Assessment 
 From your experience, how long does it take for family 
physicians to assess patients and refer them to your clinic?  
i. Is there a time lag? Why is that?  
ii. What happens to the patient’s condition when there is 
a long wait time?  
iii. How are patients usually selected and assessed by the 
referring physician to go to your clinic?  Does it differ 
for high risk patients?  
 Do AMS providers have resources providing up-to-date 
comprehensive exam tools:  
i. Evidence-based guidelines: CHADS2, HAS-BLED to assess 
appropriateness for OAT? 
ii. Clinical frailty tools?  
 How do these resources (or the lack of) influence the 
implementation of patient selection and assessment for 
appropriate OAT?    
- 7. Laboratory Monitoring  
 Is there access to point-of-care devices? How many?    
 Is there access to testing strips?  How often do you have to 
order?  
 Is there adequate management and quality control of the 
point-of-care devices?  
 If there are issues with the device or strips, who do you 
contact to troubleshoot? Is help available and managed 
properly?  
 How will these resources influence the implementation of 
regular laboratory monitoring? How is this important in the 




i. Prompt re: special characteristics that make it difficult 
for them to come out for regular testing, so the 
resources need to be available and working at clinic 
- 8. Initiation and Stabilization of Warfarin Therapy &  
9. Maintenance of Therapy  
 Are there AMS providers available who are knowledgeable 
about their patients to provide appropriate advice?   
 What resources are available for AMS providers to start or 
maintain warfarin dosing to the required standard?  
i. Prompt: Are evidence-based nomograms available?  
 What available resources do you find are useful for patients 
to reduce dosing errors?  
i. Prompt: What are used to keep track of dosing 
schedule for patients?  
o A calendar booklet, electronic reminders, 
relatives, pill box, tablet strength (1mg vs. 
breaking tablets), etc.?  
 How else do resources influence initiation, stabilization and 
maintenance of therapy?   
 
(11) Social influences (norm)- To what extent do social influences facilitate or 
hinder following the selected recommendation(s)?  
  Specific Probes 
- 1. Qualifications of Personnel 
 Who influenced or will influence you to get additional 
anticoagulation training or mentorship? Why?  
 E.g. managers, peers, other health care professionals, etc.? 
- 2. Supervision, ask:   
 Who is primarily responsible or accountable for patient 
outcomes during OAT?  
 How do you go about obtaining a medical directive from 
referring physicians?  
i. Are there strategies learned from other people?  
ii. Is there any reluctance to provide medical directives to 
pharmacists? Why? 
iii. Does it differ between physicians, specialists and 
surgeons? Why do you think that happens?  
 How do you think inter-professional relationships can play a 
role to influence trust between health care professionals?   
- 3. Care Management and Coordination, ask:  
 Who are your “go-to” resources or networks in the community 
for questions or consultation for special cases? 
 Are there internship opportunities for others to observe 




 Additionally, what happens to the patient’s OAT management 
when they enter another institution, such as a hospital, long-
term care, retirement home, another pharmacy, etc.?  
- 5. Patient Education, ask:  
 How does social support facilitate patient education?  
i. Social support such as personal, professional, 
organizational, interpersonal or community structures  
ii. Particularly, how does the interpersonal relationship 
between patient-provider influence the uptake or not of 
patient education?   
iii. Are there any conflicting messages provided to 
patients by different health care providers? If so, how 
do you see that affecting the patient?   
- 6. Patient Selection and Assessment 
 What social influence will influence appropriate patient 
selection and assessment for OAT, especially for frail elderly 
patients?  
i. In other words, what social support will help this 
process? 
o Prompt: having trust from patients and their 
relatives, or the physicians?  
ii. What social pressures, processes or relationships will 
hinder it?  
o Prompt: reluctant physicians or specialists, 
conflict with other pharmacists in business, etc. 
- 7. Laboratory Monitoring  
 How does the social context influence regular monitoring of 
INR in patients?  
i. How does social support from managers, organization, 
and community play a role?  
ii. Inter-professionalism between pharmacist-physician?  
iii. Social support from family/ relatives?   
 
- 8. Initiation and Stabilization of Warfarin Therapy & 
9. Maintenance of Therapy, ask:  
 What social supports are in place to ensure appropriate 
initial dosing and stabilization, or maintenance therapy for 
your patients?  
i. How do inter-professional relationships with the 
referring physician, specialists, pharmacists and other 
health care professionals play a role?  
ii.  How about with patients and their families?   
 What are social pressures that hinder the implementation 




i. How do conflicts—such as competing demands, roles or 
change in management—interfere with 
implementation?  
ii. How about conflicts with the organization commitment 
to the program?   
iii. Are there other social groups?  
 
(12) Emotion- To what extent do emotional factors facilitate or hinder following 
the selected recommendation(s)?  
 Specific probes:  
 How about emotions such as stress, burn-out, anticipated 
regret, cognitive tiredness, threat, positive/negative affect, 
anxiety/depression?  
 
5.0 Ways for improving implementation of the selected guideline 
recommendation(s) 
 
(13) Behavioural regulation – What preparatory steps do you think are 
required to implement the guideline recommendation(s), especially in a frail 
elderly population?  
 Reiterate question for clarification:  
- Are there ways of working that encourage following the selected 
recommendation(s)? Why?  
- What are the action plans to implement the recommendation(s)?  
 Specific Probes to prompt topics not mentioned:  
- Preparatory steps such as goal/target setting, action planning, self-
monitoring, prioritizing goals, generating alternatives, obtaining 
feedback, etc.?  
- Explain how these action steps are facilitators for applying the 
selected recommendation(s) in practice?  
 
 (14) Behavourial Change- What behaviour do you think should become a habit 
for improving the implementation of the recommendation(s)?   
 Topic specific probes:  
- Think of a situation involving your selected recommendation(s) that 
was handled well by yourself or a colleague. What is the behaviour 
that should be exemplified here?  
- Is this a new behaviour or an existing behaviour?  
- Who needs to do what differently?  
 
(15) What do you think can prompt the new behaviour as a long term change?  
 Specific Probes:  
- When would you do it? Where? How often? With whom? Why would 




- How about clinic layout, reminder systems or equipment as 
prompts? 
- Are there current systems for maintaining this long term change? 
Why or why not?  
  
 
4.0  Closing  
Is there any other information that you think we should know about what else 
influences the delivery of the selected guideline recommendation(s) to a frail, 
elderly population?  
 
Do you have any questions about this interview, or what we talked about? 
 
Thank you for sharing your time and insights with me today, and I hoped you 





APPENDIX F- Justification of Questions 
 
Table 3. Justification of Interview Guide Questions for Key Informants  
Question # Reasoning (To answer research 
question) 
General Probes 
Caution: Watch tone of voice 
and facial expressions 
To avoid criticism when talking about sensitive 
topics, such as a respected individual’s skills or 
knowledge  
Probe 1. Silence  To give time for the participant to think and 
process  
Probe 2. Clarification of vague 
terms before using more probes  
e.g. "Can you give me an example of the 'term?'  
To clarify ambiguous terms to probe for more 
information  
Probe 3. Encourage more 
information  
Asking neutral prompts just in case the participant 
does not have anymore things to say 
1. Tell me a little about yourself and the 
clinic. 
To know the characteristics of the participant 
to identify the individual or personal factors 
that affect perceptions 
Specific 
Probes 
Type 1. Employment details  The specific probes will enable investigators to 
create a frequency table of the characteristics to 
describe the key informants and the AMS clinic.     
Type 2. POCT device and software 
Type 3. Clinic details (# patients & staff) 
2. As we are targeting a vulnerable 
older population, we tend to see frailty. 
What is your take on frailty and how it 
influences patient selection and 
assessment for anticoagulation 
therapy? 
To assess the baseline understanding of frailty 
and its implications on patient selection and 
assessment for OAT.  
Probes 
Reiterate Question in other words To stay on topic by reiterating the question to 
remind the participant of what is being asked 
3. Knowledge (Generic version): What is 
currently being done? What do you 
think the guideline says about the 
recommendation(s)? Why do you think 
it was necessary?  
 
To identify the status quo and clinicians’ 
knowledge of the  selected guideline 
recommendation(s), guided by the component 
constructs of (1) Knowledge from Michie et 
al.’s psychological theory  
4. Skills- How easy or difficult do you 
find implementing the 
recommendation(s) to the required 
standard in the context of a frail 
elderly population? 
 
To identify the clinicians’ view on personnel 
competence/skills that may affect the 
implementation of the selected guideline 
recommendation(s). This question is guided by 
the component constructs of (2) Skills from 
Michie et al.   
Specific 
Probes 
Type 1. Reason for difficulty  Because question asks the level of difficulty, we 
want to probe the reason why it is easy or difficult 
to implement in the context 
Type 2. Interpersonal skills If interpersonal skills does not come up as a 
reason, this probe will ask for the clinicians’ 




specific skill influences the implementation 
process 
Type 3. Skills Training & Development To find out about what skills need to be developed  
Type 4. Skills Assessment To find out how AMS providers are qualified to 
work in the clinic 
5. Social/Professional role and 
identity- Is apply the guideline 
recommendation(s) compatible or in 
conflict with professional 
standards/identity?   
 
To identify the clinicians’ views on how the 
social/professional role and identity influences 
the implementation of guideline 
recommendation(s), guided by the component 
constructs of (3) from Michie et al.  
Specific 
Probes 
Type 1. Professional Role  To identify whether the implementation of the 
selected recommendation(s) align with 
professional identity 
Type 2. Social norm To identify group norms of implementing the 
recommendation(s) 
6. Beliefs about capabilities (self-
efficacy)- How comfortable do you feel 
about following the selected 
recommendation(s)? 
 
To identify the clinician’s views on how the 
beliefs about capabilities influence the 
implementation of guideline 
recommendation(s), guided by component 
constructs of (4) from Michie et al.  
    
Specific 
Probes 
Type 1. Problems Encountered  To identify any issues that interfere with 
professional confidence  
Type 2. Initiatives to Help To identify any initiatives that would help 
empower self-efficacy 
Type 3. Optimism/ Pessimism To identify perceived behavioural control over 
task 
7.  Beliefs about consequences 
(anticipated outcomes/ attitudes) – 
What do you think will happen if you 
follow the guideline 
recommendation(s)? 
To identify the clinicians’ view on how the 
benefits about consequences  influence the 
implementation of guideline 
recommendation(s), guided by component (5) 
from Michie et al.  
Probes 
Probe 1. Reiterate Question in other 
words 
To stay on topic by reiterating the question to 
remind the participant of what is being asked 
Specific Probe Type 1.  Outcome 
expectancies to stakeholders 
To prompt participant on consequences to 
different stakeholders to jog their memory  
Specific Probe Type 2. Timeline 
consequences 
To prompt key informants on the short and long 
term consequences  
Specific Probe Type 3. Resulting 
Emotion Consequences  
To prompt the key informants on how they feel if 
they follow or do not follow the selected 
recommendations  
8. Motivation and goals (intention)- Do 
you feel that the implementation of the 
selected recommendation(s) is a goal 
priority for this clinic?  Why or why 
not? 
To identify how the clinicians’ motivation and 
goals influence the implementation of the 
guideline recommendation(s), guided by the 
construct components of (6) from Michie et al.  
Specific 
Probes 
Type 1. Incentives To identify if there are positive incentives for 
implementation  
Type 2. Conflicts with others To identify if there are negative conflicts with 




Type 3. Conflict leading to commitment 
issues 
To identify if commitment issues stem from lack 
of intrinsic motivation due to conflict with other 
professionals  
9. Memory, attention and decision 
processes – Might you decide not to 




To identify how the memory, attention and 
decision processes of clinicians influence the 
implementation of guideline 
recommendation(s), guided by (7) from Michie 
et al.  
Specific 
Probes 
Probe 1. Memory To identify if participant remembers to do the task 
Probe 2. Attention To identify if participant pays attention to the task 
Probe 3. Decision making factors  To identify if participant makes a decision not to 
follow it due to time or task constraints   
10. Environmental context and 
resources- How does the physical 
environment or resources facilitate or 
hinder implementation?   
To identify the view of clinicians on how 
environmental context and resources influence 
the implementation of guideline 
recommendation(s), guided by (8) from Michie 








Type 1. Availability of resource   To identify if that resource is available, and does 
it facilitate or hinder implementation  
Type 2. Management of resource  To identify if the available resource is managed 
properly, and if not, does it hinder 
implementation?  
Type 3. Environmental stressors To identify if there are time or task constraints on 
obtaining the resource  
Type 4. Knowledge of task environment To identify if AMS providers know how to reach 
implementation goals with the resources available 
to them 
11. Social influences (norm)- To what 
extent do social influences facilitate or 





To identify the clinicians’ view on how the 
social influences, affect the implementation of 
the guideline recommendation(s), guided by 




Type 1. Who influences the uptake or not 
of the selected recommendation(s)?   
To identify the stakeholders who are influential in 
the implementation process  
Type 2. Inter-professionalism and team 
working  
To identify how interpersonal relationships 
between health care professionals, and/or patient-
providers play a social support role in the 
implementation process 
Type 3. Professional roles, 
power/hierarchy and group conformity 
To identify how professional roles, hierarchy and 
group conformity of referring doctors, specialists, 
surgeons, or other health care providers may 
hinder the implementation of the guidelines by 
pharmacists.   
Type 4. Learning and modelling  To identify if mentorship or internship programs 
influence the implementation process 
Type 5. Social pressures To identify conflicts at different social levels that 
may influence the implementation process  
12. Emotion- To what extent do 
emotional factors facilitate or hinder 
To identify the clinicians’ view on how 








guideline recommendation(s), guided by  (10) 
from Michie et al.  
Specific 
Probes 
Type 1. Examples of Emotional factors  To bring up the specific emotions such as stress, 
burn out, etc. to probe participant on the extent of 
emotional influence  
13. Behavioural regulation – What 
preparatory steps do you think are 
required to implement the guideline 




To identify the clinicians’ view on how 
behavioural regulation influences the 
implementation of the guideline 
recommendation(s), guided by  (11) from 
Michie et al. 
Probes 
Probe 1. Reiterate Question  To keep participant on track and clarify question 
in other words 
Specific probe type 1. Preparatory steps 
examples  
To bring up examples of preparatory steps to jog 
the participant’s memory for a response 
Specific probe type 2. Reason that action 
steps are facilitators  
To probe the reason that these action steps are 
required if not mentioned 
14. Behavourial Change- What 
behaviour do you think should become 
a habit for improving the 
implementation of the 
recommendation(s) 
 
To identify the clinicians’ view on how 
behavioural  change influences the 
improvement of implementing the guideline 
recommendation(s), guided by  (12) from 
Michie et al. 
Specific 
Probes 
Type 1. Situational Probe  To help the participant think of a proposed 
behaviour by directing them to a particular 
situation where an ideal behaviour was displayed 
to implement the selected recommendation(s).  
Type 2. Novel or Existing Behaviour  To identify if the behaviour is new or existing?  
Type 3. Who needs to change?  To identify the stakeholders involved in the 
behaviour change 
15. What do you think can prompt the 




To identify the clinicians’ view on what 
prompts are required for long-term behaviour 
change for implementing the selected guideline 
recommendation(s), guided by  (12) from 
Michie et al. 
Specific 
Probes 
Type 1. Freestyle 5W’s  To probe the participant’s idea on how to maintain 
the new behaviour in the long-term through 
answering the 5W’s 
Type 2. Examples To bring up examples if the participant does not 
have ideas 
Type 3. Pragmatic question To probe the participant on how realistic it is to 
maintain long term changes with the current 







APPENDIX G- Recruitment Email Correspondence  
 
Dear (insert participant's name),  
My name is Brenda Trinh and I am a MSc. student working under the supervision of Dr. George 
Heckman in the School of Public Health and Health Systems at the University of Waterloo. I am 
contacting you because we are conducting a study that will be a stepping stone for the 
implementation of a coordinated, regional approach to oral anticoagulation therapy (OAT). Our 
study aims to understand the clinician’s perceptions on the uptake of a systematic approach to 
key elements for optimal OAT practices. This research will generate a list of benefits, barriers 
and facilitators for effective implementation. We are currently seeking key informants for this 
study who are pharmacists and nurses with certifications to work in specialized anticoagulation 
management service (AMS) clinics using point-of-care technology (i.e., CoaguChek XSTM and 
computerized software) for at least 6 months within the WWLHIN community (Waterloo-
Kitchener, Cambridge and Guelph).  
Participation in this study involves a 30-minute interview at a time and place convenient to you. I 
hope to book your time in advance when there are no patients scheduled to come in at the AMS 
clinic. Interviews will be between October and November 2016, but if a later date is necessary, I 
would be pleased to coordinate with you.  Before the interview, I will send you an information 
sheet about the study and a short article to read ahead of time: Delivery of Optimized 
Anticoagulation Therapy by Garcia et al. (2008). I would like to assure you that our study has 
been reviewed and received ethics clearance through a University of Waterloo Research Ethics 
Committee. However, the final decision about participation is yours. 
If you are interested in participating, please contact me at b2trinh@uwaterloo.ca and list your top 
two availabilities. I will then send a confirmation email indicating that you’ve been signed up for 
an interview time slot and discuss further details.  
 








MSc. candidate  
University of Waterloo  




APPENDIX H- Confirmation Email to Respondents 
 
Subject: Confirmation of Participation in Study   
Hi (insert participant’s name): 
You have recently responded to our invitation to participate in the study entitled ““Clinical 
pharmacists and nurses’ perceptions on implementing anticoagulation therapy recommendations 
for the frail elderly: An exploratory study based on psychological theory.”  
This is an email to confirm that our interview is scheduled at (insert time) at the (insert 
location).  
As a reminder, please find attached the information sheet and a short article by Garcia et al. 
(2008) on the 9 key recommendations for the delivery of optimized anticoagulant therapy.  
I would like you to select 1 or 2 out of the 9 key recommendations by Garcia et al. for our 
interview:  (1) Qualifications of Personnel, (2) Supervision, (3) Care Management and 
Coordination, (4) Documentation, (5) Patient Education, (6) Patient Selection and Assessment, 
(7) Laboratory Monitoring, (8) Initiation and Stabilization of Warfarin Therapy, and (9) 
Maintenance of Therapy.  
If you require more information or have any questions, please do not hesitate to email me at 
b2trinh@uwaterloo.ca. Otherwise, please reply to this email with your 1-2 selected 
recommendations so that I may prepare accordingly for our interview. If you have to reschedule 




MSc. candidate  
University of Waterloo  






APPENDIX I- Non Response Follow Up Email 
 
Subject: Follow-up for Study   
Hi (insert participant’s name): 
I recently sent an email message to invite you to participate in a study. This study aims to 
understand how we can implement a broader, more uniform approach to oral anticoagulation 
therapy (OAT). Since I have not heard back from you, I wanted to inquire as to whether you’ve 
made a decision. If we are still under consideration, I would like to again express my interest in 
conducting an interview with you for this study. I believe that your expertise and knowledge 
would be a valuable contribution for this research.  
 
If you are looking for more flexible timing, I would be happy to coordinate with you to find a 
time and place convenient to you.  
Again, I would like to assure you that our study has been reviewed and received ethics clearance 
through a University of Waterloo Research Ethics Committee. However, the final decision about 
participation is yours. 
If you are still interested in participating, please contact me at b2trinh@uwaterloo.ca and list 
your top two availabilities. I will then send a confirmation email indicating that you’ve been 
signed up for an interview time slot and discuss further details on the location.  
I look forward to your reply!  
Sincerely, 
Brenda Trinh 
MSc. candidate  
University of Waterloo  





APPENDIX J- Participant Feedback/Appreciation Letter 
 
University of Waterloo 
(Insert Date) 
Dear (Insert Name of Participant), 
I would like to thank you for your participation in this study entitled “Clinical pharmacists and 
nurses’ perceptions on implementing anticoagulation therapy recommendations for the frail 
elderly: An exploratory study based on psychological theory.” As a reminder, the purpose of this 
study is to explore perceptions of pharmacists and nurses about the uptake or not of a systematic 
approach to key recommendations for optimal oral anticoagulation therapy (OAT). The larger 
goal is to aid in the implementation process of an integrated regional approach to OAT.    
Please remember that any data pertaining to you as an individual participant will be kept 
confidential.  Once all the data are collected and analyzed for this project, I plan on sharing this 
information with the research community through seminars, conferences, presentations, and 
journal articles.  If you are interested in receiving more information regarding the results of this 
study, or would like a summary of the results, please provide your email address, and when the 
study is completed, anticipated by January 2017, I will send you the information.  In the 
meantime, if you have any questions about the study or findings, please do not hesitate to contact 
any of the following people: Student Investigator- Brenda Trinh, b2trinh@uwaterloo.ca; or 
Faculty  Supervisor in the School of Public Health and Health Systems Department– George 
Heckman, ggheckman@uwaterloo.ca.  
As with all University of Waterloo projects involving human participants, this study has been 
reviewed and received ethics clearance through a University of Waterloo Research Ethics 
Committee.  Should you have any comments or concerns resulting from your participation in this 
study, please contact the Chief Ethics Officer, Office of Research Ethics, at 1-519-888-4567 ext. 
36005 or ore-ceo@uwaterloo.ca. 
 
Brenda Trinh 
Student Researcher  
University of Waterloo 






APPENDIX K- Codebook using Nodes from NVIVO 
 
Name of Node (inductive or deductive) 
Guideline Recommendations 
Care Management and Coordination 




Initiation and Stabilization of Warfarin Therapy 
Lab Monitoring 
Maintenance of Therapy 
Patient Education 
Patient Selection and Assessment 










Communication & Collaboration 
Continuing Education 





Older Population with AF 
Adherence issues 
Frailty 
Psychological Theory 12 Domains 
Anticipated Outcomes & Attitudes  
Behavioural Regulation  
Emotion  
Environmental Context & Resources  
Intention  
Knowledge  
Memory, Attention & Decision Processes  
Professional Role and Identity  
Self-Efficacy  
Skills  
Social Influences  
Family & Caregiver 
Other allied HCPs 
Other pharmacists  
Patients  
Physicians  










APPENDIX L- Coding Issues & Assumptions 
 
During the data coding process, the researcher noticed the following issues and/or assumptions:   
1. There was overlap in the data on software used for dosing adjustments so there was 
conflict on whether or not it should be coded as documentation, care 
management/coordination or maintenance therapy:  
“Like the dosing recommendations are a bit blunt, so big dosing recommendation 
changes when it's not, the computer of course can't look at the patient and can't see the 
whole picture as to explaining why an INR might be out of range. And it might be much 
better to do a very small one-time dose adjustment, whether it'd be a boost or a reduction 
one time and then continue the maintenance dose and recheck, right? Whereas dosing 
algorithms tend to be quick to make broad sweeping adjustments to the maintenance dose 
with a bit of over testing. So the clinical experience with Warfarin comes to say yes but 
the patient in front of me has these characteristics, this is the clinical scenario and no I 
don't agree with the dosage algorithm suggestion because I know that we'd be better off 
to make a very small adjustment or none at all, and simply recheck.”  
 
So, the investigator and second coder went through the process of elimination while 
consulting the definitions from the guidelines. At first, documentation was considered as 
the main recommendation because the participant spoke about the computerized 
software, but it was not coded as such because it did not talk about the documentation 
process. Care management and coordination was also considered but not coded because 
the focus was not on the policies and procedures as a clinical tool for managing warfarin 
therapy. The content was more about the maintenance therapy aspect because the focus 
was on the uptake or not of the dosing algorithm for longitudinal adjustment of Warfarin. 
So, after re-analyzing the participant’s quote in its context, the second coder and the 
researcher came to the consensus that the main recommendation was maintenance of 
therapy. The next step was to determine what factor from Michie et al. influenced the 
implementation or not of this recommendation. The credibility of this systematic process 
for long-term dose adjustments was critiqued as being too blunt and as such, the 
participant said that it should not be used as a ‘tell-all’ to guide their practice, so it was 
clearly in conflict with the professional standards. Therefore, it was coded as 
maintenance therapy as the key recommendation and professional/social role or identity 
as the factor from the psychological theory. This process of re-analysis and discussion 
was done by the researcher and second coder for each transcript to ensure that all themes 
were coded as closely to the definitions in the documents for deductive themes.  
2. Difficulty categorizing the data content as maintenance of therapy or care 
management/coordination because of overlap in concepts. It is coded as maintenance of 
therapy if it talks about the systematic process for longitudinal Warfarin management. 
This would include using checklists for follow-ups, and validated algorithms as a 
systematic approach to stable dosing, dealing with extreme INR values, interrupting and 
restarting for invasive procedures, and managing adverse or interacting events (e.g. 
number of days between INR testing). CMC is referring to the procedures or policies as a 
clinical tool to resolve issues of Warfarin management and coordination, or in other 




3. There were coding conflicts with the second coder due to subjective interpretations. For 
example, the researcher coded the data based on the participant’s point-of-view and 
context in the community. FHTs have mixed clinicians so the researcher considered the 
perspective of the nurses and pharmacists, but there are just pharmacists in community 
pharmacies.  
 A community pharmacist successfully receives patient referrals to his clinic from 
nurses because they know the pharmacist is knowledgeable and has a good inter-
professional relationship with the nurses. This content was coded as care 
management/coordination, positive, benefit, knowledge, social influence (other 
allied professionals).   
 The second coder interpreted it in the community nurse’s perspective because 
they did not have knowledge for Warfarin management, so she coded it as care 
management/coordination, negative, barrier, knowledge 
 In the end, the researcher and second coder agreed to code all transcripts based on 
the participant’s point of view. 
4. The researcher and second coder assumed that from the interview’s introduction that 
subsequent questions were about the target population: older adult with frailty and AF  
5. Patient selection and assessment refers to any content related to the systematic approach 
of assessing the risk and benefits for patients to initiate OAT. E.g. Require relevant 






APPENDIX M-Output of Similarly Coded Text 
 
Table 4. Output of Similarly Coded Text where all the terms in each row applies. E.g. ‘Frailty’  
AND ‘BARRIER’ yields 13 references of similarly coded blocks of text 
Garcia et al. 
Recommendation 
or Concept  
Factor from Michie et 
al.’s Psychological 
Theory 
Barrier, Benefit or Facilitator?  # references    




Older Population  - Barrier 0 
Benefit 4 





Any Any 6 
 
 






3. Care Management/ 
Coordination 
4. Documentation  
5. Patient education 
6. Patient Selection/ 
Assessment 





Knowledge  Barrier 
(15) 
1 (Qualification) 
1 (Superv)/ 1 (MD)/ 3 
(role confusion)/ 0 
(staffing) 
4 (CMC)/ 0 (transition) 
0 (doc)/ 1 (soft)/ 1 (CC) 
0 (pt education) 
2 (pt SA) 






3 (Supervision)/ 6 (MD) /4 
(role confusion)/ 0 
(staffing)  
18 (CMC)/ 4 (transition) 
4 (doc)/ 2 (soft)/0 (CC) 
10 (Pt Education) 
5 (pt SA) 







0 (Supervision)/ 0 (MD)/  
1 (role confusion)/ 0 
(staffing)  
2 (CMC)/ 0 (transition) 
1 (doc)/ 0 (soft)/ 0 (CC) 
1 (pt edu) 
0 (ptSA) 









1 (Superv)/ 0 (MD) / 0 
(RC)/ 0 (staffing) 
9 (CMC)/ 1 (transition) 
7 (doc)/ 5 (soft) / 0(CC) 




1 (maintenance)  
Social/Professional 




1 (Superv)/ 2 (MD)/ 0 
(Staffing) 
9 (CMC)/ 1 (transition) 
1 (doc)/ 4 (soft)/ 1 (CC) 
0 (pt edu) 
1 (pt SA) 
0 (lab) 
0(Initi/Stab) 
7 (maintenance)  
Benefit  
(16) 
2 (Qual)  
1 (Superv)/ 3 (MD)/ 0 
(RC)/ 0 (Staffing) 
5 (CMC)/ 1 (transition) 
1 (doc)/ 0 (soft)/ 1 (CC) 
0 (pt edu) 
0 (pt SA)  






0 (Superv)/  0 (MD)/  0 
(RC)/ 0 (Staffing) 
3 (CMC)/ 0 (transition) 
0 (doc)/ 0(soft)/0 (CC) 
0 (pt edu) 






0 (Qual)  
0 (Superv)/ 0 (MD)/ 1 
(RC)/ 0 (Staffing)  
3 (CMC)/ 3 (transition) 
0 (doc)/ 1 (soft)/ 1 (CC) 
0 (pt edu) 










0 (Superv)/ 0 (MD)/ 1 
(RC)/ 0 (Staffing) 
4 (CMC)/ 0 (Transition) 




0 (pt edu) 
0 (pt SA) 
0 (lab) 
0 (init/stab) 





1 (Superv)/ 0 (MD)/ 0 
(RC)/ 0 (Staffing) 
5 (CMC)/ 1 (Transition) 
1 (doc)/ 1 (soft)/ 1 (CC)  
3 (pt edu) 
1 (pt SA) 
0  (lab) 
1 (init/stab) 
0 (maintenance)  
Intention  Barrier 
(12) 
0 (Qual) 
0 (Superv)/ 2 (MD)/ 0 
(RC)/ 0 (Staffing) 
5 (CMC)/ 0 (Transition) 
0 (doc)/ 4 (soft)/ 0 (CC) 
0 (pt edu) 







0 (Superv)/ 0 (MD)/ 0 
(RC)/ 0 (Staffing) 
7 (CMC)/ 2 (Transition) 
0 (doc)/ 1 (soft)/ 0 (CC) 
0 (pt edu) 




Memory, attention and 




0 (superv)/ 0 (MD)/ 0 
(RC)/ 0 (Staffing)  
0 (CMC)/0 (Transition) 
2 (doc)/ 1 (soft)/ 0 (CC) 
0 (pt edu) 







0 (superv)/ 0 (MD)/ 0 
(RC)/ 0 (Staffing) 
0 (CMC)/ 0(Transition) 
0 (doc)/ 0(soft)/ 0 (CC) 
0 (pt edu) 













0 (superv)/2 (MD)/ 1 
(RC)/ 5 (Staffing) 
32 (CMC)/ 5 (Transition) 
5 (doc)/ 9 (soft)/ 2 (CC) 
1 (pt edu) 
0 (pt SA) 
0 (lab) 
0 (init/stab) 




 1(superv)/ 1 (MD)/ 0 
(RC)/2 (Staffing) 
21 (CMC)/ 2 (Transition) 
8 (doc)/ 2 (soft)/ 3(CC) 
5 (pt edu) 




Social Influences Barrier 
(44) 
0 (qual) 
0 (superv)/ 2 (MD)-
physicians/ 1 (RC)-
Family/0 (Staffing) 
1 (CMC)/ 1 (CMC)- 
Family/ 1 (CMC) –Other 
Allied HCPs/ 3 (CMC)- 
Other Pharmacists/ 3 
(CMC)- patients/ 
11(CMC)- physicians/ 1 
(CMC)-3rd party  
 
2 (Transition)/ 1 
(Transition)- Family/3 
(Transition)- Other HCPs/ 
4 (Transition)- Patients/ 1 
(CMC)-Physicians/ 1 
(CMC)- 3rd party 
 
0 (doc)/2 (doc)-physician 
 
0 (soft)/ 1 (soft)-patients/ 2 
(soft)-physicians 
0 (CC) 
0 (pt edu) 




0 (maintenance)/ 1(main)- 






1(superv)- physicians/ 2 




(MD)- patients/ 0 (RC)/ 0 
(Staffing) 
3 (CMC)/ 2 (CMC)- other 
HCPs/ 3 (CMC)- other 
pharmacists/ 8 (CMC)-
patients/ 18 (CMC)- 
physicians 
 
5 (Transition)/ 2 
(Transition)-Other HCPs/ 












0 (pt edu)/1 (pt edu)-
family/ 2 (pt edu)-patients 
 
0 (pt SA)/1 (pt SA)-family 
 
0 (lab) 
0 (init/stab)/ 1 (init/stab)-
patients 
 
0 (maintenance)/ 2 (main)- 




0 (Qual)  
0 (Superv)/ 0(MD)/1 
(RC)/0(Staffing) 
4 (CMC)/ 0 (Transition) 
1 (Doc)/ 0 (Soft)/0 (CC) 
0 (pt edu) 






1 (Qual)  
0 (Superv)/ 0 (MD)/0 
(RC)/0 (Staffing) 
1 (CMC)/ 0 (Transition) 
0 (Doc)/ 0 (Soft)/0 (CC) 
0 (pt edu) 












 0 (Superv)/  0 (MD)/ 0 
(RC)/0 (Staffing) 
0 (CMC)/ 0 (Transition) 
0 (Doc)/0 (Soft)/ 0(CC) 
0 (pt edu) 






0 (Qual)  
1 (Superv)/ 0 (MD)/0  
(RC)/0 (Staffing) 
3 (CMC)/ 0 (Transition) 
0 (Doc)/ 2 (Soft)/0 (CC) 
0 (pt edu) 




Nature of Behaviour 
(theme coded as 
facilitator – what will 



























APPENDIX N- Reflexive Journaling 
Data Collection Process 
 I emailed a pharmacist in the community who was willing to do a dry run to practice my interview 
questions. The pharmacist was helpful in providing feedback to adjust my interview questions so that they 
are more applicable to the key informants. I also contacted my committee member with extensive 
qualitative experience to review and provide feedback on the interview guide and tips on interviewing key 
informants. I had a phone conference with that expert and then jotted the notes down: ask a few (not all) 
questions during one interview to yield quality data, form a relationship with the interviewer and keep time 
at the end for additional comments/ questions. This is where I learned that I would yield the most valuable 
answers. 
 I changed the way the questions were asked to make it more “on the ground” or applicable to pharmacists 
and nurses. I did this by making sure I had other ways of re-iterating the same point.  I also formatted the 
interview guide in a chart form because I found it easier to read.  
 Then, I proceeded to recruit and set up an interview time with the first pharmacist as outlined in the 
proposal. Once I received the reply that the selected recommendations were initiation/stabilization of 
warfarin therapy and care management/coordination, I simplified the interview guide to include questions 
about the selected recommendations only. I did this modification in order to focus on the topics rather than 
have the entire interview guide in front of me, which was too long to print and have a paper copy of. 
 During the interview, I met the pharmacist in the AMS clinic office and went through the interview 
questions one by one and provided positive feedback as the participant answered each question. The 
interview was audio recorded and I felt the first interview was a success even though I had much to 
improve on. I wrote down my first impressions about the participant and clinic right after on the back of the 
interview guide; there is a physical copy for reference. I also wrote down how to improve my interviewing 
skills and the content to focus more on in the next interview. The participant was very knowledgeable and 
provided all the necessary information without many prompts. I felt that I was confused about the care 
management/coordination recommendation after transcribing the audio file and that might have affected the 
quality of the data. So, I reviewed the recommendations again and made sure to create a checklist of the 
main points to hit during my next interview.   
 I asked the pharmacist to refer me to some nurses as a snowball sample. Soon after, I received 
correspondence from two nurses in the same family health team who were interested in my study. I sent the 
recruitment email and set up times to conduct the interview.  
 Again, I modified the interview based on their selected recommendations (supervision and documentation) 
and simplified it into a chart form with clear topic headings. I found that I needed more prompts in this 
interview compared to the first interview with the pharmacist. I made a lot of notes beside the topic 
headings after the interview about my impressions about the lack of knowledge on frailty and the clear 
chain of duty, as well as how the documentation process was done very well. I noted that the participant 
chose documentation even when it was already done well so this was a great feat for my benefit list. I 
wondered why it was chosen —maybe because it was the most comfortable aspect for her to talk about. 
However, I did ask the participant to choose recommendations based on what needed the most 
improvement, but the participant ended up picking documentation. This is interesting.  
  I interviewed the next nurse on the next day. Since the last interview was fresh in my mind, I decided to 
not use the table format and stick to the original guide in the proposal. I deleted irrelevant questions not 
related to the selected recommendation. I ended up choosing care management and coordination since the 
nurse did not reply to my email on which recommendation he/she wanted to focus on. The nurse was fine 
talking about care management and coordination, although there was some initial hesitation. The nurse was 
unsure because the participant thought he/she did not know much about the policies and procedures. 
However, as I probed the nurse with questions on how they managed and dealt with management issues, 
more information arose. It was clear that written policies were not explicitly available and communicated to 
the staff, although they were learned through experience and informal learning in the clinic. I noticed 
nurses did not have the formal training course at the School of Pharmacy, but they did have training from 
the pharmacist and Roche. This nurse was knowledgeable about frailty and raised a lot of issues about 
inter-professional relationships. I noticed the nurse was younger than the head nurse (previous participant) 
and that nurse also knew more about the policies to follow for risk assessment, initiation and etc. The nurse 




institutions and providers outside the family health team. The transitions are very choppy, unlike in the 
family health team where physicians are now all on board (although they weren’t before). I noticed a 
conversation style interview brought out more issues and themes than asking question after question.  
 I decided to make the next interview more like a case study or ask them to describe an example and then 
probe for the concepts. The next interview was not until a week later because I was sick, so I had to review 
all the concepts while transcribing my first three interviews.  
  My first interview with a community pharmacist (CP) was quite different than those at the family health 
team. The CP chose care management and coordination; documentation; and qualifications of personnel. 
There was more self-efficacy and intention to run the AMS clinic since it was managed entirely by him. I 
stuck with the original interview guide and highlighted the questions to ask. I noticed it was more difficult 
to schedule and sit down for the interview. We were interrupted once at 30 minutes because he was the 
only one who could do flu shots. There seems to be a staffing issue. This could mean that patients do not 
have the luxury to talk to the community pharmacists for as long as the pharmacists in family health teams. 
I was not interrupted once in those interviews. The scheduling in family health teams is more organized and 
they have more time with patients.  At the end of the interview, I jotted down themes related to 
coordination, intention, and general impressions. Answers were short and quick because it seemed to me 
that it was all intuitive and common sense. CP asked “why isn’t it already being done across clinics?” All 
the recommendations were claimed to be followed in this community clinic and the concern was more 
about reimbursement procurement. CP wanted to make sure I had all the information I needed and offered 
to clarify anything if needed; I just need to call or email.  
 Reimbursement seems to be a recurring theme in all my interviews so far.  
 My next interview is at a family health team. This pharmacist read the entire guideline and told me it was 
okay to focus on all of them, although the participant originally chose patient education and 
initiation/stabilization of warfarin therapy. As a matter of fact, the responses focused a lot of the education 
aspect! With this participant, I wanted to try a narrative approach where I gave a scenario: “An older 
patient is suspected to have an indication for warfarin therapy by the family physician, what do you think 
the guideline says about the next steps for the patient to get started in the clinic?” This way we were able to 
tell the story of a patient going through the system and at the same time, we discussed all the 
recommendations and I probed about the factors that might have affected their implementation. I found that 
the information came more easily to the participant when framed as a case study or example, than straight 
up question after question. The participant gave hypothetical responses (opinions and feelings) about the 
barriers that other pharmacists in the community might have compared to family health team clinicians. 
Participant really understood that the guideline implementation was in the general scope of the community 
and not just this clinic. Although I said this in previous interviews, this pharmacist was the first one to 
consider that point when answering all questions.  
 Asking about all the recommendations was overwhelming in even 40 minutes because there is A LOT of 
information, so in the next interview I want to re-focus on specific recommendations.  
 Next interview with a community pharmacist selected care management and coordination; and initiation 
and stabilization of warfarin therapy. Again, I noticed the trend that community pharmacies have less time 
than family health teams for the interview. CP provided clear and concise answers to my questions. My 
interview guide had a mix of just questions and case examples to clarify concepts. It worked very well, the 
best by far. I added a clear list of prompts for myself in case the participant wanted me to re-iterate or give 
examples. I had clear transitions between questions and the interview flowed much better. My interview 
skills improved since the first interview and I understood all the recommendations really well by now so I 
felt like I could probe and ask for clarifications from the participant much better.  In 30 minutes, I was able 
to get through 10 questions since I was clear in my questions and CP was concise in replying. CP 
mentioned that a pharmacy technician was important to free up time for pharmacists to do therapeutic 
activities.  CP was enthusiastic and excited to be the first community pharmacy to have access to Clinical 
Connect and is drafting an advocate letter to the government for reimbursement for anti-coagulation 
clinics!  
 The last two interviews and phone conference with a missing voice (pharmacist at a hospital but previously 
had extensive experience in the community and family health teams) occurred on the same day.  
 In the morning, I had an interview a pharmacist in a community pharmacy. We met at a coffee shop 
because CP did not have an office. CP showed me the documentation software and we focused on all the 




informal approach to starting the interaction with this pharmacist instead of recording the demographic 
information. As CP showed me the documentation system, I asked about the job title, training and 
experience in the clinic, as well as the patient base and trained staff. I noticed that I built a better rapport 
with the participant when the conversation was not recorded. Then we proceeded to the coffee shop and CP 
talked freely about how his clinic had a medical directive that followed a New Zealand guideline but it was 
quickly abolished. Before CP went on any more, I suggested we recorded the interview staring with the 
frailty questions. CP was happy to oblige and we continued our talk. This interview felt more like a 
conversation and he brought up many issues with strict medical directives. This participant had trouble 
identifying frailty and how it affected assessment. Initiation of warfarin therapy was not done in this clinic 
since they have a very small patient base and never had to start therapy for any of them; they just continued 
warfarin therapy that was initiated by other providers. Social networks and supports played a large role in 
this clinic; a lot was informal because there was no time or resources to formalize policies especially with 
independent physician offices. 
 In the afternoon, I had input from the pharmacist over the phone. This person was not an official participant 
because he/she no longer worked for a AMS clinic in the community, however he/she is the missing voice 
due to their experience and knowledge of the benefits, barriers and facilitators. We spoke on the phone 
without recordings, but I took extensive notes. We discussed what works, what doesn’t and what will help 
in the context of the community anti-coagulation clinics.  Many themes emerged from our conversation: 
social influences, intention/empowerment, issues with system integration of documentation processes, non-
standardized patient education materials and needing a reliable systematic approach to clinical support. 
Bridging was also discussed as a huge issue because of environmental constraints (a logistics problem). 
Then we closed with how the frail older with AF is a labour-intensive population to manage.  
 The last interview was with a pharmacist from a family health team that manages a huge patient base. We 
had the interview after her office hours in a coffee shop; he/she was busy during work and didn’t have 
space.  
 Since I had redundancy in the themes mentioned, and time was limited, the participant above talked about 
the main benefits, barriers and facilitators of the guidelines in general. I thought we could learn about what 
they have to offer since they were a deviant case. I was correct because when we were talking about the 
general benefits, barriers and facilitators, many factors influencing the uptake or not of specific 
recommendations also came up. Although the interview was still semi-structured and guided by the theory 
domains, the flow of the interview was more natural when the participant was not forced to talk about a 
certain concept via questioning. I started out with the most important question that is simple to understand: 
“Currently what’s the factors affecting how well anti-coagulation clinics are run in the community?” Once 
participant talked about what worked, what didn’t and what helped, many of Michie et al.’s psychological 
theory domains came up in the conversation.  
 The participant talked about how the clinic got started, its barriers and how they were overcome, and the 
benefits of having one clinic managing Warfarin therapy and also what they were working on. This was a 
unique perspective that none of the other clinicians had because they were not in this environment. 
Participant talked about a whole host of different factors influencing the implementation of different 
recommendations. Frailty was a big topic and he/she replied keeping this population in mind.   
 I gained a lot of insight about the themes and concepts on how these factors influenced the uptake or not of 
the 9 key recommendations in the community. I was ready to analyse the transcripts and draw inferences 
from the data.  
Transcription Process 
 I used an audio recorder to record the interviews.  
 I transcribed the audio files right after I conducted the interviews to keep it fresh in my mind. I consulted 
the field notes during transcription if things were unclear. This triangulation of various data sources ensures 
the credibility of my data.  
 If any information was unclear in the transcript and audio files, I sent the participant a quick clarification 
email and received a prompt reply. Member checking was useful when I did not probe or clarified in the 
interview. For example, I saw that the participant was unsure of the response about the number of patients 
in her clinic, so I confirmed the number through an email. Participant replied and confirmed that number.  
 In each transcript, the heading has the relevant information: location, type of clinician, date, audio file 




   I made sure to include non-verbal impressions (tone, laughs, hesitations, long pauses, etc.) in order to code 
for emotion and intention later.  
 I cleaned up the transcript of the umm’s if I said them too much but kept the integrity of the key 
informants’ responses.  
 When there was overlap of voices, I made sure include that in to show that the participant was keen to 
answer my questions.   
 I used an online program called “transcribe really” to simultaneously type and listen to the audio in one 
window. It had features to automatically play for 5 seconds and then pause for 3 seconds, then re-play for 3 
seconds. That feature helped to transcribe the audio file word-for-word more accurately. It would take 3-4 
hours to transcribe each audio file of about 30-40 minutes.  
Data Analysis Process 
 I have experience from a qualitative data course and a previous research assistant position on how to code 
interview content in Word.  
 I used NVIVO Pro 11 and watched the tutorials and read the HELP section on how to analyze interview 
transcripts. They suggested using single nodes and then using the query function to search multiple nodes 
during data analysis.  
 I categorized the hierarchy of the nodes as such:  
o Garcia et al. recommendations (9 elements)  
o Michie et al. psychological theory domains (11 domains)  
o List of … 
 Benefits 
 Barriers 




 Neutral  
o Older Population with AF 
 Frailty  
 Then I started to code the transcripts in order of when they were conducted. I used these deductive nodes to 
code the data, then I added nodes as emergent themes appeared.  
 The codebook above grew as I noticed recurrent themes in the data, such as adherence issues, different 
facilitators (reimbursement, continuing education, system integration, etc.) 
 After categorization and coding all the data, I asked a colleague with qualitative data analysis experience. 
She coded my transcripts on NVIVO 8 and we did not notice until she tried using the data comparison 
function to generate a kappa score. It was not compatible so due to time and resource constraints, we did 
the second coding to refine the codes in the transcripts. We sat together and had the program opened with 
my coding scheme, and we discussed what was meant by the data. We noticed more recurrent themes, re-
coded and un-coded strings of text from multiple sources. After our discussions, I noticed that the 
qualitative data can be organized in many different ways and I needed solid criteria to code the text. We did 
content analysis and made sure to code the main ideas of each string or block of text. It took us two full 
days (19 hours) to go through second analysis coding. As we were second coding, I noted conflicts in 
coding, why we had the discretions and how we resolved it. As we were analysing and discussing the 
themes, I revised my coding and how it fit into the themes.   
 I had a list of interesting findings as I was second coding and as I grouped recurrent themes with headings 
in the analysis, I noticed that some themes were still not coded properly since I had difficulty categorizing 
care management and coordination, and maintenance therapy. I reflected on the difference and made it 
clear what criteria made it one or the other. See analysis for clear descriptions.  
 I went through the coding a third time to fix the mistakes in the coding confusion above.  
 I decided to read more about qualitative data analysis online in order to write about all the points in my 
thesis. I found this website with a slide show talking about how to conduct qualitative studies by a Masters 
of Public Health employee:  http://www.slideshare.net/tilahunigatu/qualitative-data-analysis-11895136 
 The slides were comprehensive of all the features in qualitative data collection and analysis, so I took a few 
notes and included main points that I had previously left out.  
